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Abstract 
 
The assembly of individual protein subunits into large-scale symmetrical structures is 
widespread in Nature and confers unique biological properties which have potential 
applications in nano-technology and medicine. While efforts to functionalize and repurpose 
existing protein complexes have been mainly successful, designing well-defined de novo protein 
complexes remains an unsolved problem. A major challenge in engineering de novo 
symmetrical assemblies has been to design interactions between the protein subunits so that 
they specifically assemble into the desired structure. Prior de novo protein cages have been 
developed with moderate success, but suffer from a lack of generalizability and require 
significant computational effort and screening of mutant fusion proteins. The design and 
optimization of a simple, generalizable approach to designing novel fusion proteins which 
assemble into cage-like structures will be the subject of this dissertation. We show that by 
genetically fusing a C4-symmetric coiled-coil to the C-terminus of a C3-symmetric trimeric 
protein via a short, flexible linker, we can assemble a well-defined 24-subunit protein cage with 
octahedral symmetry. The flexible nature of these assemblies alleviates the need for rigorous 
interface modeling, requiring only minimal computation to determine the length of the linker 
sequence. This is the first de novo designed symmetrical protein complex to incorporate a C4 
symmetry element, and we anticipate this method can be applied to a wider variety of proteins 
and symmetries, which may open up a new avenue of research into designer protein cages with 
unique, built-in functionalities.
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Chapter 1  
 
Introduction 
1.1 - Natural Protein Cages 
 
The assembly of multiple copies of a protein subunit into large, hollow, and highly 
symmetric complexes, referred to in this thesis as ‘protein cages’, is found widely throughout 
Nature. These natural protein cages perform a broad range of critical functions, primarily owing 
to the unique microenvironment of the cage interior. Access to the interior of the cage is 
controlled by pores of varying sizes, sharply limiting the amount of cellular machinery that can 
interact with the interior of the cage. Second, the residues on the interior surface of protein 
cages are brought into close proximity with any molecule that enters this interior, the effect of 
which is multiplied across every subunit in the protein cage. These features lead to behavior 
that would be otherwise impossible in the exterior environment.  
A well-known example of the successful utilization of this microenvironment is the iron 
storage protein ferritin: an octahedral, 24-subunit protein cage that is highly conserved across 
all organisms. The interior surface of the ferritin cage contains a large number of negatively 
charged residues (Fig. 1.1b).1 The negatively charged residues on the interior binds ferrous iron 
atoms in close proximity, catalyzing their oxidation to the ferric form which in turn serves as a 
nucleation site for other ferrous iron atoms, which crystallizes as iron oxide. The hollow ferritin 
interior can hold up to 4,500 iron atoms, which allows ferritin to participate in iron distribution 
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pathways in a far more effective manner than a protein containing discrete binding sites for 
individual metal ions. 
Other natural protein cages function in a similar manner. Many viruses encapsulate 
their DNA or RNA in an icosahedral protein complex known as a capsid that is comprised of 
multiples of 60 protein subunits (Fig. 1.1c). The interior residues of capsid subunits are 
positively-charged, and can thus bind the viral DNA or RNA, packaging them for transmission to 
a new host. These capsids also exhibit another behavior that is critical for viral transmission: 
favorable binding interactions between adjacent capsid proteins, multiplied across the correctly 
assembled capsid, creates a cooperative binding effect that imbues the capsid with a high 
degree of stability, and protects the capsid proteins and enclosed nucleotides against 
environmental degradation.2,3  
Molecular chaperones are highly conserved protein complexes that play an important 
role in preventing the misfolding and aggregation of cellular proteins during periods of cellular 
stress, such as high heat or an oxidative environment. Many molecular chaperones exist as 
protein cages with a variety of symmetries, not only to take advantage of cooperative binding 
for increased stability of the assembled protein complex in a high-stress environment, but also 
to generate an interior microenvironment that aids in protein refolding. The interior surface of 
these chaperonin protein cages is highly hydrophobic, affording an excellent binding surface for 
exposed hydrophobic interior residues of misfolded proteins. GroEL, a barrel-shaped 14-subunit 
protein cage with a 4.5 nm wide hydrophobic interior channel (Fig. 1.1e) binds a wide range of 
proteins, with protein fragments that are unstructured in solution exhibiting alpha helical 
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properties when bound to GroEL.4 The refolding activity provided by GroEL was shown to be 
critical to cell function, as deletion of the GroEL gene was universally lethal to cells.5  
The last notable function of natural protein cages involves utilizing the interior to 
contain reaction pathways that generate unstable intermediates. The microenvironment 
provides excellent temporary storage, protecting these intermediates from interacting with 
other parts of the cell. This behavior is exemplified by pyruvate dehydrogenase, an icosahedral 
complex consisting of three proteins that catalyze the conversion of pyruvate to acetyl-CoA (Fig. 
1.1a). The initial reaction decarboxylates the pyruvate, generating an unstable thioester 
compound that is transferred quickly to a second enzyme in the complex which converts the 
thioester to acetyl-CoA.6 Similar functionality can be found in primitive bacterial organelles 
known as bacterial microcompartments (BMCs) (Fig. 1.1f). BMCs primarily comprise hexameric 
shell proteins, such that they form a honeycomb pattern, interspersed with a small number of 
kinked, pentameric shell proteins.7 The combination of these yields a large (40-200 nm in 
diameter) pseudo-icosahedral protein complex capable of encapsulating multiple enzymes in a 
reaction pathway to increase the efficiency of catalysis. The most well studied BMC is the 
carboxysome, which houses both carbonic anhydrase and RuBisCo. The carbonic anhydrase 
produces CO2 from bicarbonate, which is quickly taken up by RuBisCo to further the Calvin 
cycle. Studies that delocalized carbonic anhydrase to the cytosol showed that significant loss of 
RuBisCo function occurred, suggesting that without the carboxysome, the CO2 produced by 
carbonic anhydrase is too volatile and diffuses out of the cell.8  
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Figure 1.1. Natural protein cages.  a) Cross-section of a 3-dimensional reconstruction of the 
icosahedral pyruvate dehydrogenase complex (Image taken from Ref. 9). b) Crystal structure of 
octahedral bacterioferritin (PDB ID 3GVY). c) Crystal structure of icosahedral rhinovirus capsid 
(PDB ID 4RHV). d) Crystal structure of tetrahedral heat shock protein (PDB 2BYU). e) View along 
the 7-fold axis of the crystal structure of GroEL (PDB ID 1GRL). f) Cartoon of the assembly of 
bacterial microcompartments from hexameric and pentameric subunits (Image credit: 
Wikimedia). 
1.2 - Functionalization of Natural Protein Cages 
 
Naturally-occurring protein cages have been investigated for use in a diverse range of 
materials science and nanomedicine applications. Protein cage functionalities can be 
introduced at one or more of three distinct regions: the interior surface, the exterior surface, 
and the interfacial pores. The simplest functionalization of protein cages involves modifying a 
protein cage to perform tasks similar to its cellular function. Purified ferritin has been long 
known to react in vitro with excess iron salts to biomineralize iron oxide nanoparticles of a 
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defined size. This process was found to be quite general, with size-constrained nanoparticles of 
silver, platinum, palladium, cobalt oxide, and cadmium sulfide, among many others, being 
mineralized in ferritin’s interior cavity.10 In vitro biomineralization could also be replicated in 
heat shock proteins11-13 and viral capsids14 by mutating the hydrophobic or cationic interior of 
these proteins to metal-binding or anionic residues, with the diameters of synthesized iron 
oxide nanoparticles dictated by the interior diameter of these protein cages. Adding a short 
peptide sequence known to specifically bind an ordered assembly of CoPt to the ferritin 
microenvironment resulted in CoPt nanoparticles with ferromagnetic properties.15 Protein 
cage-derived iron-oxide nanoparticles have also been used as a nucleation site for the synthesis 
of single-walled carbon nanotubes, and the diameter of these nanotubes is proportional to the 
size of the seed iron oxide particle.16  
Size constrained nanoparticles, in particular iron and cobalt oxide, are of particular 
interest in nanoelectronics research.17 A single layer of protein cages containing nanoparticles 
can be deposited onto a precoated surface in a tight, hexagonal packing pattern, with a packing 
density close to theoretical values.18 In what is known as the bio-nano process, silicon wafers or 
other substrates are precisely patterned with hydrophobic or hydrophilic coatings, with 
nanoparticle-containing ferritin localizing only on the hydrophilic coat. This is then exposed to 
heat, burning away the ferritin to leave only the iron oxide nanoparticle, which is then reduced 
to yield a precisely-patterned array of metallic iron spheres.19 This has been used to generate 
semiconducting logic devices on the nano scale such as thin film transistor flash memory and 
floating nanodot gate memory devices.20 Parameters of the bio-nano process can be controlled 
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with superior precision than existing nanoelectronics technology21, but this technology has not 
yet scaled to market. 
The microenvironment of the protein cage interior presents an attractive target for 
entrapping catalytic species, essentially creating a bioreactor.22 Palladium nanoparticles formed 
on the inside of ferritin cages were shown to catalytically hydrogenate olefins in solution.23 The 
kinetics of this process could be controlled by varying the size of the olefin, indicating that this 
reaction is limited by diffusion of the olefin through ferritin’s nanopores. Similarly, 
encapsulated gold and silver nanoparticles could catalyze the reduction of nitrophenol24 and 
platinum nanoparticles synthesized inside of a tetrahedral heat shock protein could catalyze the 
reduction of protons to hydrogen gas.25 In both of these reactions, the catalytic rate was 
increased relative to bulk metals in solution. The hollow interior of a protein cage has also 
sparked interest for entrapment and immobilization of enzymes, fashioning a bioreactor similar 
to the carboxysome. Protein cages can be assembled around enzymes in solution, trapping 
them, and these enzymes retain their catalytic activity.26 However, this catalytic activity is 
reduced if a large number of enzymes are encapsulated in each protein cage, indicating that 
crowding may have a deleterious effect.27 Using one of the larger viral capsid shells, multiple 
enzymes in a metabolic pathway were co-localized, but this had negligible effect on turnover 
rates.28 The most promising application of protein cages as nanoreactors involves 
polymerization reactions. Rhodium (II) complexes that catalyze the polymerization of 
phenylacetylene were bound to the interior of ferritin, and polymerization was induced.29 The 
polymers formed had a very narrow size distribution of 130 ± 15 monomers, which was 
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concentration independent. This level of precision in polymerization control may open up new 
avenues of research into designed smart materials. 
 Protein cages also hold promise for medical therapeutics. Taking advantage of a viral 
capsid’s evolved ability to cross the cell membrane and release its genetic payload into a cell, 
viral capsid shell proteins are an attractive target for biocompatible functionalization. Without 
their viral genes, these assembled capsids are safe for medical applications and possess a 
sizeable interior cavity. Mimicking its natural function, the capsid interior can be loaded with 
therapeutic genes, and when fully assembled these genes are protected from DNAses by the 
capsid shell.30 Currently, functionalized capsids are able to encapsulate plasmids as large as 
17.6 kbp.31 These viral capsids, loaded with custom DNA, may be useful for therapeutic gene 
delivery. For example, when an exotoxin-encoding plasmid was packaged into a viral capsid and 
injected into tumor cells, tumor sizes were significantly reduced both in vitro and in vivo.32 DNA 
has also been encapsulated in nonviral protein cages, by mutating in positively-charged 
residues on the interior surface of the icosahedral lumazine synthase complex.33  
Small molecules such as cancer therapeutics can also be encapsulated in the capsid 
interior34, or covalently linked to the protein cages.35 Drug delivery via this method takes 
advantage of protein cages’ resilience to degradation, allowing for the timed release of 
therapeutics.36 While unmodified viral capsids loaded with doxorubicin, an important anti-
cancer drug, was shown to cause higher cytotoxicity in cancer cells than free doxorubicin in 
solution37, these therapeutic protein cages have the drawback of depositing this toxic payload 
indiscriminately. Therefore, significant research has gone into decorating the capsid exterior 
with targeting ligands that localize the therapeutic protein cage to the cell type of interest. Viral 
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capsids have been decorated with both small molecules38-40 and large biomolecules40,41 known 
to bind receptors that are overexpressed by many cancer cell types, and these functionalized 
capsids were shown to be selectively uptaken into a range of tumor cells. Several groups have 
gone farther, decorating viral capsids with peptide sequences that bind specific cancer cells 
with high selectivity. Depending on the peptide used, functionalized capsids could selectively 
target Jurkat leukemia T cells42 or human hepatocellular carcinoma cells.43 In both cases, the 
protein cages functionalized with both targeting ligand and therapeutics were delivered 
exclusively to their target cells, inducing cell death in the majority of those cancer cells without 
affecting any of the control cells.  
By loading the viral capsids with imaging agents, it is possible to follow the localization 
of protein cages within cells. For in vitro studies, optical imaging can be applied with excellent 
resolution: for example, by attaching quantum dots to the exterior of HIV viral capsids, 
individual capsids could be identified and tracked with single molecule imaging.44 Optical 
imaging is less useful for in vivo applications. Viral capsids outfitted with both cancer targeting 
and fluorescent ligands were injected into cancerous rats, and while fluorescence was localized 
to the tumor cells, these cells could only be detected in mammalian tissues to a depth of 500 
μm.45   
More promising for therapeutic imaging in vivo is the encapsulation of positron emission 
tomography (PET) imaging agents or magnetic resonance imaging (MRI) contrast agents within 
protein cages.46 The common PET imaging agent 18F was bioconjugated into viral capsids47 and 
the location of these capsids could be dynamically imaged in vivo.48 Iron oxide nanoparticles, a 
simple and effective MRI contrast agent, could be attached to viral capsids with similar 
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results.49 Incorporation of Gd3+ into the calcium-binding sites of the cowpea chlorotic mosaic 
virus led to a species with the highest relaxivity values measured to date, potentially leading to 
new applications with low-dose MRI contrast agents.50 Superparamagnetic iron oxide or Gd3+ 
nanoparticles can also be incorporated into the ferritin interior, resulting in species with high 
relaxivity values51. Multiple imaging agents can also be implemented in a single protein cage, 
and data obtained from each technique can be correlated for increased resolution.49 
Finally, and most promisingly, assembled viral capsids have a tendency to elicit strong 
immunogenic responses when introduced to a host organism.52 This feature of viral capsids has 
attracted great interest in the field of vaccine development, as the viral capsid shell offers an 
elegant solution to an unsolved issue with current vaccine technology. Most presently-
approved vaccine delivery systems exist as a compromise between effectiveness and safety 
concerns. Since vaccines generate the strongest immune response when multiple copies of an 
immunogenic epitope are presented, prior vaccine delivery systems were based around either 
removing the DNA from a live virus and adding the epitope of interest or adding an adjuvant 
such as aluminum to a vaccine displaying fewer copies of that epitope to multiply the immune 
response. Heterologously-expressed viral capsids offer a delivery system that doesn’t have to 
be studiously scrubbed of viral DNA nor require careful testing to minimize the safety concerns 
associated with adjuvants.53 In contrast, viral capsids are safe, biocompatible, bioavailable, and 
still induce a strong immune response, the only major concern being that the immune response 
must be modulated such that it does not produce any toxic effects to the subject.54,55  Currently 
over a dozen capsid-based vaccines are approved for clinical trials or clinical use, targeting 
Influenza, Hepatitis A & B, HPV, and others.56,57 More interestingly, these have been implicated 
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as suitable targets for therapeutic vaccinations, which create antigens for nonviral diseases, 
such as Alzheimer’s disease and cancer. Capsid protein displaying a 9-amino acid sequence 
from amyloid-β proteins induced an immune response in rats, and prevented some degree of 
amyloid aggregation.58 Similar therapeutic gains have been seen with arthritis and nicotine 
addiction with vaccines targeting cytokine receptors and nicotine receptors, respectively.59,60 
Cancer-targeting vaccines have shown promise as well, the main challenge here is to correctly 
target a tumor-specific antigen, as these may be similar to endogenous proteins. While initial 
results have been very limited in scope, capsid-based vaccines have shown therapeutic effects 
in the treatment of both prostate cancer and melanoma.61,62 
1.3 - Design of de novo Protein Cages 
 
Assembling protein cages de novo from constituent building blocks of choice provides an 
attractive alternative approach to re-purposing existing protein cages. The primary advantage 
of this approach is customizability: one can choose attachment sites that are sensitive to 
environmental conditions and cofactors, such that one can control cage formation and optimize 
it for functional purposes, and we can also control the pore and cavity size of designed protein 
cages. The basic requirements for making a protein cage are deceptively simple: one must have 
two symmetric protein domains connected at the proper dihedral angle (Fig. 1.2a). To form one 
of the three geometries of Euclidean solids, tetrahedral (P332), octahedral (P432), or icosahedral 
(P532), any one of six symmetry pairs can be used (Fig. 1.2b), depending on the symmetry group 
of that Euclidean solid. Each Euclidean solid can be created by combining any two of its three 
symmetry operators, so an icosahedron can be formed with symmetry pairs C3+C2, C5+C2, and 
C5+C3, provided the two symmetry axes are oriented at the proper dihedral angle. In addition to 
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these six, any symmetry pair with a C2 symmetry element has the potential to form prismatic 
geometry. This can be seen with GroEL, a 14-subunit protein cage formed from a C7+C2 
symmetry pair.  
 
Figure 1.2. Assembly of designed fusion protein assemblies. a) Rigidly linking a homodimeric 
protein (green) with a homotrimeric protein (red) will result in different complexes depending 
on the dihedral angle imparted by the rigid linker (blue) (Image adapted from Ref 24). b) Six 
different symmetry pairs of fusion proteins connected at a proper dihedral angle will result in 
the formation of closed Euclidean solids. Additionally, any symmetry pair that includes a C2 
symmetry element can assemble into a prismatic complex (Image credit: Dr. Ben Buer). 
 
 It is important to note that creating a fusion protein with a particular symmetry pair 
doesn’t necessarily encode exclusively its respective Euclidean solid(s), particularly if flexibility 
is introduced to the system. The Euclidean solids, and prismatic geometries, are simply the only 
geometries with regular dihedral angles. If these dihedral angles are malleable, then many 
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more complexes with irregular geometries can be formed (Fig. 1.3). Larger species are possible 
with all sets of symmetry pairs, the only requirement for a stable, closed system is that there 
are no unpaired symmetry elements. Thus, a C3+C2 symmetry pair may only form multiples of 
two trimers, for example, adding one trimer, with each subunit of the trimer being attached to 
a dimerizing unit, to a system of four trimers would yield 15 dimerizing units, making seven 
dimer pairs but leaving one dimerizing unit free to associate with an unpaired dimer on another 
complex. A C3+C3 symmetry pair, which is predicted to only form a tetrahedron if the two 
symmetry elements are rigidly connected at the correct dihedral angle, can associate into 
complexes consisting of any number of trimers if the two symmetry elements are flexibly 
attached, because each additional trimer adds three monomers of a trimerizing unit. If these 
two oligomerization sites are not so flexibly attached that multiple secondary oligomerization 
sites on a single trimer are unable to associate with each other (figure 1.4a), it is possible to 
envision geometrically plausible complexes with at least 4, 6, 7, or 8 trimers (a 5 trimer C3+C3 
complex involves significant subunit torsion (figure 1.4b)). The C3+C4 symmetry pair can 
assemble into any complex with multiples of 4 trimers, shown in figure 1.3 are complexes with 
8, 12, and 16 trimers that can be formed with a flexible fusion protein with a C3+C4 symmetry 
pair.  The specific species formed for each symmetry pair is dependent on the range of allowed 
dihedral angles. For example, the hexamer of trimers of a C3+C3 system  can form a ring with 
the same geometric arrangement as an octahedron but missing two opposing faces, and the 16-
mer of trimers of a C3+C4 system is an icosahedron sans any four trimers that do not touch each 
other. If the dihedral angle of a C3+C3 or a C3+C4 system was that of an octahedron or an 
icosahedron, respectively, the resulting complex should specifically form the hexamer or 16-
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mer of trimers, respectively. On the other hand, forming the heptamer of trimers with a C3+C3 
system involves considerable flexibility in the range of dihedral angles. 
 
Figure 1.3. Examples of possible oligomers that can be formed with fusion proteins utilizing 
various symmetry pairs. Blue triangles represent a trimeric building block protein, fused with a 
second symmetric protein, represented as green dots at either the edges (C2) or vertices (C3 and 
C4) of the blue triangles. These complexes may be porous and/or require a variable dihedral 
angle for formation, but have the proper oligomerization state at every point of attachment. 
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Figure 1.4. Special cases of symmetry pairs.  a) A symmetry pair connected by a long enough 
flexible linker may self-associate at multiple oligomerization sites on the same subunit, 
dramatically reducing the minimum number of subunits necessary to create a closed complex. 
In the most drastic case shown here, a flexibly-linked C3+C3 symmetry pair is stable as a single 
trimer. b) A closed five trimer complex is possible from a C3+C3 symmetry pair, but requires 
significant subunit flexibility. Whereas a six trimer complex can be closed like a ring, a five 
trimer complex must be twisted like a Mobius strip to connect unpaired symmetry elements, 
represented here as blue arrows. 
1.4 - Previously Designed de novo Protein Cages 
The field of de novo designed protein cages is still in its infancy, with 2001 marking the 
first year that a research group described a symmetric fusion protein that oligomerized into a 
homogeneous, closed, supersymmetric assembly. By rigidly combining a dimeric protein 
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domain with a trimeric protein domain at the proper dihedral angle, Padilla and coworkers 
showed that this designed fusion protein self-assembled into a rigid tetrahedron that could 
later be crystallized (Fig. 1.6a).63,64 Critical to this design was that both the C-terminus of the 
trimeric domain and the N-terminus of the dimeric coil were composed of alpha helices, so the 
connector of these two symmetric subunits could be a rigid alpha helix. The geometry of the 
species could therefore be specified by adding residues to this alpha helix connector, twisting 
the dihedral angle by 100° with each additional residue until it reached the necessary dihedral 
angle for oligomerization. When this trimeric subunit was substituted for a dimeric subunit 
(generating a C2+C2 symmetry pair), and the dihedral angle was altered to 180°, the fusion 
protein formed a filament. Multiple extended filaments utilizing a similar C2+C2 geometry have 
since been reported.65,66 Interestingly, adding flexibility to one of these dimer-dimer systems 
with a glycine-rich linker reduces the size of the oligomers formed (Fig 1.5). While the designed 
fusion protein with an additional 2 or 4 flexible residues in the intersubunit linker retained a 
filamentous structure, the addition of 6 residues yielded a tetramer of dimers, while 8 residues 
yielded a trimer of dimers, and 10 residues led to a mixture of trimers of dimers and dimers of 
dimers.67 
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Figure 1.5. A designed C2+C2 symmetry paired protein assembles into filaments with a short 
flexible linker (top) but assembles into smaller oligomers inversely proportional to the length of 
the flexible linker (bottom). Image taken from Ref 27.  
It is also possible to design fusion proteins that associate into lattices, but due to the 
extra spatial dimension that must be aligned, these are trickier to design and characterize. A 
fusion protein was designed with a combined three-fold and two-fold axis oriented at 
approximately 60° to each other, such that the resulting lattice would form a two dimensional 
honeycomb pattern a la Figure 1.2a. Instead, due to the inherent flexibility of proteins, these 
assemblies formed large spherical species approximately 100 nm in diameter, similar in size and 
shape to bacterial microcompartments.68 Recently, due to the availability of robust 
computational modeling software to efficiently design orientations, a 2-dimensional square 
lattice was formed by combining a D4-symmetric aldolase protein with a D2-symmetric 
streptavidin protein at a 90° angle (Fig. 1.6d).69,70 Similarly, a monomeric protein with multiple 
designed dimeric Zn-binding sites at axes in all three dimensions was shown to oligomerize into 
2- and 3-dimensional ordered structures upon addition of zinc, depending on the conditions 
and ratio of zinc/protein used.71 Finally, a crystallography-grade lattice was generated by the 
computational design of exterior sidechains in a homotrimeric coiled-coil, yielding a crystal with 
the infrequently-seen P6 space group.72 
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The design of closed protein nanostructures, on the other hand, has been met with 
significantly more success. For the decade after Padilla and coworkers published their seminal 
2001 paper that jump-started research into the rational design of de novo protein cages, there 
were only two notable systems of closed, spherical protein assemblies. The first was a design by 
the Burkhard group, which combined a pentameric coiled-coil with a trimeric coiled-coil. These 
elements were connected by a flexible linker sequence with a cysteine residue at each end, 
such that oxidative formation of the disulfide bond would lock the dihedral angle between the 
two coils at approximately 37°, the angle required for the formation of an icosahedron (Fig. 
1.6b). At a sufficiently high concentration in oxidative conditions, this protein formed spherical 
complexes with the majority of species being approximately the right size for an icosahedron, 
though this complex was not homogeneous and was not characterized in detail.73 Notably, 
however, this pseudo-icosahedral protein complex showed immunogenic potential: malaria 
coat proteins were added to the ends of these complexes, and when injected into rats induced 
an immune response that lasted for 6 months.74  
The second design was from this laboratory, where trimeric aldolase proteins were 
attached through a flexible linker to one of two peptides designed to form heterodimeric 
antiparallel coiled-coils through complementary electrostatic interactions, one with a strong 
positive charge and the other with a strong negative charge (Fig. 1.6c). Solutions consisting of 
solely positively- or negatively-charged trimeric proteins did not oligomerize further, but when 
mixed together, formed a mixture of complexes with molecular weights expected from a C3+C2 
system – the 6-subunit trigonal prism, 12-subunit tetrahedron, 18-subunit trigonal bipyramid, 
and 24-subunit octahedron, though these geometries could not be specifically identified.75 
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These complexes were catalytically active, indicating that protein cage formation didn’t 
interfere with the subunit’s tertiary structure. A recent study replicated this result with a 
flexibly-linked C3+C2 symmetry pair, substituting the heterodimeric coiled-coil with a 
homodimer and assembling these complexes in vivo.76  
 In 2012, the major breakthrough for designing these de novo protein cages came from 
advances in computational methods. The program Rosetta can rapidly and robustly model 
different docking conformations of protein-protein interfaces, using a built-in scoring function 
that assesses the energetic stability gained from burying hydrophobic surface residues and 
creating hydrogen bonds as well as the destabilizing effects of steric clashes and unfavorable 
Coulombic interactions. Analysis of docked protein interfaces with Rosetta has been used to 
predict the oligomerization state and binding surface of a self-associating protein from its 
crystal structure.77,78 Additionally, new protein-protein interactions can be designed by 
remodeling a docked structure to add in inter-protein hydrogen bonds and hydrophobic 
interfaces.79-81  King and coworkers exploited this technology to design protein cages by 
replicating each of the 271 proteins in the PDB that have C3 symmetry into both tetrahedral and 
octahedral space, and analyzing these assemblies for steric clashes and close contacts at the 
inter-trimer surface (Fig. 1.6e).82 Each trimeric protein was rotated 0.5° 240 times to sample the 
entire set of rotational conformations at a specific radial position that could lead to a 
designable trimer-trimer interface, after which the protein was translated 1 Å radially from the 
center of symmetry and rotational sampling continued, until the trimeric protein could be 
rotated 120° without touching a neighboring symmetry-generated trimer. The 20 trimers that 
were symmetrically docked into conformations with the largest number of surface interactions 
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without any steric clashes were selected for interface redesign, and favorable interactions were 
designed at the trimer-trimer interface. 35 potential mutants were designed from these 20 
proteins with an average of 9 mutations per design, of which 24 expressed as soluble proteins 
and 3 oligomerized into symmetrical assemblies – one into an octahedron and two into 
tetrahedrons. Crystal structures of these assemblies could be determined, and were in close 
agreement with computational models. This approach was further extended to design 
constructs in which a trimeric protein was docked at the faces of a tetrahedron and either a 
dimeric or a trimeric protein was docked at the edges or vertices respectively. The rotational 
and translational space of both of these proteins was sampled, and a heteroprotein interface 
was designed and optimized. This led to the design and crystallographic characterization of six 
tetrahedral complexes with two different geometries.83 The Rosetta framework was further 
exploited (Fig. 1.6f) to design a rigid linker between a trimeric and a dimeric protein in the same 
manner as described above by Padilla et al, but this design, even after the dihedral angle was 
optimized to form an octahedron, instead formed a mix of tetrahedrons, trigonal bipyramids, 
and octahedrons.84,85 
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Figure 1.6. Designed protein cages (left) with their respective TEM characterizations (right). a) A 
rigidly assembled C3+C2 symmetry pair as designed by Padilla et al. assembles into complexes 
with tetrahedral symmetry. Images taken from reference 24. b) A trimeric coiled-coil and a 
pentameric coiled-coil as designed by Raman et al. is connected with a disulfide linker to yield a 
proper dihedral angle and oligomerize into globular complexes with the approximate weight of 
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an icosahedron. Images taken from reference 31. c) A C3+C2 heteroprotein system as designed 
by Patterson et al. consisting of trimers flexibly attached to either positively- or negatively-
charged coiled-coils forms a variety of distinct symmetric structures when mixed together. 
Images taken from reference 33. d) A C4+C2 heteroprotein system as designed by Sinclair et al. 
with a rigid 180° dihedral angle assembles into a regular square lattice. Images taken from 
reference 29. e) A C3 protein with a computationally designed dimeric interface by King et al. 
was assembled into either tetrahedra and octahedra (shown) depending on the angle of 
interface, with well-defined symmetry axes. Images taken from reference 35. f) A rigidly-
connected C3+C2 symmetry pair designed by Lai et al. to connect with the dihedral angle of an 
octahedron instead assembles into both tetrahedra and octahedra. Images taken from 
reference 38. 
1.5 - Project Goals 
 
There is a sizeable and rapidly growing body of work in this nascent field of research, 
but there are still many symmetry pairs that have yet to be explored for their potential to form 
new protein cages. Of the six possible symmetry pairs that can generate Euclidean solids, the 
only two that have yielded robust complexes have been C3+C3 and C3+C2, and these have only 
assembled tetrahedral and octahedral protein complexes. This poses the question: why is it 
that no higher order symmetry pairs have been successfully used to assembly protein cages? Is 
it impossible to form these higher order structures without forming an array of misfolded 
complexes, larger or smaller? Most of the previously characterized cages have focused on 
designing rigid structures that precisely orient symmetry elements to achieve the desired 
geometry, but as the work by Lai et al shows, it may be difficult to separate different oligomers 
should the structure be insufficiently rigid. A more general solution to this problem, one that 
doesn’t involve screening dozens of designed mutants, is desirable. Since rigid cages can only 
be designed with a high degree of computational work, my dissertation was focused on 
producing and characterizing flexibly-attached symmetry elements to determine the oligomeric 
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species that these form. Specifically, my project aimed to produce a designed fusion protein 
that has the following properties: 
1) Contains two crystallographically-verified symmetry sites connected genetically by a 
flexible linker region. 
2) Can be expressed and purified by standard biochemical techniques. 
3) Assembles in vivo into soluble complexes, which can be further purified to yield a single, 
regular, symmetric species as predicted by the symmetries of the two subunits. 
4) Is stable, soluble, and enzymatically active after assembly. 
For the first component, we selected a trimeric esterase protein isolated from 
Pseudomonis putida (PDB ID 1ZOI), as it had several important characteristics. First, this is a 
relatively large protein – the side length of the trimer in the crystal structure is 7 nm, so the 
protein could be readily imaged by TEM. Second, this protein has strategically placed termini. 
The N-terminus is located towards the middle of the ‘face’ of the triangular protein – near the 
subunit inferface. This is well positioned for introducing a 6xHis tag to facilitate purification. The 
N-terminus is as far removed from the secondary oligomerization site as possible, minimizing 
the risk that the His-tag could interfere with protein cage assembly. The C-terminus of this 
esterase is located perpendicular to the C3 axis, near the ‘vertex’ of the triangle formed by the 
three subunits. This is where we will attach a flexible glycine linker, followed by a designed 
coiled-coil as the secondary oligomerization site. These coiled-coils are going to bind together 
multiple bulky trimers, so it’s a sensible idea to put this secondary oligomerization site in as 
sterically unhindered a location as possible. The coiled-coil is chosen as the secondary 
oligomerization site because it is small and unobtrusive, and because it is a well-characterized 
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system with a variety of designed homooligomers ranging from homodimers up to complexes 
of seven alpha helices.86,87 These are an excellent choice to add onto a trimeric building block, 
as we can create 4 of the 6 symmetry pairs discussed earlier (C3+C2, C3+C3, C3+C4, and C3+C5) by 
choosing an appropriate coiled-coil to affix to the trimer. Since the C3+C2 and C3+C3 symmetry 
pairs have already been explored by other groups and are predicted to form multiple 
complexes with similar sizes, we selected the C3+C4 symmetry pair as a potential symmetry pair 
for the goal of forming an octahedron. 
 
Figure 1.7. Assembly strategy for designed protein cages. a) The face (left) and edge (right) of 
the trimeric esterase building block we will be fusing secondary oligomerization sites to. Green 
spheres are the N-termini, where we will fuse a His-tag, and red spheres are the C-termini, 
where we will fuse a flexibly-linked coiled-coil. b) Cartoon of the assembly scheme for the 
octahedral protein cage, with coiled-coil linkers connecting at the C-terminus ‘vertices’ of 
trimeric proteins (Image credit: Ben Buer and Cullen Whitmore). 
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Chapter 2  
 
Purification and Characterization of Designed Protein Constructs 
 
 All designed fusion protein constructs were analyzed by the same set of techniques 
under similar conditions, so in this chapter I will briefly examine the analysis techniques used to 
determine the size and shape of the various complexes formed from each specific fusion 
protein. As an example for each of these techniques, I have expressed, purified, and analyzed 
the trimeric esterase building block that we will be attaching secondary oligomerization sites to. 
The analysis of this trimeric esterase provides an excellent negative control for assaying 
whether a designed fusion protein oligomerizes at all, and an excellent positive control for 
examining the behavior of a homogeneous oligomeric complex. 
2.1 - Preparation of Construct DNA 
 
The gene encoding Oct-1 in pet28b vector was purchased (Genscript) with strategically 
placed restriction sites designed between the trimer and glycine linker (Kpn1), between the 
linker and the coil (Spe1) and after the stop codon (BamHI). All DNA modifying enzymes and 
reagents were purchased from New England Biolabs. A gene that encoded fragments to be 
double digested and subsequently ligated into double-digested Oct-1 to create the trimeric 
esterase and Oct-2 were purchased (IDT Technologies). All subsequent single-stranded and 
complementary DNA fragments with complementary overhangs to the restriction sites in Oct-1 
encoding Oct-3-1, Oct-3-2, Oct-3-3, Oct-4-0, Oct-4-1, and Oct4-2 were purchased from IDT DNA 
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Technologies for annealing and insertion into Oct-1 DNA. Full DNA and protein sequences for all 
constructs discussed within this dissertation can be found in Appendix B. 
The Oct-1 gene was transformed by electroporation into XL1-Blue electrocompetent 
E.coli cells and cells containing plasmids were selected by growing transformed cells on LB agar 
plates in the presence of kanamycin (50 mg/L) at 37 °C overnight. Single colonies were used to 
inoculate 5 mL of sterile LB media with kanamycin and grown at 37 °C overnight, after which 
they were pelleted by centrifugation at 14,000 rpm for 10 min. DNA was extracted from cell 
pellets using QIAprep Spin Miniprep kit and sequenced with the T7 promoter primer at the UM 
Sequencing Core to confirm presence of Oct-1 gene. Oct-1 DNA was double digested using SpeI 
and BamHI for preparation of Oct2 and double digested using KpnI and BamHI for preparation 
of all other constructs. Double digested Oct-1 DNA was gel purified in a 0.5% agarose gel and 
extracted using a QIAquick Gel Extraction Kit.  
 The gene encoding fragments for the trimeric esterase and for Oct-2 was transformed 
and purified as described above. This gene was double digested with KpnI and BamHI to create 
the DNA fragment that was ligated into double digested Oct-1 to create the trimeric esterase, 
and double digested with SpeI and BamHI to create the DNA fragment that was ligated into 
double digested Oct-1 to create Oct-2. Both fragments were purified on a 2% agarose gel and 
extracted using QIAquick Gel Extraction Kit. Reverse complementary sequences of single 
stranded DNA with complementary overhangs to Oct-1 that were contained coil encoding 
sequences for Oct-3-* and Oct-4-* were suspended in equimolar concentrations in 1x DNA 
ligase buffer at 95 °C, and annealed by slowly ramping down to room temperature over a 
period of 10 hours. 
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Double digested and gel purified fragments of vector containing Oct-1 (6 pmol) and DNA 
fragment insert (30 pmol) were mixed in the presence of T4 DNA ligase and supplied buffer 
system to a final volume of 20 μL. 1 μL of ligated DNA was transformed into XL1-Blue 
electrocompetent cells, grown up on kanamycin-containing LB agar plates overnight, and single 
colonies were grown up in 5 mL sterile LB media containing kanamycin overnight at 37 °C. DNA 
was extracted from culture pellets and sequenced as above.  
50 ng of plasmid confirmed to contain genes encoding protein of interest was 
transformed into E.coli strain BL21-DE3, incubated on plates and then 5 ml overnight LB 
cultures as above. 700 μL of LB overnight cultures was added to 300 μL of sterile 50% glycerol 
solution, mixed by pipetting, flash frozen in liquid N2, and stored at -80 °C.  
2.2 - Expression and Purification of Fusion Protein Constructs 
 
5 μL of flash frozen stock of BL21 (DE3) E.coli with plasmid encoding fusion protein of 
interest was added to 5 mL sterile LB media containing 50 mg/L kanamycin and grown up at 37 
°C overnight while shaking at 220 rpm. Cultures were then added to 1 liter sterile 2xYT media 
with kanamycin and incubated at 37 °C while shaking at 200 rpm until the cultures reached an 
OD600 of 0.3, after which the incubation temperature was reduced to 18°C. When the 1 L 
culture reached an OD600 of 0.8-1.0, 10 μL was taken for a pre-induction sample for SDS-PAGE 
analysis and then induced with 10-20 mg IPTG, and protein expression proceeded overnight.  
After 18 hours of protein expression, another 10 μL was taken for a post-induction 
sample for SDS-PAGE analysis, and the remainder was centrifuged at 4 °C and 4500 rpm for 20 
min. 8 g of cell pellet was then resuspended on ice in 40 mL of cold lysis buffer containing 1 M 
urea, 300 mM NaCl, 50 mM HEPES, 50 mM imidazole, and 5% glycerol at pH 7.5, to which was 
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added 40 mg lysozyme, 500 units of benzonase, and one SigmaFAST protease inhibitor tablet. 
After the pellet was fully resuspended, it was lysed by sonication on ice and centrifuged for 30 
minutes at 48,000 g and 4 °C. 10 μL of the supernatant was taken for SDS-PAGE analysis, and 
remaining supernatant is filtered through a 0.2 μM filter and then injected at a rate of 1 mL/min 
onto a 5 mL Ni-NTA agarose column pre-equilibrated at 4 °C with lysis buffer. A 10 μL sample of 
the flowthrough during injection was collected and stored for SDS-PAGE analysis. The 5mL Ni 
column was washed with lysis buffer at 1 mL/min until the OD280 of the flowthrough measured 
less than 30 mAU. Protein was eluted at 0.5 mL/min on a 25 mL gradient to 100% elution buffer 
containing 300 mM NaCl, 50 mM HEPES, 750 mM imidazole and 5% glycerol at pH 7.5. Fractions 
were collected every 1 mL and samples of these fractions were analyzed by SDS-PAGE to 
determine which fractions contained His-tagged protein and/or impurities. As a general rule, 
fractions 7-12 contained some His-tagged protein and some impurities, while fractions 13-25 
contained pure His-tagged protein. Fractions containing mainly the protein of interest were 
pooled together, to which was added 500 units of benzonase to remove any transiently bound 
DNA, and dialyzed at 4 °C several times against dialysis buffer containing 100 mM NaCl, 25 mM 
HEPES, and 2 mM EDTA at pH 7.5. 
After several days, dialyzed, Ni-purified protein was centrifuged to remove precipitate 
and the absorption at 280 and 260 nm was measured to determine transiently-bound DNA 
contamination. If the sample has an A260/280 ratio above 1, additional benzonase is added and 
dialysis continues until this ratio is below 1. For all proteins except for the trimeric esterase, the 
protein sample is concentrated at 4 °C with an Amicon-15 100 kDa cutoff spin concentrator at 
3,000 g – with the trimeric esterase a 30 kDa cutoff must be used – until a final volume is 
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reached of 1-1.5mL. To avoid unwanted precipitation due to concentration gradients formed 
during centrifugation, the sample must be mixed via pipetting every five minutes. Concentrated 
protein is centrifuged to remove precipitate and stored at 4 °C for further analysis and size 
exclusion purification. 
2.3 - SDS-PAGE 
 
 For protein complexes that may oligomerize into multiple species, SDS-PAGE is a critical 
first step in analysis. Certain natural oligomeric proteins may co-purify with the designed fusion 
protein, and interfere with the size distribution analyses. The most common protein that will 
co-purify is the free esterase, formed if the secondary oligomerization site is proteolyzed during 
induction or cell lysis, and which may still have a His-tag, with which it can bind to the nickel 
column and co-elute. The second is GroEL, a protein with a monomeric molecular mass of 57 
kDa, but an oligomeric mass of 804 kDa. This is in the range expected for octahedral complexes 
of the trimeric esterase, and will be co-purified with these complexes during a size exclusion 
preparation, if not removed during initial Ni purification. The presence of both of these 
contaminating proteins can be discerned by denaturing gel electrophoresis, making SDS-PAGE 
of Ni-affinity or size exclusion fractions a crucial tool for optimizing purification conditions. 
Protein samples of interest are electrophoresed on a 12% polyacrylamide gel (BIO-RAD) at 200 
V in denaturing conditions. Protein ladder, purified trimeric esterase, and/or GroEL are included 
as standards. SEC-purified esterase trimer, with a monomeric molecular weight of 32.3 kDa, can 
be visualized as a single band on an SDS-PAGE gel between 25 and 37 kDa (Figure 2.1). 
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Figure 2.1. Purification of the esterase trimer assayed by SDS-PAGE.  a) 10% polyacrylamide gel. 
Lanes 1 and 2: pre- and post-induction samples. Lane 3: supernatant after cell lysis and 
centrifugation. Lane 4: Ni-purified trimeric esterase. b) 12% polyacrylamide gel. Lane 1: protein 
ladder, lane 2: SEC-purified trimeric esterase. 
2.4 - Size Exclusion Chromatography 
 
Size Exclusion Chromatography was a quick and efficient method to examine the 
oligomerization states of the various protein designs, and was used on both an analytical and a 
preparatory scale. For both applications, we used a Superose 6 10/300 column at 4°C 
equilibrated with 1 column volume (25 mL) of dialysis buffer with a flow rate of 0.4 mL/min. For 
analytical purposes, 100 μL of clarified sample is injected onto the column, while for 
preparation, 500 μL of clarified sample is injected, and 0.5 ml fractions are collected starting 
from 5.25 ml. The void volume of this column is   ̴7.5 mL, and the column is calibrated by 
protein molecular weight standards ferritin (440 kDa) and GroEL (804 kDa), which, when 
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injected on the column have elution profiles with peaks around 13.8 mL and 12.0 mL, 
respectively. Fractions collected from preparatory size exclusion purifications can be analyzed 
by SDS-PAGE, native PAGE, or by rechromatography on the Superose 6 column. Fractions 
containing oligomeric species of interest are pooled, concentrated with spin concentrators with 
an appropriate molecular weight cutoff, centrifuged to remove precipitate, and then stored at 
4°C for further analysis. The SEC-purified esterase trimer elutes as a single, sharp peak at 
16.5mL (Figure 2.2). 
 
Figure 2.2. SEC molecular weight standards  GroEL (804 kDa, purple) and ferritin (440 kDa, pink) 
elute at 12.0 mL and 13.8 mL respectively on a Superose 6 10/300 column. Unmodified trimeric 
esterase (96 kDa, black dashed) elutes at 16.5 mL. To reduce clutter, future SEC elution profiles 
of designed fusion proteins will denote the elution volumes of GroEL and ferritin standards by 
purple and pink vertical dashed lines. 
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2.5 - Native PAGE 
 
 Native PAGE proved to be an excellent technique to assay the range of oligomeric 
species in a sample using a very small amount of protein at a wide variety of concentrations. 
Only 10 μL of a protein sample at a concentration of 0.05-2 mg/ml is required to visualize bands 
corresponding to oligomerization states, and the resolution for this technique is significantly 
improved compared to size exclusion chromatography. Native PAGE electrophoresis separates 
species based on the size of the protein complex and its total charge; for different oligomers of 
the same protein building block the total charge varies minimally and so it provides an excellent 
tool for determining the number of different oligomers formed as well as their relative 
concentrations. Approximate size of these species can also be determined by comparing them 
to known protein standards, but as these protein standards have different shapes and charges 
than the protein of interest, a direct size comparison based on band mobility is impossible. 
Native PAGE can also be used to determine if a species is interconverting between two 
oligomerization states. If two species interconvert during the timeframe of the gel being run, 
the bands corresponding to each of those two species will be smeared towards the other. If this 
interconversion is rapid, it may not be possible to distinguish individual bands, instead 
appearing as a smear in between the two species. 
 Native PAGE was run with 3-8% Tris-Acetate polyacrylamide gels in Tris-Glycine buffer at 
pH 8.4 and 4 °C at a constant current of 70-80 V for 16-20 h. 6x native PAGE buffer (50% 
glycerol, 0.01% bromophenol blue) was added to all samples prior to electrophoresis. We used 
the two previously-described molecular weight standards ferritin and GroEL as standard 
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markers, and under these conditions the major band for ferritin migrates with an Rf of around 
0.8 and the GroEL migrates with an Rf of around 0.5, meaning we get significant resolution in 
the critical area between the two, where we would expect to find the smaller oligomeric 
species – tetramers, hexamers, and octamers of trimers. In cases where the fusion protein 
oligomerizes into a species smaller than a tetramer, the native gel was run for 24 hours at 20 V, 
or until the dye front reaches the bottom of the gel. SEC-purified trimeric esterase runs as a 
single band located slightly above the dye front, and considerably below standard proteins 
GroEL and ferritin (Figure 2.3). 
 
Figure 2.3. Native PAGE of trimeric esterase with standards. Lane 1 is the trimeric esterase, 
with a native molecular weight of 96 kDa. Lane 2 is protein standards GroEL (804 kDa, top 
arrow) and ferritin (440 kDa, bottom arrow). 
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2.6 - Analytical Ultracentrifugation 
 
A powerful tool to determine the oligomerization state of designed fusion proteins is 
sediment velocity-analytical ultracentrifugation (SV-AUC), which centrifuges the sample of 
interest at high speeds and tracks the migration of molecules either by changes in absorption or 
refractive index as they sediment radially in a specialized rotor. The sedimentation of solute 
molecules is described by the Svedberg equation below, where u is the radial velocity of a 
solute molecule, ω is the angular velocity, and r is the radial position of the solute, and where 
M is the molar mass, v is the partial specific volume of the solute, ρ is the density of the solvent, 
NA is Avogadro’s number, and f is the frictional ratio. The left hand of the Svedberg equation is 
experimentally obtained, while the right hand must be solved by using known features of the 
system. The Svedberg (S) is the most common unit of measurement for sedimentation 
coefficients and is defined as 10-13 sec.1  
𝑠 =
𝑢
𝜔2𝑟
=  
𝑀(1 − ?̅?𝜌)
𝑁𝐴𝑓
 
Since we are analyzing the behavior of various oligomers of the same protein, the partial 
specific volume will always be a constant, as will the solvent density. This leaves the 
relationship s  ̴ M/f, meaning that heavier species will sediment faster, and species with a high 
frictional coefficient will sediment slower. The frictional coefficient, defined as f/f0, is the ratio 
between the observed f-value and the f-value of a perfect sphere, as defined by the equation   
f0 = 6πɳR0, where ɳ is the solution viscosity and R0 is the radius of the theoretical spherical 
protein. Monomeric, spherical proteins generally have a frictional ratio slightly higher than 1 
due to their hydration shell, while elongated or hollow protein complexes have higher frictional 
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ratios. The pyruvate dehydrogenase complex, for example, with its hollow interior for trapping 
unstable intermediates, has a frictional ratio of 2.5.2 Highly elongated species, such as collagen 
or chromosomal DNA, have frictional ratios around 3-4. 
 
Figure 2.4. Analytical ultracentrifugation.  a) Schematic of a typical ultracentrifuge. b) A single 
scan from an ultracentrifugation experiment. Important regions are labeled. c) Four successive 
scans of an ultracentrifugation cuvette. The sedimentation coefficient can be determined by 
measuring the velocity of the boundary midpoint. Images adapted from 
http://www.bioc.rice.edu/bios576/AU/AU_Page.html and 
https://www.mun.ca/biology/scarr/Analytical_Ultracentrifugation.html 
 
Prior to advances in computation power, sedimentation coefficients were measured by 
tracking the boundary midpoint over time. Nowadays, software is able to take advantage of the 
wealth of data generated from a single run and model the underlying Lamm equation. The 
simplest, and least computationally demanding software for this task is sedfit, which applies a 
universal frictional ratio to all species in the sample, allowing a direct correlation of different 
sedimentation coefficients with molecular masses.3 The frictional ratio parameter can be 
automatically optimized to minimize the r.m.s.d. but if multiple species in a sample have 
different frictional ratios, the optimized ratio will be a weighted average of all species. This is a 
major problem for a solute containing species with widely varying frictional ratios, as elongated 
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species will be reported to have artificially high molecular masses, and vice versa for globular 
species. Nevertheless, sedfit allows a reasonable estimation of the number, distribution, and 
molecular masses of the species in a sample. Using sedfit, the sedimentation profiles for the 
trimeric esterase and GroEL were calculated. The trimeric esterase sediments as a single species 
with a sedimentation coefficient of 3.8 S and a fitted frictional ratio of 1.25 (Figure 2.6). This 
yields a calculated molecular mass of 102 kDa, reasonably close to the expected mass of 96.9 
kDa. The sedimentation profile of GroEL shows two species with sedimentation coefficients 1.8 
and 14.3 S, most likely correlating to the monomer subunit and the fully assembled complex, 
respectively. Using a published frictional ratio for GroEL of 1.3,4 this larger species has a 
calculated mass of 788 kDa, also in close agreement with the expected molecular mass of 804 
kDa. 
A more powerful tool for deconvoluting sedimentation data is Ultrascan, which 
separately calculates molecular weights and frictional coefficients for each sedimenting 
species.5 This method requires significantly more computational power, and data must be 
submitted to supercomputer clusters for multiple rounds of Monte-Carlo analysis. 
Nevertheless, this method affords the highest resolution possible and gives definitive 
determinations of both size and shape for all species in a heterogeneous sample. Ultrascan 
analysis of the trimeric esterase (Figure 2.8) revealed a single, sharply-defined species with a 
sedimentation coefficient of 5.6 and a frictional ratio of 1.23, but a calculated molecular weight 
of 83.9 kDa, which is less accurate than the molecular weight calculated by sedfit. This may 
indicate the presence of an unmodeled monomer-trimer equilibrium, but it may also reveal an 
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essential drawback of relying on calculating a frictional ratio to derive molecular masses by 
AUC. 
Analytical ultracentrifugation was performed on protein samples using a Beckman 
Proteome Lab XL-I analytical ultracentrifuge (Beckman Coulter, Indianapolis, IN) equipped with 
an AN60TI rotor.  The hydrodynamic behavior of the various proteins was analyzed at a protein 
concentration corresponding to an OD280 of 0.2. 450 μL of each protein sample was loaded into 
pre-cooled standard sector-shaped, 2-channel Epon centerpieces with 1.2 cm path-length, and 
allowed to equilibrate at 6 °C for 2 h in the non-spinning rotor prior to sedimentation.  Proteins 
were sedimented at 36,000 rpm.  Absorbance data were collected at a wavelength of 280 nm.  
Sedimentation velocity data were initially analyzed by sedfit using a continuous c(s) distribution 
and a resolution of 250, fitting the frictional ratio with a simulated annealing algorithm. 
Selected samples of interest were further analyzed by 2-dimensional sedimentation spectrum 
analysis (2-DSA) using the finite element modeling module provided with the Ultrascan III 
software (http:/www.ultrascan.uthscsa.edu).  Confidence levels for statistics were derived from 
2-DSA data refinement using a genetic algorithm followed by 50 Monte Carlo simulations.   
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Figure 2.5. Raw AUC data for a) GroEL, and b) unmodified trimeric esterase. Violet traces 
represent the first scans, red traces represent the final scans. 
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Figure 2.6. Sedimentation profiles of trimeric esterase and GroEL, analyzed by sedfit. GroEL 
(purple) sediments as both monomeric (57 kDa) and tetradecameric (804 kDa) species. The 
trimeric esterase (96 kDa, black dashed) sediments as a single species. 
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Tri-Est s20,w M.W. (kDa) 
((K(kDa) 
f/f0 Conc. % 
Species 1 5.67 ± 0.004 83.9 ± 0.9 1.23 ± 0.01 95.0% 
Figure 2.7. Ultrascan analysis of the trimeric esterase. The trimeric esterase could be identified 
as a single species by both 1D (a) and 2D (b) analytical methods, but the mass accuracy could 
not be improved over the lower resolution sedfit analysis. 
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2.7 - Transmission Electron Microscopy   
Although analytical ultracentrifugation proves to be a powerful tool for determining the 
oligomerization states of protein assemblies, it gives only limited insight into the geometry of 
these species. Using Transmission electron microscopy (TEM) it is possible to directly identify 
the distribution of size and shape of individual oligomers in a sample, and with a high enough 
resolution, identify their geometry as well. Preliminary investigations of sample proteins were 
conducted using negative-stain TEM. Samples of interest were diluted to 0.02 mg/mL and 
adsorbed on a glow-discharged Formvar 400 carbon grid using conventional negative staining 
procedures. Imaging was performed at room temperature with a Morgagni 268(D) transmission 
electron microscope (FEI Company) equipped with a tungsten filament operated at an 
acceleration voltage of 100 kV and a mounted Orius SC200W CCD camera (Gatan Inc.). Negative 
stain TEM images of the trimeric esterase show a homogeneous sampling of triangular species 
with edge lengths of 5-7 nm, in close agreement with lengths derived from the crystal structure 
(Figure 2.7). 
If a protein sample is deemed oligomerically homogeneous by other methods, higher 
resolution images can be attained with cryo-TEM , where adsorbed particles are flash frozen in 
liquid ethane to preserve them in their native state, as the dehydration that is a consequence of 
negative staining may perturb the protein cage’s structure. This, as well as the small B-factors 
from the low temperatures maintained throughout imaging, allows significantly more regular 
images to be obtained, which can be selected and then averaged to generate a series of 
reference-free class averages that, with enough averaged particles, should represent all the 
unique arrangements of the protein complex that can be viewed from the top-down. The 
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electron density of selected class averages can be reconstructed in 3-dimensional space and the 
resolution improved by applying the known symmetry of the particle and by modeling in the 
known crystal structure of that particle or a similar complex.  
For Oct-4-4, 3 μL of a protein sample concentrated to an OD280 of 0.5 was adsorbed onto 
a glow-discharged Quantifoil grid (R2/2 200 mesh) and vitrified using a Vitrobot (FEI Mark IV). 
The sample was imaged on a Tecnai TF20 transmission electron microscope (FEI) equipped with 
a field emission electron gun operated at 200 kV. Images were recorded at a magnification of 
41667x on a Gatan K2 Summit camera, and binned (2 x 2 pixels) resulting in a pixel size of 4.4 Å 
on the specimen level. All the images were acquired using low-dose procedure to minimize 
radiation damages to the samples, with a defocus value in the range of 2 - 4 μm. 
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Figure 2.8. Negative stain transmission electron microscopy of trimeric esterase.  Esterase is 
visually identifiable as possessing C3 trimeric symmetry, with approximate side length of 7 nm. 
Scale bar is 20 nm. 
2.8 - Ion Mobility-Mass Spectrometry 
 
This technique can theoretically yield the highest resolution for the molecular masses of 
protein complexes, but is also the newest and poses its own unique challenges. Mass 
spectrometry has been successfully applied to native protein complexes in the gas phase for 
over two decades. More recently, it was discovered that a weak electric field, if applied to 
native protein complexes in the gas phase, induced an additional separating effect. Similar to 
native PAGE, these slightly positively-charged complexes pass through the electric field at a rate 
proportional to their collisional cross-section, which can not only be used to distinguish several 
species with similar masses for proteomic applications, but can also be used to probe protein 
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structure, dissociation, and unfolding pathways. Recently, this technique was successfully 
applied to other protein cages, identifying the molecular masses of a C3+C2 system and 
obtaining accurate masses for the mixture of 12-subunit tetrahedron, 18-subunit trigonal 
bipyramid, and 24-subunit octahedron.6 This has interesting applications for our use, both in 
confirming the oligomerization state of protein complexes and in describing the shape of these 
complexes. The primary concern with analysis of proteins by IM-MS is that the buffer 
conditions must be complete free of sodium ions, which in the case of large protein complexes 
with many ionic groups can be difficult to achieve.  
To achieve higher resolving powers, all proteins submitted to MS analysis were purified 
in dialysis buffer with 100 mM ammonium acetate replacing sodium chloride, buffered with 
acetic acid and ammonium hydroxide, then buffer exchanged into buffer containing only 100 
mM ammonium acetate before ionization. When purifying large protein complexes for MS 
analysis, ammonium acetate was substituted for sodium chloride in all buffers used in 
purification: lysis, elution, and dialysis. Ammonium acetate is used in place of sodium chloride 
because both counterions are volatile, and as such are removed during the transition to the gas 
phase. Samples prepared for mass spectrometry were purified as described above and then 
concentrated to 40 μL. The minimum concentration of protein required for analysis is 1 μM, 
with higher concentrations preferred. Sample were then loaded into gold plated needles 
prepared in house according to 7. Nano-electrospray-ion-mobility-TOF mass spectrometry was 
performed using a Synapt G2 Traveling-Wave IM-MS instrument (Waters Corp, Manchester, 
U.K.). Ions were generated by applying a voltage of 1.5kV between the needle and the 
instrument source, with further voltage drops aiding in acceleration and desolvation as ions 
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passed through the skimmer region of the instrument. The quadrupole region was set to RF-
only mode for collection of complete mass spectra, and in some cases was tuned to isolate 
selected peaks for MS/MS analysis. A range of collision energies were tested for enhanced 
transmission and desolvation of the ions, and in some cases dissociation of the ion into its 
component subunits. The base values for collision energies were 20-50 V, however energies up 
to 150 V were utilized for dissociation experiments. The IMS region of the instrument was 
operated at 4mBar of nitrogen, with wave heights and wave velocities of 15 V and 150 m/s, 
respectively. The instrument time of flight mass analyzer was operated in sensitivity mode, and 
mass spectra were collected from 1000 to 15000 m/z. Data analysis was performed using the 
manufacturer-provided Masslynx software.  
IM-MS analysis of the unmodified trimeric esterase shows one major species with m/z 
peaks between 4,000 and 5,000 (Figure 2.8). These calculate to a molecular mass of 97.7 kDa, 
the most accurate mass of all the aforementioned techniques. The positive correlation between 
m/z and drift time indicates that this species retains its folded structure throughout analysis. 
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Figure 2.9. Native IM-MS of trimeric esterase.  a) 2-D plot showing separation of m/z and drift 
time, in logarithmic scale. Species with lower charge states have a higher collisional cross 
section, which correlates to a higher drift time. b) 1-D plot of m/z, in linear scale. The major 
species has a molecular weight of 97.7 kDa, very close to the calculated molecular weight of 
96.9 kDa. 
2.9 - Conclusions  
 
 In this chapter I have surveyed a wide range of experimental techniques that can gauge 
size and/or shape of various protein complexes. These techniques differ in resolution and 
sample prep complexity and as such will be applied to analysis of designed fusion protein 
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complexes in roughly the order presented in this chapter. Using the trimeric esterase building 
block as a control protein, I showed that this suite of techniques as described above can 
accurately and complementarily identify the structure and oligomerization state of a protein 
complex. In this case, these techniques confirmed that the native esterase exists stably as a 
trimer with C3 symmetry, and does not oligomerize further at the concentrations tested. These 
attributes make it an excellent building block for future investigations. 
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Chapter 3  
 
Initial attempts at protein cage design 
 
In keeping with a design philosophy that constrains as few parameters as possible, the 
initial fusion protein was designed using only basic geometric considerations. A previous 
student working on this project used a dimeric, antiparallel coiled-coil connected to the trimeric 
building block with a short flexible linker to assemble a mixture of cage-like structures.1 For our 
system, we plan to use tetrameric, rather than dimeric coils, as well as coils oriented in a 
parallel, rather than antiparallel orientation, both of which orient the attached esterase 
subunits in close proximity to each other. We therefore ensured that steric hindrance between 
symmetric subunits would not be a concern by attaching a 12-residue linker containing 10 
glycines to the C-terminus of the trimeric esterase. This was followed by a 7-heptad coiled-coil 
sequence that contained phenylalanine residues at all but one of the a and d positions on the 
coiled-coil heptad repeat, and which had previously been crystallographically verified to 
associate into a parallel tetramer. 
3.1 - Oligomerization of Coiled-Coils  
 
Since this project employs coiled-coil motifs as a fundamental symmetric building block, 
it is worthwhile to engage in a brief overview of the theory behind coiled-coil assembly and 
prediction of their oligomerization states, as this plays a critical part in this project as well as for 
future research aims and protein cage functionalization. The alpha helix is the most common 
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protein secondary structure and is highly regular, with every residue twisting the helix by 100°. 
This means that every seven residues the helix will have completed slightly under two turns, 
and the sidechain of the eighth residue will be oriented in the same direction as the first 
residue. Therefore, a common way to represent the packing of alpha helix sequences is by 
breaking down the sequence into heptad repeats, denoted by letters a-g. When two or more 
alpha helices are placed next to each other, creating a coiled-coil, residues at the a and d 
positions of each alpha helix will be in closest proximity to each other, as shown in Figure 3.1. 
These residues are usually hydrophobic, such that they pack with a ‘knobs into holes’ design, 
although polar contacts and salt bridges have also been observed at these interior positions. 
Consequently, the other five residues in the heptad repeat tend to be hydrophilic to minimize 
disruption of this hydrophobic pocket. Also of note are the e and g positions (and in higher 
oligomerization states, the b and c positions) in the heptad repeat, which, although usually 
hydrophilic, interact with e and g residues on neighboring alpha helices, allowing for Coulombic 
interactions and hydrogen bonding to further determine specificity and increase the enthalpy 
of assembly.2  
While this associative behavior has been known to exist in coiled-coils since the 1950’s3 
and the heptad repeat pattern was discovered in 19724, the relationship between the 
hydrophobic packing region and the oligomerization state was not elucidated until 1993, when 
Harbury and coworkers discovered that the organization of the hydrophobic residues leucine, 
isoleucine, and valine in the a and d positions heavily influenced the oligomerization state of 
the coiled-coil.5 Particularly, they found that a dimeric coil could be specified by using residues 
of isoleucine and leucine at the a and d positions respectively, a trimeric coil could be specified 
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with a,d = I,I, and a tetrameric coil could be specified with a,d = L,I. Higher oligomerization 
states can also be directed by mutating in hydrophobic residues at the e and g positions.2  
Furthermore, orientation of the coiled-coil systems could be specified by controlling the 
identity of the e and g positions.6 In a parallel orientation, e residues pack next to neighboring g 
residues, while in an antiparallel orientation, e residues pack next to neighboring e residues, 
and g residues pack next to neighboring g residues. Therefore, to specify a parallel orientation 
with a dimeric coil, one simply makes the e and the g residues two amino acids with opposing 
charges, and to specify an antiparallel orientation, one makes two separate helices, one with all 
negatively-charged residues at the e and g positions, and the other with all positively-charged 
residues at those positions.7 It is also possible to specify a homodimeric antiparallel coiled-coil 
by making the e and g positions on the N-terminal half of the coil negatively-charged, but 
positively-charged on the C-terminal half of the coil.8   
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Figure 3.1. Spatial placement of the members of the heptad repeat in different coiled-coil 
systems, taken from Ref. 8. A) A parallel dimeric coiled-coil. B) An antiparallel dimeric coiled-
coil. C) A parallel trimeric coiled-coil. D) A parallel tetrameric coiled-coil. E) Parallel coiled-coils 
pack all a and all d residues next to a and d residues on neighboring alpha helices. F) 
Antiparallel coiled-coils pack a residues next to d residues on neighboring alpha helices. 
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Considerable research since then has gone into determining the oligomerization states 
of various natural and de novo designed coiled-coil systems,9 and for the purposes of this 
project, any parallel tetrameric coiled-coil would suffice. We therefore initially chose a de novo-
designed coiled-coil tetramer based upon a membrane-bound trimeric coiled-coil system found 
in E.coli. Liu et al. found that if the a and d interior residues of this trimeric coil were replaced 
entirely by phenylalanine residues, the coiled-coil would form a pentamer with a spiral packing 
motif (Figure 3.2).10 If, however, a central phenylalanine residue is mutated into a methionine, 
this spiral motif is disrupted and instead oligomerizes as a tetrameric coiled-coil with a more 
classical knobs-into-holes arrangement. It is this tetrameric coiled-coil that was added into Oct-
1 (Figure 3.3). This coiled-coil has one other unusual property: its thermal midpoint of unfolding 
(Tm), at 54 °C, is much lower than can be expected from a seven-heptad coil. For a comparison, 
the four-heptad tetramer coiled-coil described by Harbury has a Tm of over 100 °C. This low Tm 
indicates that the coiled-coil system is not tightly associated and may be in equilibrium with the 
monomer, which could be either a good or bad thing for the successful oligomerization of an 
octahedron. A loosely-associating coil would be good if these oligomerizing proteins have a 
tendency to become kinetically trapped into higher order oligomers, as it would slowly re-
associate into the entropically preferable octahedral complex. If the coil is too loose, however, 
it could lead to the octahedron breaking apart, and if enough proto-octahedron complexes 
assemble together, it can lead to aggregation rendering the complexes insoluble, meaning we 
should see this complex slowly falling out of solution over time. 
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Figure 3.2. Crystal structures of the tetrameric coiled-coil motif inserted into Oct-1 and the 
pentameric coiled-coil that it is based on. The pentameric coil (bottom, PDB ID 2GUS) has 
phenylalanines at every a and d position and packs with a spiral motif, whereas the tetrameric 
coil (top, PDB ID 2GUV) has a single methionine at the d position that breaks this spiral motif in 
favor of a knobs-into-holes arrangement. 
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Figure 3.3. Schematic of the design of fusion protein Oct-1.  The 6xHis tag is at the N-terminus. 
Residues at the a and d positions on the coiled-coil are bolded. 
3.2 - Characterization of Oct-1 
 
 Oct-1 was successfully transformed, expressed, and purified as described in Chapter 2. 
Oct-1 yielded around 25 mg/L protein after Ni purification with modest (  ̴90%) purity, and could 
be size exclusion purified to remove all other visible protein contaminants (Figure 3.4). 
 
Figure 3.4. SDS-PAGE purification of Oct-1. Lane 1: protein standards ladder. Lane 2: trimeric 
esterase. Lane 3: supernatant. Lane 4: flowthrough. Lane 5: Ni-purified Oct-1. Lane 6: SEC-
purified Oct-1. 
3.2.1 - Size Exclusion Chromatography of Oct-1 
 
Size exclusion profiles of Oct-1 one day after Ni purification shows the protein forms a 
broad range of oligomers larger than the unmodified esterase trimer. Sizeable amounts of 
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these oligomers appear in the void volume, indicating that these are complexes that are too 
large to interact with the column matrix ( >5 MDa, for the Superose 6 beads). The profile of the 
same sample after 1 week in 4 °C shows a similarly broad range of species, but all with a much 
lower absorbance. After two weeks, however, the size exclusion profile shows something 
markedly different: nothing soluble remains in the void volume, and a single, broad peak is left 
at 15.4 ml – slightly larger than the absorbance of the trimeric esterase (Figure 3.5). 
 
Figure 3.5. Size exclusion profiles of Ni-purified Oct-1 after 1 day of storage at 4 °C (black), 5 
days (red), and 2 weeks (blue). Elution profile of trimeric esterase is indicated as black dashed 
line. Elution volumes of standard proteins GroEL (purple, 804 kDa) and ferritin (pink, 440 kDa) 
are denoted by vertical dashed lines. 
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Figure 3.6. SEC purification of Oct-1. a) Elution profile of Oct-1 with fractions at bottom. b) 
Native PAGE of Ni-purified Oct-1 with corresponding purification fractions from (a). Ladder lane 
consists of GroEL (top band) and ferritin (bottom band). 
 
This Ni-purified Oct-1 sample was then concentrated and purified using a preparatory 
Superose 6 column, and fractions were collected (Figure 3.6). Native PAGE of concentrated, Ni-
purified Oct-1 shows at least 8 distinct bands with a wide range of molecular weights and 
smearing in between them, indicating that there is interconversion between different species 
during electrophoresis. This could be from gaining or losing oligomers, or it could be from 
interconversion from a compact to an extended state. Native PAGE analysis of column fractions 
taken from the SEC purification of Oct-1 and stored at 4 °C for several hours shows that a broad 
range of bands can be observed in all fractions, indicating that Oct-1 rapidly interconverts 
between different species.  
As indicated in figure 3.6, fractions 18-22 were pooled and analyzed by both SEC and 
AUC. The size exclusion profile of this Oct-1 preparation has an expected broad band with a 
peak at 15.6 ml, near where the trimeric esterase elutes (Figure 3.7). SEC analysis of this same 
61 
 
fraction after 2 weeks at 4 °C shows a similar, slightly broadened elution profile indicating that 
this distribution of oligomers is fairly stable in solution. 
 
Figure 3.7. Size exclusion elution profiles of Ni-purified Oct-1 (blue), SEC-purified Oct-1 after 1 
day of storage at 4 °C (black), and SEC-purified Oct-1 after 2 weeks of storage at 4 °C (red). In 
comparison to Figure 3.5, SEC-purified Oct-1 appears to be much more stable. Trimeric esterase 
is indicated as black dashed line. 
3.2.2 - Analytical Ultracentrifugation of Oct-1 
 
Analysis of the sedimentation velocity analytical ultracentrifugation profile of SEC-
purified Oct-1 depicts a mixture of sedimenting species (Figure 3.9). Using the program ‘sedfit’ 
to fit the sedimentation data, we can resolve three major species with sedimentation 
coefficients of 4.5, 7.1, and 10.7 S. Using the fitted frictional ratio of 1.48, these species 
correspond roughly to molecular masses of 177, 349, and 642 kDa, which represent complexes 
of approximately two (225 kDa), four (450 kDa), and six (675 kDa) trimers of Oct-1 respectively. 
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Several smaller peaks corresponding to larger complexes can also be observed. More 
concerningly, there is a small side peak corresponding roughly to the s-value of the trimer, 
indicating that the coil on Oct-1 does in fact associate weakly and spontaneously dissociates. 
Obviously, this is a poor attribute when one is trying to design a system of associating trimers. 
 
Figure 3.8. Raw sedimentation velocity data for Oct-1.  Violet traces represent the first scan, 
Red traces represent the final scan. 
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Figure 3.9. Sedimentation profile of Oct-1 after SEC purification (red). Sedimentation profiles of 
standard proteins GroEL (804 kDa, purple) and esterase trimer (96 kDa, black dashed) are 
included. 
3.2.3 - Transmission Electron Microscopy of Oct-1 
 
Negative-stain TEM images of SEC-purified (F18-F22) Oct-1 show a variety of small 
oligomers of trimers with no discernable pattern to oligomerization or geometry (Figure 3.10a). 
TEM images of the void volume fraction of Oct-1 purified in salt- and urea-free buffers show 
much larger species, some with the proper geometry of an octahedron and roughly 8 trimers, 
but most particles are larger than expected for an octahedral cage (b).  
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Figure 3.10. Negative stain TEM of Oct-1 after purification in 100 mM NaCl (a), and 0mM NaCl 
(b). Scale bars are 20 nm. 
3.3 - Insertion of a More Stable Coiled-Coil and Design of Oct-2  
Oct-1 seems to exist in a multitude of interconverting oligomeric states, many of which 
are unstable over time. It is a reasonable assumption that the weakly-associating tetrameric coil 
was the cause of this behavior. To test this hypothesis, we replaced the coiled-coil on Oct-1 
with one based on the tetrameric coiled-coil sequences designed by Fletcher et al, which has a 
thermal midpoint of unfolding of over 100 °C.11 Inadvertently, an error was introduced into this 
coiled-coil design that was not realized until a thorough characterization was undertaken. 
Instead of the canonical a,d = L,I interior hydrophobic packing sequence that yields a parallel 
tetrameric coiled-coil, we inserted a sequence with a,d = L,L, known to form an antiparallel 
trimeric coiled-coil12, but with single residue modifications can be turned into either a dimeric 
or a trimeric parallel coiled-coil, suggesting oligomerization is highly context dependent.5,13,14 
Regardless of whether this coil oligomerizes into a dimer, a trimer, or possibly both, having a 
strongly-bound coiled-coil system should mean the protein building blocks, when formed into 
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stable oligomers, will be less likely to dissociate and become insoluble aggregates over time. 
However, because of the long length of their linkers compared to the length of the base 
esterase trimer, there exists the possibility that these coils may associate with other coils on the 
same trimer, leading to the creation of a stable monomer or other small aggregates. The 
second generation of this fusion protein system, consisting of the trimeric esterase connected 
via a 12 residue linker to a 4 heptad a,d = L,L coiled-coil, was termed Oct-2. 
  
66 
 
 
 
 
Figure 3.11. Crystal structures of the parallel, tetrameric motif that was supposed to be 
inserted to replace the coil in Oct-1, and the antiparallel, trimeric motif that was inserted into 
Oct-2. The tetrameric motif (top, PDB ID 3R4A) has leucine residues (brown) at the a positions 
and isoleucine residues (purple) at the d positions, while the trimeric coil (bottom, PDB ID 
1COS)  has leucine residues at both a and d positions. Tryptophan residues (teal) at the N-
terminus of each strand of the trimeric coil are highlighted to illustrate the antiparallel 
orientation of the coiled-coil. 
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Figure 3.12. Schematic of the design of fusion protein Oct-2. The 12 residue linker was retained, 
while the coiled-coil in Oct-1 was swapped for a coiled-coil with leucine residues at the a and d 
positions. The amino acid sequence encoding the coiled-coil contains minor mutations at the e, 
f, and g positions to accommodate restriction sites added to the DNA, but will henceforth be 
abbreviated to the heptad repeat. 
 3.3.1 - Characterization of Oct-2 
 
 Plasmid containing Oct-2 was successfully transformed into competent E.coli cells and 
expressed by standard methods. Oct-2 expressed as a soluble protein in yields of around 10 
mg/L after Ni purification, and a protein of a similar size to Oct-1 could be identified as one of 
the major bands in SDS-PAGE (Figure 3.13). When this impure protein is analyzed by size 
exclusion chromatography, the resulting elution profile is unexpected: the major peaks all elute 
significantly later than the unmodified esterase trimer (Figure 3.14). This implies that if this 
impure protein mixture contains Oct-2 at all, then the vast majority of Oct-2 doesn’t even 
oligomerize into a trimer.  There is a very small, broad peak that appears to elute at a similar 
volume to the unmodified esterase trimer, but this fraction could not be purified in sufficient 
quantity to analyze. Native PAGE of Ni-purified Oct-2 shows a single band of protein at the dye 
front, and several faint bands around standard proteins ferritin and GroEL (Figure 3.15).  
Transmission electron microscopy of nickel-purified Oct-2 confirmed the presence of small 
assemblies consisting of 2-5 trimers, but these seem to associate in an arbitrary manner with no 
discernable geometry (Figure 3.16). As with Oct-1, there are also a number of unassociated 
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trimeric species present, but from a raw particle count from the TEM micrographs, the relative 
concentration of unassociated trimeric species in Oct-2 appears much higher. 
 
Figure 3.13. SDS-PAGE of Oct-2 purification. Lane 1: ladder. Lane 2: trimeric esterase. Lane 3: 
Oct-1. Lanes 4 and 5: Oct-2 before and after induction. Lanes 6 and 7: Oct-2 supernatant after 
lysis and flowthrough after injection on Ni column. Lane 8: concentrated, Ni-purified Oct-2. 
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Figure 3.14. Size exclusion chromatography of Oct-2.  Ni-purified Oct-2 (solid black) elutes 
noticeably later than the unmodified trimeric esterase (black dashed). Molecular weight 
standards GroEL (804 kDa) and ferritin (440 kDa) are purple and pink vertical lines, respectively. 
 
Figure 3.15. Native PAGE of Oct-2.  Lane 1: protein standards ferritin and GroEL. Lane 2: 
unmodified esterase trimer. Lane 3: Ni-purified Oct-2. 
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Figure 3.16. Negative stain TEM of Oct-2 shows a heterogeneous mixture of small complexes 
and unassociated trimers. Scale bar is 20nm. 
3.4 - Conclusions 
 
The ultimate goal of this project is to design protein constructs that efficiently assemble 
into larger, regular complexes in a symmetry-controlled manner. Using the series of 
characterization techniques described in Chapter 2, I have analyzed two designed fusion 
proteins. These fusion proteins comprise three parts: the trimeric esterase building block, the 
flexible linker, and the oligomerizing coiled-coil. The first construct, Oct-1, had a 12-residue 
linker attaching the trimeric esterase to a weakly-associating tetrameric coiled-coil. Oct-1 
purified in fairly high yields as a broad range of species but over a period of weeks re-associated 
into both aggregate and various small oligomers, with the majority of stable species having 
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masses corresponding to 2, 4, and 6 trimers. The second construct, Oct-2, retains this long 
glycine-rich linker but had a more strongly-associating coiled-coil that could plausibly 
oligomerize into either a dimer or a trimer, depending on environmental conditions. This 
construct could not be purified in either high yields or high purity, but small, arbitrarily-
associating complexes of trimers were visible in TEM images.  
The conclusion from the characterization of these two initial constructs is that neither of 
them oligomerized as intended, regardless of the symmetries of their appended coiled-coil. This 
indicates that the problem doesn’t lie with the identity of the coiled-coil, but rather with one of 
the other two parts of the fusion protein. Our focus, therefore, turned toward optimization of 
the flexible linker sequence. 
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Chapter 4  
 
Optimization of Linker Length and Purification of Oct-3 
4.1 - Optimization of Linker Length 
 
In the previous chapter I examined two fusion protein constructs consisting of a trimeric 
esterase bound by a 12 residue glycine-rich linker to one of two coiled-coils: a weakly-
associating tetrameric coiled coil and a strongly-associating coiled-coil that may be either 
dimeric or trimeric. Both of these constructs formed a heterogeneous mixture of complexes, 
the majority of which were smaller than an octahedron. This suggests the possibility that 
multiple coils on a single trimer may be associating with each other, which would dramatically 
lower the number of trimers necessary to create a closed system in which every coil 
oligomerizes correctly. Therefore, we undertook an effort to minimize the glycine linker length 
and observe the effects on oligomerization.  
 A rough calculation indicates that a twelve residue linker is sufficiently long to bridge 
the gap between two C-termini of the esterase (Figure 4.1). To prevent trimer self-association, 
the length of the linker needs to be less than half of the distance between two C-termini. While 
it would be possible to systematically decrease the linker length until a suitable length is 
determined, it is far easier, and in line with the this project’s goals of designing as few 
constructs as possible, to approach this problem computationally and model the approximate 
minimal distance it would take to bridge the two symmetric subunits when assembled into an 
octahedron. As noted in Chapter 1, this type of modeling has already been applied with 
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significant success by the Yeates and Baker labs to generate crystallographically-verified 
complexes of tetrahedrons and octahedrons.1-3  
We collaborated with Neil King in the Baker lab to use Rosetta to generate a model 
containing the trimeric and tetrameric subunits replicated at their respective locations in 
octahedral space, similar in design to Ref. 1. Crystal structures of these subunits were each 
independently rotated and radially translated by 0.5° and 1 Å, discarding all models with steric 
clashes, as defined by having 2 backbone atoms from separate subunits within 4 Å of one 
another (Figure 4.2). We then collected the distance between the C-terminus of the trimeric 
esterase and the N-terminus of the tetrameric coiled-coil of every model without steric clashes, 
and the 20 models with the lowest interterminus distance were saved as coordinates files. The 
interterminus distances of these models ranged from 9.1 to 17 Å. As an amino acid generally 
spans around 3.5 Å, this implies the gap between subunits could be bridged by a minimum of 3 
residues.  
4.2 - Design of Oct-3 Constructs 
 
Based on this modeling, we designed three new fusion proteins constructs of the 
trimeric esterase fused with the coil in Oct-2 by three different lengths of linkers consisting of 3, 
4, and 5 residues long. Although the residue that would add the most degrees of freedom to 
the fusion protein is glycine, the restriction site that was added to Oct-1 to allow for genetic 
modification encodes for a glycine and a threonine. Therefore, the three linkers we created had 
amino acid sequences: Esterase-GTG-Coil, Esterase-GTGG-Coil, and Esterase-GTGGG-Coil, which 
we termed Oct-3-3, Oct-3-4, and Oct-3-5, the second number referring to the length of the 
glycine-rich linker (Figure 4.3). While linkers with a threonine in them will have lower flexibility 
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due to the restricted range of Ramachandran angles compared to glycine, this may prove not to 
matter too much in practice. A more central concern is that the linker disrupts the alpha helices 
at the C-terminus of the esterase and the N-terminus of the coil, which would lower the 
effective length of adjacent residues in the linker. Since there are glycines bracketing the 
threonine in these designed linkers, the threonine’s presence should not be a confounding 
factor. Optimizing this linker sequence may be a potential avenue of further research. 
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Figure 4.1. Potential problems with a long flexible linker. a) A C3+C3 symmetry pair with a long 
enough linker can stably self-assemble into a single trimer. b) A model of a single trimeric 
subunit of Oct-1. The length of the 12 residue linker from Oct-1 and Oct-2 is roughly equivalent 
to the length from one C-terminus on an esterase subunit to another, indicating that some 
degree of trimer self-association is likely occurring in previous constructs. 
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Figure 4.2. Symmetry-constrained model of minimum interterminus distances. a) Crystal 
structures of the trimeric esterase (blue) and tetrameric coil (green) were oriented along their 
individual symmetry axes. Each symmetry element was independently rotated and then radially 
translated, after which they were replicated to octahedral space. Models without steric 
hindrance had the interterminus distances measured. Two models, one with the coils on the 
inside (b) and one with the coils on the outside (c) both had the minimum interterminus 
distance of 9.1 Å. 
78 
 
However, the coil implemented in Oct-3 is not a tetramer-forming coil but rather a coil 
that may form either a dimer or a trimer, or potentially both. This means there will be fewer 
trimers crowded around a single coiled-coil, so we can anticipate that the minimum linker 
length to prevent steric effects will be shorter than the model predicted. Since the C-terminus 
of the esterase is located perpendicular to its C3 axis, structures with a larger dihedral angle 
such as tetrahedrons and trigonal prisms may still be sterically precluded from forming.  
 
Figure 4.3. Design of the three Oct-3 fusion proteins.  The 6xHis-tag is located at the N-
terminus. Bolded residues represent oligomerization-determining a and d positions. 
4.3 - Purification of Oct-3 Constructs  
All three Oct-3 proteins could be transformed and expressed by methods previously 
discussed. Ni-affinity purification yielded 1-3 mg of impure protein for each construct, and all 
other protein contaminants detectable by SDS-PAGE could be removed by size exclusion 
chromatography (Figure 4.4). Size exclusion chromatography of the Ni-purified constructs 
showed that all three constructs had well-defined peaks eluted near molecular weight 
standards GroEL and ferritin, indicating that these constructs are forming small complexes of 
trimers. While there are also peaks in the Ni-purified samples that correspond to smaller 
complexes and larger complexes, these peaks are minor and distinct from the peaks of interest, 
and can be removed by SEC purification. After SEC purification, all Oct-3 complexes are stable in 
solution at 4 °C for months, and purified complexes do not re-oligomerize into larger or smaller 
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species. This is in direct contrast to the behavior exhibited by Oct-1, where a SEC column 
fraction re-oligomerizes into a broad range of complexes just hours after purification. 
 
Figure 4.4. SDS-PAGE analysis of Oct-3 constructs.  Lane 1: ladder. Lane 2: trimeric esterase. 
Lane 3: Oct-1 after SEC purification. Lanes 4, 5: Oct-3-3 after Ni and SEC purification, 
respectively. Lanes 6, 7: Oct-3-4 after Ni and SEC purification, respectively. Lanes 8, 9: Oct-3-5 
after Ni and SEC purification, respectively. 
4.4 - Size Exclusion Chromatography and Native PAGE of Oct-3 Constructs 
 
 Size exclusion chromatography analysis of SEC-purified Oct-3 complexes shows that Oct-
3-4 and Oct-3-5 have very similar elution profiles, both with fairly sharp peaks and elution 
volumes of 12.7 and 12.5 ml, respectively (Figure 4.8). SEC-purified Oct-3-3 elutes with a 
comparatively broader peak with an elution volume of 11.85 ml and a shoulder peak at 13.5 ml. 
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None of these constructs exhibit absorbance in the range expected for a free trimer, which is a 
promising sign.  
Native PAGE offers a higher resolution window into the relative concentration and sizes 
of each of the complexes formed by the three Oct-3 constructs. Correlative with the results 
from size exclusion chromatography, Oct-3-4 and Oct-3-5 appear to comprise the same three 
distinct complexes that are barely resolved (Figure 4.9). The relative concentration of these 
three bands differs between constructs, however. In Oct-3-4, the band correlating to the 
smallest species appears to be the highest relative concentration, whereas in Oct-3-5 the 
reverse is apparent. The native PAGE of Oct-3-3, on the other hand, shows a much broader 
distribution of complex size. The lowest band in Oct-3-3, which migrates with the same Rf as the 
lowest band in Oct-3-4 and Oct-3-5, also appears to be in the highest concentration. This is 
interesting, because the SEC elution profile of Oct-3-3 indicates that in sum the larger species 
are more prevalent. The lack of smearing in all three constructs additionally shows that there is 
very little interconversion between different complexes, confirming that these species are well-
formed and thermodynamically stable. 
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Figure 4.5. Size exclusion profiles of Ni- and SEC-purified Oct-3-3. The two side peaks present in 
Ni-purified Oct-3-3 are removed after size exclusion purification. Standard proteins GroEL (804 
kDa, purple dashed) and ferritin (440 kDa, pink dashed) are marked.  
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Figure 4.6. Size exclusion profiles of Ni- and SEC-purified Oct-3-4. The two side peaks present in 
Ni-purified Oct-3-4 are removed after size exclusion purification. Standard proteins GroEL (804 
kDa, purple dashed) and ferritin (440 kDa, pink dashed) are marked. 
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Figure 4.7. Size exclusion profiles of Ni- and SEC-purified Oct-3-5.  The two side peaks present in 
Ni-purified Oct-3-5 are removed after size exclusion purification. Standard proteins GroEL (804 
kDa, purple dashed) and ferritin (440 kDa, pink dashed) are marked. 
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Figure 4.8. SEC profiles of Oct-3 constructs after SEC purification. Oct-3-4  (blue) and Oct-3-5 
(green) assemble into complexes with a similar size. Oct-3-3 (red) assembles into species with a 
wider range of sizes. None of these constructs form complexes with sizes close to the 
unmodified trimeric esterase (black dashed). Elution volumes of standard proteins GroEL (804 
kDa, purple dashed) and ferritin (440 kDa, pink dashed) are marked. 
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Figure 4.9. Native PAGE of SEC-purified Oct-3 complexes.  Lane 1: Ladder comprised of standard 
proteins GroEL (top band) and ferritin (bottom). Lanes 2, 3, and 4: SEC-purified Oct-3-3, Oct-3-4, 
and Oct-3-5, respectively. All three constructs show multiple complexes in the region expected 
for a tetrahedron or an octahedron, with Oct-3-4 and Oct-3-5 behaving similarly, and Oct-3-3 
having a comparatively broader range of complexes formed. 
4.5 - Analytical Ultracentrifugation of Oct-3 Constructs 
 
For a closer look at the individual complexes formed from each construct, SEC-purified 
samples of Oct-3 complexes were analyzed by analytical ultracentrifugation. Sedfit analysis of 
SV-AUC data collected from SEC-purified Oct-3 constructs revealed a distribution of complexes 
that correlated well with native PAGE (Figure 4.11). Oct-3-3 exists as an assortment of 
complexes with a broad range of s-values from 9.8 to 25, with the most prevalent species also 
being the smallest. Using a fitted frictional ratio of 1.29, this species at 9.8 S has a molecular 
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weight of 476 kDa, around the expected mass of a tetrahedron. A peak at 9.8 S is also found to 
a lesser degree in Oct-3-4 and possibly Oct-3-5, matching with results from the native gel. In 
Oct-3-4 there appear to be three major species with similar concentrations and a tight 
distribution of s-values from 9.8 to 12.8. This species with an s-value of 12.8 is also the only 
major peak in Oct-3-5. Fitting the frictional ratio for the Oct-3-5 dataset yields a frictional ratio 
of 1.5; using this value we can calculate a molecular weight of 860 kDa for the major species at 
12.8 S, very close to the expected molecular mass of an octahedron. However, it should be 
noted that these are fitted according to a least-squares algorithm, and may not reflect true 
molecular weights. For example, if the frictional ratio is 1.3, the species with an s-value of 12.8 
would have a molecular weight of 675 kDa, or approximately six trimers. In theory, it follows 
that if a globular species is hollow, like is expected from a well-formed symmetrical protein 
cage, the size of the hollow interior should grow faster than the molecular mass. As such, it 
makes sense that larger well-formed protein cages would have higher frictional ratios. We can 
use this relation to identify large complexes with a low (near unity) frictional ratio as being 
misfolded and collapsed, but it is of little use to validate the frictional ratios and molecular 
masses of specific peaks.  
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Figure 4.10. Raw sedimentation velocity-AUC data for Oct-3-3 (a), Oct-3-4 (b), and Oct-3-5 (c). 
Violet traces represent the first scan, Red traces represent the final scan. 
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Figure 4.11. Sedimentation traces of Oct-3 constructs analyzed with sedfit. Oct-3-3 (red), Oct-3-
4 (blue), and Oct-3-5 (green) each have multiple peaks with a distribution that correlates to 
native PAGE analysis. The major peaks for all three fusion proteins are between the s-values of 
the unmodified trimer (black dashed) and GroEL (purple dashed). 
4.6 - 2-Dimensional Sedimentation Analysis of Oct-3-4   
In an attempt to gain a fuller understanding of the characteristics of specific complexes 
formed by these three constructs, we analyzed the sedimentation data from the Oct-3-4 
construct with Ultrascan. Analysis of the data from Oct-3-4 by Ultrascan dropped the r.m.s.d. of 
the fit from 0.12 to 0.027, a dramatic increase in resolution (Figure 4.12). Five distinct species 
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were isolated in total, three major and two minor species. The two minor species have 
molecular weights of 281 and 786 kDa, and in total account for a tenth of the total 
concentration. Both of these species have frictional ratios near 1, indicating that these species 
are collapsed and do not maintain a hollow interior. The three major species exist in similar 
concentrations and have s20,w-values of 14.08, 17.1, and 20.02, with frictional ratios between 
1.63 and 1.51, indicating that these species are either elongated or have a hollow interior. 
These three species calculate to molecular weights of 510, 633, and 783 kDa, fairly close to the 
molecular masses expected from species of five (537 kDa), six (645 kDa), and seven (752 kDa) 
trimers. Conspicuously absent from this analysis is the 4-trimer tetrahedron, which likely 
indicates that none of these linkers are sufficiently long to overcome the steric hindrance of 
forming a tetrahedron. The presence of a 5-trimer species is also a curiosity, as even with a 
C3+C3 symmetry pair, this species requires extremely flexible geometry to place every alpha 
helix into a trimeric coiled-coil (see Figure 1.4b). This points to the a,d = L,L alpha helix used in 
Oct-3 being either stable as an unbound monomer or stable as a dimeric coiled-coil, while 
primarily oligomerizing as a trimeric coiled-coil. Both cases are viewed as possible outcomes, 
but due to the amphiphilic nature of the coil, it is more likely that this coil dimerizes than exists 
as a random-coil monomer.  
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Oct-3-4 s20,w M.W. (kDa)  f/f0 Conc. % 
Species 1 3.31 ± 0.08 281 ± 14 1.00 ± 0.01 3.7% 
Species 2 14.08 ± 0.04 510 ± 23 1.63 ± 0.05 23.5% 
Species 3 17.1 ± 0.04 633 ± 19 1.55 ± 0.03 35.5% 
Species 4 20.02 ± 0.03 783 ± 10 1.51 ± 0.02 30.6% 
Species 5 29.5 ± 0.07 786 ± 16 1.04 ± 0.02 6.4% 
Figure 4.12. 2D-sedimentation analysis of Oct-3-4 by Ultrascan. Three major and two minor 
species were isolated, the characteristics of which are tabulated above. Species 2, 3, and 4 
correspond to well-formed, hollow complexes with molecular masses consistent with those 
predicted for 5, 6, and 7 trimers, while species 5 corresponds to a complex of 7 trimers that is 
misformed and lacks a hollow interior. 
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4.7 - Transmission Electron Microscopy of Oct-3-4 
 
 Finally, negative stain TEM images were collected for SEC-purified Oct-3-4. These 
showed a heterogeneous mixture of mostly globular structures around 15-25 nm in diameter 
(Figure 4.13). In some of these structures, there is an apparent C3 axis, while in other structures, 
single trimers appear to be attached to the complex only at the vertex of a single trimer, with 
the other two oligomerizing vertices are exposed to solution. The presence of these exposed 
single trimers may indicate that the coil attached to Oct-3 is stable as a monomer in solution, 
but could also be caused by the protein cages collapsing upon exposure to negative stain.  
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Figure 4.13. Transmission electron micrographs of Oct-3-4. Observed particles have sizes 
ranging from 15-25 nm in diameter and are mainly globular. Geometry on most species is 
indistinct, but with several cases a C3 symmetry axis is apparent. Several complexes (red circles) 
appear to have an isolated trimer attached at only one or two vertices. Scale bar is 20 nm. 
 
4.8 - Conclusions 
 
Following up on the work done in Chapter 3 where two trimer-coil systems with 15 
residue linkers were shown to inadequately oligomerize, I designed in collaboration a modeling 
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algorithm of the octahedron that minimized the distances between the termini of the two 
oligomerizing groups without steric clashes. This model yielded a minimum interterminus 
distance of 9.1 Å, which was used to design fusion proteins with 3, 4, and 5 residues in their 
linkers. These fusion proteins all oligomerized into multiple complexes in the size range 
expected for an octahedron, and while aggregates were present, there were no detectable free 
trimers in any of the samples. Complexes in the appropriate size range could be isolated by size 
exclusion chromatography, and after purification each fusion protein contained at least 3 
distinct species. Analytical ultracentrifugation identified the smallest complex formed by all 
three fusion proteins as a species consisting of 5 trimers, which theoretically requires a highly 
flexible system. Since this system is designed with low flexibility, this points to the possibility of 
the coiled-coil in Oct-3 oligomerizing into multiple oligomerization states. While this may be 
worth looking into in more detail, such a line of research is outside of the scope of this project, 
and so the next chapter will explore the effects of replacing the a,d = L,L coil with the 
crystallographically verified tetrameric coil where the a and d positions on the heptad repeat 
are comprised of leucine and isoleucine, respectively. 
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Chapter 5  
 
Purification of Oct-4 and Visualization of the Octahedron 
5.1 - Design of Oct-4 Constructs 
 
Following the realization that instead of the intended, crystallographically verified 
tetrameric coiled-coil, we had accidentally attached to the trimeric esterase a coiled-coil that 
may exist as a mixture of dimers and trimers, we redesigned the DNA insert to replace all four 
leucine residues at the d positions in the coiled-coil heptad with isoleucines. We designed three 
constructs, with 2, 3, and 4 residues in the linker, as it had occurred to us that it would be 
interesting to investigate the effect of making a fusion protein construct with a linker that was 
shorter than the predicted minimum inter-terminus distance. These constructs had the linker 
sequences: Esterase-GT-Coil, Esterase-GTG-Coil, and Esterase-GTGG-Coil, and were named Oct-
4-2, Oct-4-3, and Oct-4-4, respectively (Figure 5.1). As noted in section 4.1, the linker sequence 
of Oct-4-2 may have an intrinsic problem:  there is no glycine separating the threonine residue 
in the linker from the coiled-coil, so this threonine residue may adopt an alpha helical 
conformation. This would reduce both the effective length of the linker and potentially the 
range of allowable dihedral angles between the two oligomerizing subunits. However, Oct-4-2 
is designed to not oligomerize correctly, as the two residues in its linker would not be long 
enough in any conformation to bridge the theoretical minimum inter-terminus distance. 
Therefore, regardless of the degree of lost flexibility in the threonine, Oct-4-2 should be 
expected to oligomerize in an irregular pattern. 
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Figure 5.1. Design of the three Oct-4 fusion protein constructs. The 6xHis-tag is located at the 
N-terminus. Bolded residues represent oligomerization-determining a and d positions. 
5.2 - Expression and Purification of Oct-4 Constructs 
 
All three Oct-4 constructs could be transformed and expressed by methods described in 
Chapter 2. After lysis and centrifugation, Oct-4-2 and Oct-4-4 were found primarily in the 
insoluble fraction, but 1-3 mg/L of soluble fusion protein could be isolated after Ni-affinity 
purification. In contrast, only a miniscule amount of Oct-4-3 was present in the cell supernatant 
after lysis and centrifugation, and yields from Ni-affinity purification were not high enough to 
further purify by size exclusion. This is an unexpected result, and currently there is no definitive 
explanation for this behavior. Further purification of Oct-4-2 and Oct-4-4 by size exclusion 
chromatography removed all remaining protein impurities detectable by SDS-PAGE (Figure 5.2). 
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Figure 5.2. SDS-PAGE of Oct-4 constructs. Lane 1: ladder. Lane 2: trimeric esterase. Lane 3: 
GroEL. Lane 4: Oct-4-2 after Ni purification. Lane 5: Oct-4-3 after Ni purification. Lane 6: Oct-4-4 
after Ni purification. Lane 7: Oct-4-4 after SEC purification. 
5.3 - Size Exclusion Chromatography and Native PAGE of Oct-4 Constructs 
 
After nickel affinity purification, the SEC elution profiles of the three Oct-4 constructs 
display features similar to the elution profiles of the Oct-3 constructs: a peak in roughly the 
same region as the Oct-3 constructs and molecular weight standards GroEL and ferritin, 
bracketed by a peak in the void volume and a peak that elutes later than the unmodified 
trimeric esterase (Figure 5.3). Size exclusion purification of both Oct-4-2 and Oct-4-4 was able 
to remove both of these contaminant peaks. Oct-4-3 and Oct-4-4 have similar elution profiles 
and run identically on a native PAGE, the only difference being the reduced yield of Oct-4-3. 
This elution profile is characterized by a sharp peak at 12.1 ml, with the front of the peak being 
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broader than the tail (Figure 5.5). This is promising, as it indicates a sharp lower bound for the 
size of the complexes formed. It is also the sharpest peak of any of the constructs purified thus 
far. Oct-4-2, on the other hand, has a broader peak centered around 10.5-11 ml (Figure 5.4). 
Both sides of this peak are equally broad, indicating that Oct-4-2 forms a range of complexes 
with minor species that are both smaller and larger than the major species. Native PAGE of the 
Oct-4 complexes confirms these observations (Figure 5.6). Oct-4-2 electrophoreses as at least 
five distinct major bands with a number of minor bands also present, both smaller and larger 
than the major bands. All of these bands, excepting a few minor species, have a much lower R f 
than standard protein GroEL. Oct-4-3 and Oct-4-4 have electrophoresis profiles similar to Oct-3-
3: the band with the highest intensity is also the smallest species on the gel, with 4-5 minor 
bands corresponding to larger species. The major species in Oct-4-3 and Oct-4-4 has a slightly 
lower Rf than GroEL, which is also promising as the octahedron is expected to be slightly heavier 
than GroEL. Since the major species in Oct-4-4 is also the smallest, we attempted to selectively 
purify this species by collecting and combining fractions from the tail end of the size exclusion 
peak. 
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Figure 5.3. Elution profiles of Ni-purified Oct-4 constructs. Oct-4-2 (red) elutes as a broader 
range of larger species, while Oct-4-3 (blue) and Oct-4-4 (green) have similar elution profiles. 
None of the Oct-4 constructs show a peak at the elution volume of the unmodified trimeric 
esterase (black dashed). Elution volumes of standard proteins GroEL (804 kDa, purple dashed) 
and ferritin (440 kDa, pink dashed) are marked. 
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Figure 5.4. Elution profile of Oct-4-2 after Ni purification (dotted red) and SEC purification (solid 
red). The two side peaks present in Ni-purified Oct-4-2 are removed after size exclusion 
purification. Elution volumes of standard proteins GroEL (804 kDa, purple dashed) and ferritin 
(440 kDa, pink dashed) are marked. 
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Figure 5.5.  Elution profile of Oct-4-4 after Ni purification (dotted green) and SEC purification 
(solid green). The two side peaks present in Ni-purified Oct-4-4 are removed after size exclusion 
purification. Elution volumes of standard proteins GroEL (804 kDa, purple dashed) and ferritin 
(440 kDa, pink dashed) are marked. 
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Figure 5.6. Native PAGE of Oct-4 constructs. Lane 1: standard proteins GroEL (top, 804 kDa) and 
ferritin (bottom, 440 kDa). Lane 2: Ni-purified Oct-4-2. Lane 3: Ni-puriifed Oct-4-3. Lane 4: Ni-
purified Oct-4-4. Lane 5: SEC-purified Oct-4-4. Careful SEC purification can remove the majority 
of oligomeric impurities. 
 
Ni-purified Oct-4-2 and Oct-4-4 were chromatographed on the Superose 6 size exclusion 
column and fractions were collected every 0.5 ml. These fractions were then analyzed on both 
the size exclusion column1 and native PAGE the following day. As indicated in Figure 5.8, SEC 
fractions of Oct-4-2 rechromatographed as broad peaks roughly centered around the fraction 
                                                     
1
 Note: The rechromatography experiments described in the next two paragraphs were done on a Superose 6 
column with a larger bed volume, thus the elution volume for all samples is slightly higher than previously 
described. 
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they were taken from: fraction 9, taken from 9.25-9.75 ml, has a peak centered at 10.1 ml; 
fraction 12, taken from 10.75-11.25 ml, has a peak centered at 11.0ml; fraction 15, taken from 
12.25-12.75 ml, has a peak centered around 11.5 ml. Native PAGE of these SEC fractions 
confirms that multiple species were found in all fractions, although some degree of oligomeric 
purification can be attained – the smallest complexes are not found in the earliest fractions, 
and the largest complexes are not found in the latest fractions (Figure 5.8b). These complexes 
are only somewhat stable – after a day, the peak of fraction 9 has a higher elution volume than 
the fraction it was taken from, while the peak of fraction 15 has a lower elution volume than 
the fraction it was taken from. This indicates that the larger complexes isolated in fraction 9 and 
the smaller complexes isolated in fraction 15 are re-equilibrating to the broad range of 
complexes seen in the Ni-purified Oct-4-2, in a manner analogous to the behavior seen in SEC-
purified Oct-1 (see Figure 3.7), although on a slower timescale. Taken together, these data 
suggest that Oct-4-2 forms a mixture of semistable complexes in continual equilibrium with 
each other, which is the behavior predicted for a fusion protein that is sterically precluded from 
forming a stable complex because of a linker that is too short. 
In contrast, analysis of the SEC fractions of Ni-purified Oct-4-4 paints a much rosier 
picture (Figure 5.9). While fraction 13, taken from 11.25-11.75 ml, eluted at 11.8 ml, and 
fraction 14, taken from 11.75-12.25 ml, eluted at 12.3 ml, fractions 15, 16, and 17, taken from 
12.25-12.75 ml, 12.75-13.25 ml, and 13.25-13.75 ml respectively, all eluted at 12.5 ml. 
Additionally, native PAGE shows only one visible band in fractions 16 and 17. When these 
fractions were concentrated, the native PAGE of the resulting concentrate shows one very 
sharp band with two minor bands above it (Figure 5.6 - Lane 5), and this species is stable at 4 °C 
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for months. Further characterization is necessary to determine if this isolated single species of 
Oct-4-4 with what appears to be the correct size for an octahedron, is actually the 8-trimer 
octahedron.  
 
Figure 5.7. Analysis of fractions of the SEC purification of Oct-4-2.  a) Re-chromatography of SEC 
fractions from Oct-4-2. Three 0.5 ml fractions from Ni-purified Oct-4-2 (black) were re-
chromatographed on Superose 6 column. All three fractions had elution volumes close to 
where they were collected, but all were shifted towards the elution volume of the Ni-purified 
Oct-4-2, indicating that re-equilibriation had occurred. b) Native PAGE of SEC purification 
fragments from Oct-4-2. Lane 1: standard proteins GroEL (top, 804 kDa) and ferritin (bottom, 
440 kDa). Lane 2: SEC-purified Oct-4-4. Lane 3: Ni-purified Oct-4-2. Lane 4: SEC fraction 6 of Oct-
4-2. Lanes 5-14: SEC fractions 8-17 of Oct-4-2. 
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Figure 5.8. Analysis of fractions of the SEC purification of Oct-4-4. a) SEC fractions from Ni-
purified Oct-4-4 (black) were re-run on a Superose 6 column. Fractions 15, 16, and 17 all had 
the same elution volume, indicating that the major species in Ni-purified Oct-4-4 is also the 
smallest. b) Native PAGE of SEC purification fractions from Oct-4-4. Lane 1: protein standards 
GroEL (top, 804 kDa) and ferritin (bottom, 440 kDa). Lane 2: Ni-purified Oct-4-4. Lanes 3-9: SEC 
fractions 11-17 of Oct-4-4. 
5.4 - Analytical Ultracentrifugation of Oct-4 Constructs 
 
 The major species isolated from Oct-4-4 was further analyzed by sedimentation velocity 
analytical ultracentrifugation (Figure 5.10). Using the program sedfit, we could identify two 
distinct species, the first having a sedimentation coefficient of 11.9 and comprising 74% of the 
sedimenting species, the second with a sedimentation coefficient of 15.2 and comprising 18% 
of the sedimenting species. Using a fitted frictional ratio of 1.37, this species at 11.9 S 
corresponds to a molecular weight of 645 kDa, or roughly six trimers. However, it should be 
noted that the r.m.s.d. of the sedimentation analysis using this fitted frictional ratio (0.00270) is 
only marginally better than the r.m.s.d. of the sedimentation analysis where f/f0 = 1.70 
(0.00273), which correlates to a molecular weight of 890 kDa, much closer to the expected 
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molecular weight of the octahedron. The latter frictional ratio would also be consistent with the 
hypothesis proposed in the previous chapter, that hollow protein cages should increase in 
frictional ratio as their size increases. 
The Oct-4-2 construct was also analyzed by SV-AUC, with results that matched well with 
native PAGE, and with a good r.m.s.d. of 0.0026.  Analysis by sedfit identifies (at least) five 
distinct peaks with sedimentation coefficients of 16.7, 21.1, 25.8, 29.4, and 32.5 S. The peaks at 
21.1, 25.8, and 29.4 S are well-defined and correspond to relative concentrations of 22%, 32%, 
and 20%, respectively. Fitting the frictional ratio via the Marquis-Levenburg algorithm resulted 
in an impossible frictional ratio of 0.69, so for a rough molecular weight calculation we used a 
frictional ratio of 1. This yields molecular weights of 943, 1260, and 1560 kDa for each of the 
major species, which roughly corresponds to complexes of 10-16 trimers if the assumed 
frictional ratio is accurate. Given the degree of uncertainty that still remains from the sedfit 
analysis of the Oct-4 complexes, we turned to Ultrascan for a more detailed analysis of both 
constructs. 
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Figure 5.9. Raw SV-AUC data  for SEC-purified Oct-4-2 (a) and Oct-4-4 (b). Violet traces 
represent the first scan, red traces represent the final scan. 
 
Figure 5.10. Sedimentation traces of Oct-4 constructs analyzed with sedfit.  Oct-4-2 (red) has at 
least four distinct peaks with sedimentation coefficients larger than GroEL (purple dashed). Oct-
4-4 (green) has one major peak and one minor peak with sedimentation coefficients near 
GroEL. Neither fusion protein has a species that sediments near the unmodified trimeric 
esterase (black dashed). 
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5.5 - 2-Dimensional Sedimentation Analysis 
 
Both the Oct-4-2 and Oct-4-4 data were analyzed by the program Ultrascan, which 
yielded detailed 2-dimensional sedimentation plots for each construct. Six distinct species in 
Oct-4-2 could be identified, all with frictional ratios approaching 1 (Figure 5.11). These species 
had s20,w coefficients of 24.8, 31.5, 38.0, 43.5, 49.8, and 57.3 S, which calculated to molecular 
weights of 650, 905, 1120, 1357, 1681, and 2113 kDa respectively, and relative concentrations 
of 2.2%, 21.5%, 27.4%, 20.3%, 13.9%, and 7.4%, respectively. These roughly correspond to the 
molecular masses of complexes with six (642 kDa), eight (856 kDa), ten (1070 kDa), twelve 
(1284 kDa), sixteen (1712 kDa), and twenty (2140 kDa) trimers, though it is impossible to verify 
the true oligomerization states of these complexes. Regardless of the degree of accuracy that 
can be obtained from 2DSA, this confirms that Oct-4-2 forms a mix of multiple soluble 
complexes that range from 6-20 trimers in size, and that none of these complexes are well-
formed with a hollow interior. This is another important piece of information, because as 
discussed in section 1.4, a C3+C4 symmetry pair with a restricted dihedral angle still has the 
potential to form a hollow 16-mer with icosahedral symmetry. Being able to distinguish 
between these larger, but well-formed complexes and large, misfolded complexes is an 
important part of future characterization of designed fusion protein constructs. 
Ultrascan analysis of Oct-4-4 identified one major species and three minor species 
(Figure 5.12). The three minor species had larger sedimentation coefficients than the major 
species, having s20,w coefficients of 22.1, 27.7, and 37.3 S and relative concentrations of 18.6%, 
4.4%, and 2.3%. All three minor species had frictional ratios close to 1, and have calculated 
molecular weights of 489, 726, and 1144 kDa, respectively, indicating that these are not well-
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formed complexes, or perhaps are transition states. The major species, comprising 73.3% of the 
sample, has a sedimentation coefficient of 17.6, and a frictional ratio of 1.89. This calculates to 
a molecular weight of 886 kDa, very close to the expected molecular weight of the octahedron. 
The frictional ratio of 1.89 is much higher than all other complexes measured, and is consistent 
with a large hollow complex or a highly elongated complex. To investigate the meaning of this 
high frictional ratio, we turned to negative stain TEM to directly visualize the particles. As 
discussed in section 5.3, Oct-4-4 was determined to be highly spherical by TEM, thereby 
providing further evidence for the hypothesis that large, hollow protein complexes have high 
frictional ratios. 
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Oct-4-2 s20,w M.W. (kDa) 
((K(kDa) 
f/f0 Conc. % 
Species 1 24.80 ± 0.36 649 ± 96 1.09 ± 0.11 2.2% 
Species 2 31.55 ± 0.63 905 ± 67 1.07 ± 0.05 21.5% 
Species 3 38.03 ± 0.16 1,128 ± 63 1.03 ± 0.04 27.4% 
Species 4 43.55 ± 0.33 1,357 ± 93 1.01 ± 0.05 20.3% 
Species 5 49.82 ± 0.81 1,681 ± 174 1.02 ± 0.06 13.9% 
Species 6 57.34 ± 1.14 2,113 ± 199 1.03 ± 0.07 7.4% 
Figure 5.11. 2D-sedimentation analysis of Oct-4-2 by Ultrascan. Four major and two minor 
species were isolated, the characteristics of which are tabulated above. All species had 
frictional ratios near 1, indicating none of these species is well-formed and has a hollow 
interior. These species correlate to complexes of 6-20 trimers. 
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Oct-4-4 s20,w M.W. (kDa) f/f0 Conc. % 
Species 1 17.59 ± 0 885 ± 14 1.89 ± 0.02 73.3% 
Species 2 22.11 ± 0.07 489 ± 26 1.01 ± 0.04 18.5% 
Species 3 27.74 ± 0.30 728 ± 114 1.05 ± 0.10 4.5% 
Species 4 37.33 ± 0.20 1145 ± 194 1.06 ± 0.09 2.3% 
Figure 5.12. 2D-sedimentation analysis of Oct-4-4 by Ultrascan. One major and three minor 
species were isolated, the characteristics of which are tabulated above. The three minor species 
have frictional ratios consistent with collapsed species, while the major species is a well-
formed, hollow complex with a molecular weight slightly higher than what is expected for an 8-
trimer complex. 
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5.6 - Transmission Electron Microscopy 
 
Transmission electron microscopy images of SEC-purified Oct-4-2 and Oct-4-4 were 
obtained (Figures 5.13, 5.14). These show that both constructs exist as primarily globular 
complexes, with diameters of 15-25 nm for Oct-4-2 and 17-19 nm for Oct-4-4. While particles of 
Oct-4-2 have no distinguishable pattern of geometry, in Oct-4-4 there are several particles that 
have a clearly visible 4-fold symmetry axis that connects 4 trimers at their vertices. As with Oct-
3-4, the resolution isn’t good enough on either of these constructs to identify density that 
correlates to coiled-coils. 
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Figure 5.13. Transmission electron micrographs of SEC-purified Oct-4-2. Most particles 
observed are globular, though it appears some particles consist of multiple associated globular 
species. No particle has an observable symmetry. Particle diameter varies significantly from 15-
25 nm for single globular species, larger for multiple associated species. Scale bar is 20 nm. 
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Figure 5.14. Transmission electron micrographs for SEC purified Oct-4-4. All observed particles 
are globular, with a narrow range of diameters from 17-19 nm. In several particles highlighted 
with arrows, C4 geometry can be seen connecting trimers. Scale bar is 20 nm. 
 
Since the TEM images of Oct-4-4 show particles that are highly regular, it was possible to 
perform cryo-EM studies and obtain class averages and reconstruct a 3D model of the 
purported octahedral complex. In collaboration with Dr. Min Su, we selected 44,856 particles 
imaged on cryogenically frozen carbon grids of SEC purified Oct-4-4 and subjected these to 
reference-free class averaging. 406 class averages were generated, of which 95 class averages 
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were selected for 3D electron reconstruction on the basis of resolution and cage distortion 
(Figure 5.15). In many of these class averages, the 4-fold symmetry axis is apparent, and 
unexpectedly, many of these class averages have at the center of their 4-fold axis a region of 
strong electron density. This additional density is presumed to correspond to the coiled-coil, 
but density correlating to the coiled-coil cannot be seen at any peripheral location on almost all 
of the class averages. There are several explanations for this – there may be too much flexibility 
in the linker, or that the coiled-coils point into the interior of the cage structure, and are thus 
only visible when viewed from the top-down. Regardless, the end result is significant – in the 
initial 3D electron density reconstruction and symmetrization into octahedral space, this region 
appeared as a dense sphere of density located in the supposedly hollow protein cage interior 
(Figure 5.16a). This rough model was further improved by fitting the crystal structure of the 
trimeric esterase to the electron density, which yielded a much improved reconstruction that 
has a resolution of 17 Å at the 0.5 level of Fourier shell correlation. This improved model shows 
the trimeric esterases oriented to align their C-termini with the C4 axis, in close agreement with 
the computational model generated in section 4.1. This is a detailed enough reconstruction to 
confirm the identity of the reconstructed species as an octahedron arranged with distinctly 
identifiable C3 and C4 symmetry sites, so although there are still many open questions about the 
location and orientation of the coiled-coils, those questions are outside the scope of this 
dissertation and are appropriate for future directions.  
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Figure 5.15. Reference-free 2-D class averages of particles of Oct-4-4 imaged by cryo-EM.  a) 
The full set of 406 class averages generated from the 44,856 particles imaged. b) The 95 class 
averages used in the 3-D electron density reconstruction of Oct-4-4. 
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Figure 5.16. 3D electron density reconstruction of Oct-4-4.  a) Initial electron density map after 
selected particles were symmetrized into octahedral space, serving as a starting point for 
further refinements. b) Electron density map after refinement with the crystal structure of the 
trimeric esterase, overlaid with the crystal structure of a single trimeric esterase (Image credit: 
Min Su and Georgios Skiniotis). c) Overlay of the Rosetta-generated model of the octahedron 
with the 3-dimensional electron density map of Oct-4-4. 
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5.7 - Ion Mobility-Mass Spectrometry of Oct-4-4 
 
The previously-described data collected for the major species of Oct-4-4 provides very 
good evidence that it assembles into an octahedral cage. It is therefore an interesting target for 
analysis by a broad range of techniques, which would help gain an understanding of the 
strengths and limitations of each analytical technique as it applies to other designed fusion 
constructs going forward. IM-MS is a promising new technology that is designed to assay the 
molecular weight and surface area of designed protein constructs in their native states, and has 
been used previously to determine the molecular weight of designed fusion protein cages with 
similar masses.1  
We attempted to analyze SEC-purified Oct-4-4 by IM-MS, but the conditions required 
may not be feasible for analysis. IM-MS requires that buffers and constructs be carefully 
prepared to remove all salt from the sample, involving multiple buffer exchanges into 
ammonium acetate solution. Every sodium ion attached to a native protein will mask a charge 
on that protein, complicating the calculation of molecular weight by comparing m/z peaks. On a 
large molecule such as the octahedron this is difficult, and considering the octahedron has 6 
bundles of 4 coiled-coils, with 3 lysines and an arginine on each coil, it proved to be impossible 
to remove enough salt from Oct-4-4 to see definitive m/z peaks. Despite this, we were able to 
see a broad peak that was detected in the 10,000-12,000 m/z range, that consisted of multiple 
smaller, but poorly-defined peaks (Figure 5.17). Calculating the mass from these m/z peaks 
gives a mass of 855-890 kDa, an encouraging result despite the low data quality. Further 
attempts to outcompete the remaining salt molecules by increasing the concentration of 
ammonium acetate to 1 M during buffer exchange were unsuccessful in improving the mass 
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resolution. These results are preliminary, and a higher resolution could be obtained with a 
more concentrated sample of Oct-4-4 or a more careful preparation to remove salt. 
 
Figure 5.17. Ion-mobility mass spectrographs of Oct-4-4.  a) Plot of m/z against drift time shows 
a distribution characteristic of a single species, but without distinctly identifiable m/z peaks. b) 
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Mass calculations from m/z peaks yield a molecular weight very close to the predicted 
molecular weight of the octahedron. 
 
5.8 - Effect of Urea on Oligomerization State of Oct-4-4 
 
A common theme throughout this project has been the relationship between the 
binding strength of the coiled-coils and the oligomerization state of the assembled species. We 
saw previously during the analysis of Oct-1 that attaching a weakly-associating coil to the trimer 
led to a broadly oligomerizing species in constant equilibrium, but it is also easy to picture a 
fusion protein complex where an attached coiled-coil that binds too tightly may become 
kinetically trapped into large and irregular species. We therefore explored the possibility of 
using urea to loosen the hydrophobic interactions in the coiled-coil domain that mediate 
assembly. Research on this topic was also limited by project constraints but data was gathered 
in two areas – the effects of adding urea during lysis and Ni-affinity purification, and the effects 
of adding urea to SEC-purified octahedron.  
Addition of urea to the lysis buffer was considered early on in the analysis of Oct-4-4 as 
the prior buffer conditions for Ni purification (0-100 mM NaCl, 0 M urea, 40 mM imidazole) led 
to nonspecific binding of other proteins on the column resin, including GroEL. As noted in 
section 2.3, GroEL is a problematic contaminant because it co-elutes with the octahedron 
during size exclusion purification. Thus, cells expressing Oct-4-4 were lysed and nickel-affinity 
purified under four different buffer conditions. The first two had lysis buffer that contained no 
urea, and either 0 M or 300 mM NaCl. The second two had lysis buffer that contained 1 M urea 
and either 0 M or 300 mM NaCl. All four preparations were eluted with the elution buffer 
described in chapter 2, containing 300 mM NaCl, 50 mM HEPES, 500 mM imidazole and 5% 
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glycerol, but which did not contain urea. Native PAGE of concentrated, dialyzed, Ni-purified 
samples from each of these four preparations revealed that in both buffers containing urea, 
GroEL was removed, while it was present in both buffers lacking urea (Figure 5.18). Raising the 
urea content of the lysis/wash buffer to 2 M, however, resulted in greatly reduced yield, and 
dialyzing the Ni-purified Oct-4-4 into dialysis buffer that contained 1 M urea and storing at 4 °C 
resulted in all of the protein precipitating out over the course of several weeks. 
 
Figure 5.18. Native PAGE of four different buffer conditions for lysis and Ni-affinity purification 
for Oct-4-4.  Lane 1: ferritin (440 kDa). Lane 2: GroEL (804 kDa). Lane 3: Concentrated Oct-4-4 
after Ni purification in buffer containing 1 M urea and 300 mM NaCl. Lane 4: Concentrated Oct-
4-4 after Ni purification in buffer containing 1 M urea and 0 mM NaCl. Lane 5: Concentrated 
Oct-4-4 after Ni purification in buffer containing 0 M urea and 300 mM NaCl. Lane 6: 
Concentrated Oct-4-4 after Ni purification in buffer containing 0 M urea and 0 mM NaCl. Both 
preparations with 1 M urea did not contain the contaminant GroEL. 
 
The second set of experiments concerned the effects of Oct-4-4 after size exclusion 
chromatography purification. Size exclusion profiles were collected one day after concentrated, 
SEC-purified Oct-4-4 samples had 0.5, 1, 2, or 3 M urea added to them (Figure 5.19). The 
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resulting elution profiles show that adding 0.5 M urea causes little perturbation in the 
oligomerization state of Oct-4-4, but at higher concentrations of urea, the coiled-coil 
connections loosen enough to re-equilibrate into larger complexes, although this may be also 
caused by general unfolding and aggregation of the fusion proteins. This is an interesting effect, 
but its relevance to the design of future studies is unclear. 
 
Figure 5.19. SEC elution profiles of Ni-purified Oct-4-4 after addition of different concentrations 
of urea. Oct-4-4 with up to 0.5 M urea shows no change in absorption, but upon increased 
addition of urea the peak at 12 ml corresponding to the octahedron is reduced and broadened, 
indicating that equilibrium between the octahedron and larger species was induced. 
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5.9 - Conclusions 
 
In this chapter, we have finally put all the pieces together, attaching a tightly-binding 
tetrameric coiled-coil to the trimeric esterase via an optimized linker. I designed three fusion 
protein constructs with 2, 3, or 4 residues in the linker, named Oct-4-2, Oct-4-3, and Oct-4-4. 
Oct-4-2 expressed and purified as a mix of collapsed, soluble, globular aggregates consisting of 
6-20 trimers. Oct-4-3 expressed mainly as inclusion bodies and could not be purified in high 
enough quantities for a detailed analysis, but displays some characteristics expected for an 
octahedral protein cage. Oct-4-4 expressed as soluble protein that purifies as multiple large 
species by Ni-affinity, of which the smallest species can be purified by size exclusion to 73% 
purity. This species was characterized by AUC as an approximately spherical, hollow protein 
complex with a molecular weight of slightly more than 8 trimers. By TEM the C4 axis could be 
observed connecting the vertices of 4 trimeric proteins, and a cryo-EM class averaging and 3-D 
electron density reconstruction of Oct-4-4 resulted in a 3-dimensional model with modest 
resolution, but which nonetheless confirmed the presence of both trimeric esterases and 
coiled-coils in an octahedral configuration. These results confirm the first successful synthesis 
and purification of an octahedral protein cage built from a de novo designed fusion protein with 
a C4+C3 symmetry pair, as well as one of only a handful of soluble protein cages incorporating a 
flexible linker. The successful oligomerization of this construct opens up a smorgasbord of 
potential avenues of research as well as the possibility of functionalization for industry 
application. 
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Chapter 6 Conclusions and Future Directions 
 
In this dissertation, I have evaluated a general method for the design, optimization, and 
purification of protein cages with arbitrary symmetries. Like previously designed protein cages, 
this method consists of selecting two Cn-symmetric protein building blocks and linking them by 
genetic fusion.  But unlike the majority of these protein cages, the two symmetric building 
blocks are connected by a flexible linker. The flexible linker allows us to avoid one of the major 
difficulties in protein cage design: significant computational power must be exhausted to design 
mutants that have precisely oriented dihedral angles between symmetry axes and many of 
these designed proteins do not express as soluble, assembled protein complexes. In contrast, 
employing a flexible linker only requires consideration of the length of the linker to avoid 
unwanted steric hindrance or self-association. One of the major disadvantages of using a 
flexible linker is that a flexibly-linked, designed fusion protein can assemble into a broad range 
of stable, closed (though potentially porous) complexes, provided that the range of dihedral 
angles required for that specific complex can be imparted by the flexibility of the linker. 
However, it was recently shown that a rigidly linked fusion protein designed to assemble into a 
cube, instead formed a variety of symmetries, indicating that the inherent flexibility of proteins 
may complicate the design of rigid symmetric protein cages.1 The difficulty of rigid protein cage 
design most likely increases with the size of the protein cage – to wit, only one example 
currently exists of a rigid fusion protein construct that assembled into a protein cage with a 
higher symmetry than a tetrahedron.2 Therefore, we set out to connect a C3 symmetric building 
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block with a C4 symmetric building block with the end goal to synthesize, purify, and 
characterize an octahedral protein cage complex. 
The initial protein construct, dubbed Oct-1, consisted of a trimeric esterase building 
block connected to a tetrameric coiled-coil by a 12 residue glycine-rich linker. Oct-1 could be 
purified and was found to consist of multiple complexes of various sizes, the majority being 
smaller than the octahedron, and a small percentage of Oct-1 existed as an unbound trimer. 
Additionally, these complexes were shown to rapidly re-equilibrate to a broad range of 
complexes following isolation of specific fractions from a size exclusion column. This behavior 
was assumed to be caused by the tetrameric coiled-coil, which had a low Tm and was judged to 
be weakly-associating. We replaced this weakly-associating tetrameric coiled-coil with a 
strongly-associating coiled-coil that has been known to form either a dimer or a trimer, 
depending on environmental conditions and sequence identity. This construct, dubbed Oct-2, 
could not be purified in large amounts, but TEM images showed small, randomly-associated 
complexes of 2-5 trimers.  
We then redesigned the flexible linker using Rosetta in collaboration with Dr. Neil King, 
modeling the two protein building blocks replicated to their respective coordinates in 
octahedral symmetry. Each set of building blocks was then independently rotated and 
translated until a configuration was found with the lowest inter-terminus distance between the 
C-terminus of the C3 building block and the N-terminus of the C4 building block. This distance 
was 9.1 Å, or roughly three residues long. The Oct-2 construct was thus redesigned and three 
new fusion proteins were expressed with 3, 4, and 5 residues in the linker, termed Oct-3-3, Oct-
3-4, and Oct-3-5. All three of these fusion proteins could be purified and each characterized as a 
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different mixture of complexes between approximately 5 and 16 trimers in size. The complexes 
formed by these three fusion protein constructs, unlike the previous generations of Oct 
proteins, were stable in solution and appeared roughly globular by TEM with identifiable 
symmetry elements. 
After discovering the error in the sequence of the coiled-coil in the second and third 
generations of Oct proteins, we inserted the correct coil that was previously verified to 
oligomerize into a tightly-bound tetramer. Three fusion proteins were designed and expressed 
with 2, 3, and 4 residues in the linker, termed Oct-4-2, Oct-4-3, and Oct-4-4. Of these three, 
Oct-4-3 expressed almost entirely as insoluble protein, and Oct-4-2 formed a mixture of 
collapsed, globular proteins between approximately 6 and 20 trimers in size. Oct-4-4, however, 
could be purified into a single species that was shown by 2DSA to be hollow and well-formed, 
with a molecular weight very close to the predicted molecular weight of an octahedron. Further 
analysis of Oct-4-4 by TEM showed particles with a narrow size distribution of 17-19 nm, in the 
range of the size of the complex modeled by Rosetta, and the C4 symmetry site could be 
visualized in several of the particles. A cryo-EM electron reconstruction of Oct-4-4 resulted in a 
visualization of the octahedral complex with moderate resolution, in which the trimeric building 
blocks are oriented with their termini aligned with the C4 symmetry axis. 
While the individual characterization techniques used in this dissertation do not provide 
the resolution that can be obtained from crystallography of rigid protein complexes, I have 
shown that a fusion protein consisting of two symmetry elements connected by a flexible linker 
can definitively assemble into a single, characterizable protein cage with defined symmetric 
features. This octahedral fusion protein complex is the first ever de novo designed symmetric 
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cage protein to utilize a C4 symmetry element and the second de novo designed octahedral 
protein cage to be successfully purified and characterized. This marks the beginning of a new 
chapter into the design of novel protein cages, since the general method used to create the 
octahedron described here is in principle applicable to any combination of symmetry elements 
provided the linker length has been optimized. 
Future directions for this project are numerous. The scope of this dissertation has only 
covered a small range of the possible constructs and conditions that could be used to optimize 
the assembly of a protein cage. Immediately, one could explore more fully the relationship 
between linker length and protein cage formation, as all we have done is found the minimum 
distance required for an octahedron to form. It is an open question as to how many residues 
can be added to the linker before two coils on a single trimer can self-associate to generate 
misformed protein complexes that are smaller than the octahedron. This research has 
interesting implications for designing porous materials, as the pore size of he assembled 
complex will increase linearly with the linker length.  
Another vein of research involves varying the length and strength of the tetrameric 
coiled-coil. It is well-known that the number of heptads in a coiled-coil is correlated to the 
association behavior of that coiled-coil, with more heptads inducing a more strongly-bound coil. 
For medicinal purposes that must be conducted at body temperatures, a coiled-coil that is 
resistant to heat may be necessary to prevent the therapeutic protein cage from dissociating, 
and so it is a worthwhile pursuit to investigate a variety of homotetrameric coiled-coils for their 
binding strength, and to correlate that data with the association behavior of protein cages with 
those coils attached. It should be noted to this end that the Oct series of proteins as purified 
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are all unstable at room temperature, falling out of solution as aggregates within a few days, so 
there is a lot of intellectual space that could be devoted to improving the thermal stability of 
these designed protein cages. 
While all of the soluble Oct proteins have been found to be enzymatically active in a 
simple kinetic assay involving the de-esterification of para-nitrophenol acetate, the exact effect 
of cage formation on the enzymatic activity needs to be explored further. Currently there is 
only one other study that has investigated the effect of cage formation on the kinetic activity of 
the building block enzyme,3 and exploring this topic should have implications regarding 
industrial applications of enzymes, particularly if it were shown that protein cages have 
properties that made them superior for a specific application than the building block enzymes. 
 Furthermore, significantly more work has to be done to test the generalizability of this 
method, as its major benefit is that it can be theoretically applied to any combination of two 
symmetric proteins, provided the linker length has been sufficiently optimized. Most 
immediately, we can substitute the tetrameric coiled-coil in Oct-4 for a well-characterized 
dimeric, trimeric, or a pentameric coiled-coil, to induce formation of prismatic, tetrahedral, or 
icosahedral protein cages, respectively. Of particular interest is protein cages with icosahedral 
geometries, as currently there are no examples of a de novo designed icosahedral cage, and the 
large cavity size in the interior of an icosahedron could prove useful for industrial and medical 
purposes. Additionally, we could look at substituting a large, symmetric protein building block 
in the place of the coiled-coil, to attempt to create a protein cage with a much greater size than 
currently purified. We can also look into replacing the esterase trimer with another building 
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block, as there are two symmetry pairs (C4+C2 and C5+C2) that are inaccessible by using the 
trimeric esterase. 
Further work could also focus on the design of environmentally-responsive coiled-coils, 
for example, there are several parallel trimeric coiled-coils that have been designed to 
dissociate or associate in a pH-dependent manner or have assembly-directing metal binding 
sites.4-7 This would allow for the possibility of controllably inducing cage formation, which 
would have use in various sensing applications as well as for in vivo applications that are 
designed to dissociate upon crossing the cell membrane.  
Finally, any and all of these protein cages could be functionalized for any of the 
purposes described in section 1.2. Controllably altering the linker length or protein building 
blocks will allow us control of the size of the interior cavity, which has direct implications in the 
field of nanoparticle formation and other syntheses that proceed on the interior of the protein 
cage. Designed protein cages can be functionalized to carry targeting or therapeutic molecules, 
and there exists a strong possibility that these protein cages, by nature of their repeat units, 
can be used to induce immune responses to either the protein building blocks or to attached 
epitopes. Though at this moment it is unclear which application would gain the most from using 
de novo designed protein cages over natural protein cages, it is clear that there are a broad 
range of possibilities that are now able to be explored. 
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Appendix A  
 
Design of a coiled-coil control system using GFP 
 
A.1 – Design of the GFP fusion construct  
As it became increasingly clear that the coil inserted into the Oct-2 and Oct-3 constructs 
was not oligomerizing as intended, it was deemed necessary to design a control system wherein 
we could probe the oligomerization state of coiled-coils prior to attaching them to the trimeric 
esterase. To this end, we designed a fusion protein construct which substituted out the trimeric 
esterase for a monomeric protein, allowing us to characterize the mass of the resulting protein 
complex and determine the oligomerization state of the attached coiled-coil. This system is 
similar to the Oct protein system in that the coiled-coils are formed by in vivo expression, 
whereas the coiled-coils that have been crystallographically verified were synthesized by 
stitching together amino acids. This is an important difference, as a particular coiled-coil 
sequence may be toxic to the expression system or be a target for proteolysis. As we can see 
with Oct-4-3, some designed fusion proteins may be expressed almost exclusively as inclusion 
bodies despite having optimized components. Therefore, this control system has the additional 
purpose of screening coiled-coils for their compatibility with the expression vectors used for 
designed fusion protein cage constructs.  
For this study, we used green fluorescent protein (GFP) as a monomer, for two reasons. 
First, this protein is well-studied and is known to be a monomer at concentrations up to 50 μM. 
Second, GFP is highly fluorescent, and as such it is trivial to visually confirm that the GFP-coil 
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fusion protein has expressed, or has bound to a column during purification. We inserted 
sequences encoding coiled-coils to GFP in two different locations – either at the N-terminus of 
GFP or at the C-terminus, in both cases with a linker consisting of 6 glycine residues. Full 
peptide sequences for the constructs are reported in appendix B. Along with monomeric GFP, 
seven fusion protein constructs were designed with the coiled-coil at the N-terminus, and four 
fusion protein constructs were designed with the coiled-coil at the C-terminus. These are 
denoted by the nomenclature “GFP – residues at the a and d positions on the coiled-coil – 
number of heptad repeats – location of coil”, so a GFP fusion construct with a C-terminal coiled-
coil identical to the one inserted into Oct-4 is named “GFP-LI-4-C”, as the coil in Oct-4 has 4 
heptad repeats, and leucine and isoleucine residues at the a and d positions in its heptad 
repeat.   
The vector that encodes for monomeric GFP is pMCSG18, which is designed for C-
terminal addition of GFP to a target nucleotide sequence. Therefore, it has a plethora of 
restriction sites in the open reading frame on the N-terminal side of the GFP construct, whereas 
on the C-terminal side of the GFP construct, there are several restriction sites immediately after 
the stop codon, but none immediately before the stop codon, where we would be inserting the 
coiled-coil. The closest restriction site that is still within the ORF is 100 nucleotides away from 
the stop codon. When this project was first designed, we were assembling fusion protein 
constructs by annealing two single stranded DNA pieces together, generating a dsDNA fragment 
with complementary overlaps to the double digested vector. Adding a coiled-coil to the C-
terminus of pMCSG18 would have required a ssDNA length that was too large (>200 nt) to 
order from standard suppliers. Thus, we opted to instead insert the coiled-coil at the N-
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terminus, situated between a 6xHis tag and a thrombin cleavage site. We designed seven N-
terminal coiled-coil constructs: One with the F,F coil motif from Oct-1 (GFP-FF-7-N), one with 
the L,L coil motif from Oct-2 and Oct-3 with 4 heptads (GFP-LL-4-N), two with the L,I coil motif 
from Oct-4 with 3 and 4 heptads (GFP-LI-3-N and GFP-LI-4-N), two with a crystallographically 
verified trimeric I,I coil motif with 4 and 5 heptads (GFP-II-4-N and GFP-II-5-N), and one seven 
heptad coil identical to the one in Oct-1 but with all the interior residues replaced with 
tryptophans (GFP-WW-7-N). 
 
 
 
Figure A.1. Crystal structure of the parallel trimeric coiled-coil motif to be inserted into GFP.  In 
this coil (PDB ID 4DZL), the a and d positions in the heptad repeat consist of isoleucine residues 
(purple). 
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Figure A.2. Schematic of design of N-terminal GFP constructs. The His-tag is located on the N-
terminus. The crystallographically-determined oligomerization state is in parenthesis. Bolded 
residues represent oligomerization-determining a and d positions. 
 
A.2 – Characterization of the N-terminal GFP constructs 
 
All seven fusion protein constructs were transformed into E.coli BL21(DE3) cells, and all 
but the GFP-WW-7-N protein construct expressed as soluble protein, as measured by the green 
color of the cells after overnight expression. Yields for soluble protein varied from 30-150 mg/L 
cell media, a vastly increased yield compared to Oct protein constructs. GFP constructs were 
purified by Ni-affinity and size exclusion chromatography by the same methods as described in 
chapter 2, except using a Superdex 200 column for size exclusion instead of a Superose 6, in lieu 
of the difference in molecular weight between GFP and Oct constructs. After purification, GFP 
constructs were stable at 4 °C for several months. 
The six soluble N-terminal GFP constructs could all be purified to remove nearly all 
contaminants detectable by SDS-PAGE (Figure A3). When these purified complexes are injected 
onto the size exclusion column, their behavior is curious and unexpected: GFP-LL-4-N, GFP-FF-7-
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N, GFP-LI-4-N, and GFP-II-5-N all have similar elution volumes, with no discernable pattern 
present: GFP-FF-7-N and GFP-LI-4-N are both based off tetrameric motifs, and have elution 
volumes of 11.7 and 12.1 mL, respectively. GFP-LL-4-N and GFP-II-5-N are both based off 
trimeric motifs, and have elution volumes of 12.4 and 12.8 mL, respectively. However, GFP-LI-3-
N and GFP-II-4-N elute at 14.3 and 15.4 mL, closer to the elution volume of the unmodified GFP 
of 15.4 mL. While the 3 heptad coiled-coil in GFP-LI-3-N may be expected to not oligomerize, 
the 4 heptad coiled-coil in GFP-II-4-N is based off a coiled-coil that is well-known to oligomerize 
into a trimer. That the GFP-II-4-N fusion construct elutes as the same size of the unmodified 
monomeric GFP is cause for some concern, as this system is supposed to faithfully replicate the 
oligomerization state of these coiled-coils. 
Native PAGE proved to be unwieldy and yielded the same level of accuracy as size 
exclusion chromatography. Due to time and resource constraints, only a few N-terminal 
constructs were analyzed by native PAGE, which showed that GFP-LL-4-N and GFP-LI-4-N had 
similar Rfs, and both fusion constructs ran similarly to the unmodified trimeric esterase used as 
the building block for the Oct series of proteins (96 kDa). The monomeric GFP (32 kDa), on the 
other hand, had a similar Rf to BSA (66 kDa). Although native PAGE shows single sharp bands for 
all three GFP constructs, these results show a total disconnect between protein size and 
electrophoretic behavior, and as such conditions for native PAGE were not optimized further. 
Analytical ultracentrifugation yielded significantly higher resolution data than size 
exclusion chromatography or native PAGE. After a sedfit analysis, patterns in the 
oligomerization states for the six GFP constructs could be observed. GFP-LI-3-N and GFP-II-4-N 
had s-values of 2.0 and 1.7 respectively, close to the s-value of unmodified monomeric GFP of 
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1.7. This indicates that the coils on these two constructs do not oligomerize at the 
concentrations (0.2-1.0 mg/ml) tested. Using a fitted frictional ratio of 1.28, the monomeric 
GFP is calculated to have a molecular weight of 32 kDa, close to its expected molecular weight 
of 32.4 kDa. GFP-LL-4-N has two peaks, one at 2.0 and one at 2.8 s, indicating that this construct 
may be weakly bound and exists as both a monomer and an oligomer. Using a fitted frictional 
ratio of 1.24, this species at 2.8 s correlates to a molecular weight of 67.4 kDa, which is close to 
the hypothetical molecular weight of a GFP dimer (70 kDa). GFP-LI-4-N and GFP-II-5-N have 
similar s-values of 3.1 and 3.2, which calculate to molecular weights of 85.2 and 87.7 kDa using 
the fitted frictional ratio of 1.27. This is also a highly unusual result, as it suggests that the LI coil 
motif, long known to oligomerize as a tetramer, actually oligomerizes as a trimer when 
attached to GFP. Finally, GFP-FF-7-N has an s-value of 4.2, which calculates to a molecular mass 
of 131 kDa using a fitted frictional ratio of 1.31. This is in line with what is expected from a 
tetrameric coiled-coil. 
We further investigated the curious oligomerization states of GFP-coil constructs by IM-
MS, as this technique should give much more accurate masses that do not rely on assumptions 
about frictional ratios. Four constructs were re-purified by SEC into ammonium acetate buffer 
and analyzed by IM-MS as described in Chapter 2. Two of these four constructs – GFP-mono 
and GFP-II-4-N had masses of 28 and 32 kDa, consistent with monomers. The third construct, 
GFP-LL-4-N, had a mass of 61-66 kDa, consistent with a dimer. The fourth construct, GFP-LI-4-N, 
had a measured mass of 101-106 kDa, consistent with a trimer.  
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Figure A.3 Purification of N-terminal GFP constructs. a) SDS-PAGE shows that all six soluble N-
terminal GFP constructs could be purified to high purity. B) Native PAGE shows that the three 
N-terminal constructs tested migrate as mainly a single band, but the migration patterns have 
little relation with the expected molecular weight. 
 
 
 
Figure A.4. Size exclusion chromatography profiles of N-terminal GFP constructs.  Elution 
volumes of the GFP constructs can be roughly divided into two clusters – the first comprised of 
GFP-FF-7-N (light blue), GFP-LI-4-N (dark blue), GFP-LL-4-N (brown), and GFP-II-5-N (magenta), 
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and the second comprised of monomeric GFP (green), GFP-LI-3-N (blue dashed), and GFP-II-4-N 
(red). 
 
Figure A.5. Analytical ultracentrifugation of N-terminal GFP constructs. Constructs have 
sedimentation coefficients corresponding to one of four oligomerization states. GFP-LI-3-N 
(blue dashed) and GFP-II-4-N (red) both have s-values similar to the monomeric GFP (green), 
GFP-LL-4-N (brown) sediments as a dimer, GFP-LI-4-N (blue) and GFP-II-5-N (magenta) both 
sediment as trimers, and GFP-FF-7-N (light blue) sediments as a tetramer. 
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Figure A.6. Ion mobility-mass spectrometry of N-terminal GFP constructs. Correlative with AUC 
data, GFP-II-4-N (d) has a native mass similar to the monomeric GFP (a), while GFP-LL-4-N (c) 
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has a native mass of around two subunits and GFP-LI-4-N (b) has a native mass of around three 
subunits. 
 
A.3 – Design and Characterization of C-terminal GFP Fusion Protein Constructs 
After getting unexpected oligomerization states from multiple constructs, we decided to 
re-attach the coiled-coil onto the C-terminus of GFP to determine if these unexpected results 
were caused by the coil being too close to the His-tag, or were independent of coil location. 
Using Gibson assembly, we were able to design larger dsDNA sequences that retained the 120 
nucleotides that were excised from the C-terminal double digestion of pMCSG18, in addition to 
the glycine linker and coiled-coil insert. Four constructs were designed, one with the L,L motif 
and 4 heptads (GFP-LL-4-C), one with the L,I motif and 4 heptads (GFP-LI-4-C), and two with the 
I,I motif and either 4 or 5 heptads (GFP-II-4-C and GFP-II-5-C). DNA encoding these constructs 
was successfully ligated and transformed into BL21(DE3) E.coli cells, and purified as above. 
 
Figure A.7. Schematic of design of C-terminal GFP constructs. The His-tag is located on the N-
terminus. The crystallographically-determined oligomerization state of the attached coils is in 
parenthesis.Bolded residues represent oligomerization-determining a and d positions. 
 
All four of these constructs could be purified to remove all contaminants detectable by 
SDS-PAGE. Analysis of SEC-purified GFP constructs by size exclusion showed oligomerization in 
all four constructs. The monomeric GFP had an elution volume of 16.5 mL, while GFP-LL-4-C had 
an elution volume of 13.9 mL, and the other three constructs had elution volumes of 13.3 mL. 
141 
 
These data are backed up by native PAGE, which shows that GFP-LL-4-C migrates between 
monomeric GFP and the three other C-terminal GFP constructs, although just like the native 
PAGE of N-terminal GFP constructs, the oligomerizing constructs migrate very close to each 
other, with no relation to the migration patterns of standard proteins. Sedfit analysis of 
analytical ultracentrifugation data confirms these oligomerization states. GFP-LL-4-C has an s-
value of 2.8, identical to the s-value of GFP-LL-4-N, while the other three C-terminal constructs 
all have major peaks with identical s-values of 3.6. These almost certainly correlate to a dimer 
and three trimers, which was confirmed by IM-MS analysis. IM-MS analysis of the four C-
terminal constructs showed that GFP-LI-4-C, GFP-II-4-C, and GFP-II-5-C all had molecular masses 
between 97 and 99 kDa, consistent with formation of a trimer, while GFP-LL-4-C had multiple 
m/z peaks, the major peak correlated to the dimeric species, and smaller signals correlating to 
the monomeric and the trimeric species. This is most likely an artifact from the process of 
native mass spectrometry, as minor peaks correlating to larger or smaller species can be found 
in all spectra. 
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Figure A.8. Purification of C-terminal GFP fusion constructs. a) SDS-PAGE shows that all four C-
terminal GFP constructs could be purified to high purity. B) Native PAGE shows that all four C-
terminal constructs migrate as mainly a single band, but the migration patterns have little 
relation with the expected molecular weight. 
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Figure A.9. Size exclusion chromatography of C-terminal GFP constructs. All four constructs 
have sharp peaks and significantly smaller elution volumes than the monomer, with GFP-LL-4-C 
(brown) eluting at 13.9 mL, and the other three constructs eluting at 13.3 mL.  
144 
 
 
Figure A.10.Analytical ultracentrifugation of C-terminal GFP constructs. Correlative with results 
from size exclusion chromatography, GFP-LL-4-C sediments as a dimer, while the other three 
constructs sediment mainly as trimers. 
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Figure A.11.Ion mobility-mass spectrometry of C-terminal GFP constructs. Though other species 
are present the major peak in GFP-LL-4-C (a) corresponds to a dimer, while the other three GFP 
constructs (b-d) have major peaks corresponding to trimers. 
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A.4 - Conclusions 
The goal of creating a GFP-coil fusion construct was to develop a system that would test 
and confirm the oligomerization of coiled-coils that have been previously characterized 
exclusively in vitro. It was hypothesized that the attachment of these coils onto a protein or the 
biological expression of this fusion construct might effect a change in the coils’ oligomerization 
states. In this chapter I designed and characterized eleven different GFP fusion constructs, with 
varying degrees of success. Many of the GFP constructs tested had different oligomerization 
states than were expected for the attached coiled-coil, in particular GFP-LI-4, which was 
trimeric when attached to both the C- and N-terminus. This contradicts multiple crystal 
structures of coiled-coils with leucine and isoleucine residues at the a and d positions, as well as 
cryo-EM data from the Oct-4-4 construct that shows an octahedron formation with a C4 axis at 
the location of the coiled-coil. Additionally, it was shown that this system is sensitive to small 
perturbations – while GFP-II-4-N could be shown to not oligomerize at all, adding an extra 
heptad (GFP-II-5-N) or relocating the coil to the C terminus (GFP-II-4-C) induced trimerization of 
the coiled-coil.  
The major success of this experiment was to demonstrate a robust method for 
characterizing the oligomerization states of fusion constructs, which will undoubtedly be useful 
for characterization of more exotic coiled-coils, for example, a coil whose association can be 
controlled by environmental conditions such as metal availability or pH. With this system, we 
could ascertain the extent of association at various environmental conditions, and thus 
determine if a coil is appropriate to attach to the trimeric esterase to yield a protein cage with 
the desired properties. 
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Appendix B  
DNA and protein sequences of protein building blocks and fusion constructs 
 In this appendix, I will detail the DNA and protein sequences of each protein construct 
that was analyzed in the previous thesis and appendix. Restriction sites in the open reading 
frames of the DNA are noted where applicable. All Oct proteins were ligated into the pet28b 
vector and all GFP proteins were ligated into the pMCSG18 vector. 
Oct-1 DNA sequence: 
  
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat  
                                                                  NdeI  
 61      ---------+---------+---------+---------+---------+---------+    120 
         atgagttatgtcaccacgaaagatggcgtgcagatcttttataaagactggggtccgcgt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gatgcgccggtgatccatttccatcacggttggccgctgtccgcagatgactgggatgca  
 181     ---------+---------+---------+---------+---------+---------+    240 
         cagctgctgtttttcctggcgcacggttatcgtgtggttgcacatgaccgtcgcggtcac  
 241     ---------+---------+---------+---------+---------+---------+    300 
         ggtcgtagctctcaagtctgggatggccatgacatggatcactacgcggatgacgttgcg  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gccgtcgtggcacatctgggcattcagggtgctgtgcatgttggtcactctaccggcggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         ggcgaagttgtccgttatatggcccgccacccggaagataaagttgcgaaagcagtcctg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         atcgcagctgtgccgccgctgatggttcaaacgccgggtaacccgggtggcctgccgaaa  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tcagtgtttgacggtttccaggcgcaagttgcctcgaatcgtgcacagttttaccgcgat  
 541     ---------+---------+---------+---------+---------+---------+    600 
         gtgccggctggcccgttctatggttacaaccgtccgggcgttgaagcaagcgaaggcatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         atcggtaattggtggcgccagggcatgattggtagcgcaaaagctcattatgatggtatc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         gtggctttttctcaaaccgacttcacggaagatctgaaaggcattcagcaaccggtcctg  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gtgatgcatggtgatgacgatcagatcgttccgtacgaaaacagcggcgtcctgtctgcg  
 781     ---------+---------+---------+---------+---------+---------+    840 
         aaactgctgccgaatggtgccctgaaaacctataaaggctacccgcatggtatgccgacc  
 841     ---------+---------+---------+---------+---------+---------+    900 
         acgcacgccgacgttattaacgcagatctgctggcttttatccgcagtggtaccggtggc  
                                                         KpnI        
 901     ---------+---------+---------+---------+---------+---------+    960 
         ggtggcggtggcggtggcggtactagttccaacgcaaaatttgaccagttctcatcggat  
                              SpeI                                   
 961     ---------+---------+---------+---------+---------+---------+    1020 
         tttcaaaccttcaatgcgaaatttgaccagttcagtaacgatatgaatgcctttcgttcc                                                                      
 1021    ---------+---------+---------+---------+---------+---------+    1080 
         gattttcaggcatttaaagacgattttgctcgtttcaaccaacgctttgataatttcgcg                                                                      
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 1081    ---------+---------+---------+---------+---------+---------+    1140 
         accaaatatcgctaatttaaatagggatcc 
                                 BamHI 
 
Protein sequence for Oct-1: 
 
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MSYVTTKDGV QIFYKDWGPR DAPVIHFHHG WPLSADDWDA  
        70         80         90        100        110        120  
QLLFFLAHGY RVVAHDRRGH GRSSQVWDGH DMDHYADDVA AVVAHLGIQG AVHVGHSTGG  
       130        140        150        160        170        180  
GEVVRYMARH PEDKVAKAVL IAAVPPLMVQ TPGNPGGLPK SVFDGFQAQV ASNRAQFYRD  
       190        200        210        220        230        240  
VPAGPFYGYN RPGVEASEGI IGNWWRQGMI GSAKAHYDGI VAFSQTDFTE DLKGIQQPVL  
       250        260        270        280        290        300  
VMHGDDDQIV PYENSGVLSA KLLPNGALKT YKGYPHGMPT THADVINADL LAFIRSGTGG  
       310        320        330        340        350        360  
GGGGGGGTSS NAKFDQFSSD FQTFNAKFDQ FSNDMNAFRS DFQAFKDDFA RFNQRFDNFA  
 
Calculated molecular weight: 39,842 kDa 
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Oct-2 DNA sequence: 
 
  1       ---------+---------+---------+---------+---------+---------+    60 
         atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat  
                                                                  NdeI  
 61      ---------+---------+---------+---------+---------+---------+    120 
         atgagttatgtcaccacgaaagatggcgtgcagatcttttataaagactggggtccgcgt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gatgcgccggtgatccatttccatcacggttggccgctgtccgcagatgactgggatgca  
 181     ---------+---------+---------+---------+---------+---------+    240 
         cagctgctgtttttcctggcgcacggttatcgtgtggttgcacatgaccgtcgcggtcac  
 241     ---------+---------+---------+---------+---------+---------+    300 
         ggtcgtagctctcaagtctgggatggccatgacatggatcactacgcggatgacgttgcg  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gccgtcgtggcacatctgggcattcagggtgctgtgcatgttggtcactctaccggcggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         ggcgaagttgtccgttatatggcccgccacccggaagataaagttgcgaaagcagtcctg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         atcgcagctgtgccgccgctgatggttcaaacgccgggtaacccgggtggcctgccgaaa  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tcagtgtttgacggtttccaggcgcaagttgcctcgaatcgtgcacagttttaccgcgat  
 541     ---------+---------+---------+---------+---------+---------+    600 
         gtgccggctggcccgttctatggttacaaccgtccgggcgttgaagcaagcgaaggcatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         atcggtaattggtggcgccagggcatgattggtagcgcaaaagctcattatgatggtatc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         gtggctttttctcaaaccgacttcacggaagatctgaaaggcattcagcaaccggtcctg  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gtgatgcatggtgatgacgatcagatcgttccgtacgaaaacagcggcgtcctgtctgcg  
 781     ---------+---------+---------+---------+---------+---------+    840 
         aaactgctgccgaatggtgccctgaaaacctataaaggctacccgcatggtatgccgacc  
 841     ---------+---------+---------+---------+---------+---------+    900 
         acgcacgccgacgttattaacgcagatctgctggcttttatccgcagtggtaccggtggc  
                                                         KpnI        
 901     ---------+---------+---------+---------+---------+---------+    960 
         ggtggcggtggcggtggcggtactaggctggcggccctgaagcaggaactggcagctctg  
 961     ---------+---------+---------+---------+---------+---------+    1020 
         Cggtccgaactggcagcactgaagcacgagctggcagctctgaagcaagatggc 
 
Protein sequence for Oct-2: 
 
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MSYVTTKDGV QIFYKDWGPR DAPVIHFHHG WPLSADDWDA  
        70         80         90        100        110        120  
QLLFFLAHGY RVVAHDRRGH GRSSQVWDGH DMDHYADDVA AVVAHLGIQG AVHVGHSTGG  
       130        140        150        160        170        180  
GEVVRYMARH PEDKVAKAVL IAAVPPLMVQ TPGNPGGLPK SVFDGFQAQV ASNRAQFYRD  
       190        200        210        220        230        240  
VPAGPFYGYN RPGVEASEGI IGNWWRQGMI GSAKAHYDGI VAFSQTDFTE DLKGIQQPVL  
       250        260        270        280        290        300  
VMHGDDDQIV PYENSGVLSA KLLPNGALKT YKGYPHGMPT THADVINADL LAFIRSGTGG  
       310        320        330  
GGGGGGGTRL AALKQELAAL RSELAALKHE LAALKQDG  
 
Calculated molecular weight of Oct-2: 36,310 Da           
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DNA sequence for trimeric esterase: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat  
                                                                  NdeI  
 61      ---------+---------+---------+---------+---------+---------+    120 
         atgagttatgtcaccacgaaagatggcgtgcagatcttttataaagactggggtccgcgt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gatgcgccggtgatccatttccatcacggttggccgctgtccgcagatgactgggatgca  
 181     ---------+---------+---------+---------+---------+---------+    240 
         cagctgctgtttttcctggcgcacggttatcgtgtggttgcacatgaccgtcgcggtcac  
 241     ---------+---------+---------+---------+---------+---------+    300 
         ggtcgtagctctcaagtctgggatggccatgacatggatcactacgcggatgacgttgcg  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gccgtcgtggcacatctgggcattcagggtgctgtgcatgttggtcactctaccggcggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         ggcgaagttgtccgttatatggcccgccacccggaagataaagttgcgaaagcagtcctg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         atcgcagctgtgccgccgctgatggttcaaacgccgggtaacccgggtggcctgccgaaa  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tcagtgtttgacggtttccaggcgcaagttgcctcgaatcgtgcacagttttaccgcgat  
 541     ---------+---------+---------+---------+---------+---------+    600 
         gtgccggctggcccgttctatggttacaaccgtccgggcgttgaagcaagcgaaggcatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         atcggtaattggtggcgccagggcatgattggtagcgcaaaagctcattatgatggtatc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         gtggctttttctcaaaccgacttcacggaagatctgaaaggcattcagcaaccggtcctg  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gtgatgcatggtgatgacgatcagatcgttccgtacgaaaacagcggcgtcctgtctgcg  
 781     ---------+---------+---------+---------+---------+---------+    840 
         aaactgctgccgaatggtgccctgaaaacctataaaggctacccgcatggtatgccgacc  
 841     ---------+---------+---------+---------+---------+---------+    900 
         acgcacgccgacgttattaacgcagatctgctggcttttatccgcagtggtacc  
 
Protein sequence for trimeric esterase: 
 
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MSYVTTKDGV QIFYKDWGPR DAPVIHFHHG WPLSADDWDA  
        70         80         90        100        110        120  
QLLFFLAHGY RVVAHDRRGH GRSSQVWDGH DMDHYADDVA AVVAHLGIQG AVHVGHSTGG  
       130        140        150        160        170        180  
GEVVRYMARH PEDKVAKAVL IAAVPPLMVQ TPGNPGGLPK SVFDGFQAQV ASNRAQFYRD  
       190        200        210        220        230        240  
VPAGPFYGYN RPGVEASEGI IGNWWRQGMI GSAKAHYDGI VAFSQTDFTE DLKGIQQPVL  
       250        260        270        280        290  
VMHGDDDQIV PYENSGVLSA KLLPNGALKT YKGYPHGMPT THADVINADL LAFIRSGT  
Calculated molecular weight of trimeric esterase: 32485 Da 
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DNA sequence for Oct-3-3: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat  
                                                                  NdeI  
 61      ---------+---------+---------+---------+---------+---------+    120 
         atgagttatgtcaccacgaaagatggcgtgcagatcttttataaagactggggtccgcgt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gatgcgccggtgatccatttccatcacggttggccgctgtccgcagatgactgggatgc  
 181     ---------+---------+---------+---------+---------+---------+    240 
         cagctgctgtttttcctggcgcacggttatcgtgtggttgcacatgaccgtcgcggtcac  
 241     ---------+---------+---------+---------+---------+---------+    300 
         ggtcgtagctctcaagtctgggatggccatgacatggatcactacgcggatgacgttgcg  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gccgtcgtggcacatctgggcattcagggtgctgtgcatgttggtcactctaccggcggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         ggcgaagttgtccgttatatggcccgccacccggaagataaagttgcgaaagcagtcctg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         atcgcagctgtgccgccgctgatggttcaaacgccgggtaacccgggtggcctgccgaaa  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tcagtgtttgacggtttccaggcgcaagttgcctcgaatcgtgcacagttttaccgcgat  
 541     ---------+---------+---------+---------+---------+---------+    600 
         gtgccggctggcccgttctatggttacaaccgtccgggcgttgaagcaagcgaaggcatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         atcggtaattggtggcgccagggcatgattggtagcgcaaaagctcattatgatggtatc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         gtggctttttctcaaaccgacttcacggaagatctgaaaggcattcagcaaccggtcctg  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gtgatgcatggtgatgacgatcagatcgttccgtacgaaaacagcggcgtcctgtctgcg  
 781     ---------+---------+---------+---------+---------+---------+    840 
         aaactgctgccgaatggtgccctgaaaacctataaaggctacccgcatggtatgccgacc  
 841     ---------+---------+---------+---------+---------+---------+    900 
         acgcacgccgacgttattaacgcagatctgctggcttttatccgcagtggtaccggcctg  
                                                         KpnI        
 901     ---------+---------+---------+---------+---------+---------+    960 
         gcagcactgcggtccgaactggccgcactgaagcaggaactggcggccctgaaacaagaa  
 961     ---------+---------+---------+---------+---------+---------+    1020 
         Ctggcagctctgaagcaagatggataag 
 
Protein sequence for Oct-3-3: 
 
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MSYVTTKDGV QIFYKDWGPR DAPVIHFHHG WPLSADDWDA  
        70         80         90        100        110        120  
QLLFFLAHGY RVVAHDRRGH GRSSQVWDGH DMDHYADDVA AVVAHLGIQG AVHVGHSTGG  
       130        140        150        160        170        180  
GEVVRYMARH PEDKVAKAVL IAAVPPLMVQ TPGNPGGLPK SVFDGFQAQV ASNRAQFYRD  
       190        200        210        220        230        240  
VPAGPFYGYN RPGVEASEGI IGNWWRQGMI GSAKAHYDGI VAFSQTDFTE DLKGIQQPVL  
       250        260        270        280        290        300  
VMHGDDDQIV PYENSGVLSA KLLPNGALKT YKGYPHGMPT THADVINADL LAFIRSGTGL  
       310        320  
AALRSELAAL KQELAALKQE LAALKQDG  
 
Calculated molecular weight for Oct-3-3: 35588 Da.  
152 
 
DNA sequence for Oct-3-4: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat  
                                                                  NdeI   
 61      ---------+---------+---------+---------+---------+---------+    120 
         atgagttatgtcaccacgaaagatggcgtgcagatcttttataaagactggggtccgcgt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gatgcgccggtgatccatttccatcacggttggccgctgtccgcagatgactgggatgca  
 181     ---------+---------+---------+---------+---------+---------+    240 
         cagctgctgtttttcctggcgcacggttatcgtgtggttgcacatgaccgtcgcggtcac  
 241     ---------+---------+---------+---------+---------+---------+    300 
         ggtcgtagctctcaagtctgggatggccatgacatggatcactacgcggatgacgttgcg  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gccgtcgtggcacatctgggcattcagggtgctgtgcatgttggtcactctaccggcggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         ggcgaagttgtccgttatatggcccgccacccggaagataaagttgcgaaagcagtcctg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         atcgcagctgtgccgccgctgatggttcaaacgccgggtaacccgggtggcctgccgaaa  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tcagtgtttgacggtttccaggcgcaagttgcctcgaatcgtgcacagttttaccgcgat  
 541     ---------+---------+---------+---------+---------+---------+    600 
         gtgccggctggcccgttctatggttacaaccgtccgggcgttgaagcaagcgaaggcatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         atcggtaattggtggcgccagggcatgattggtagcgcaaaagctcattatgatggtatc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         gtggctttttctcaaaccgacttcacggaagatctgaaaggcattcagcaaccggtcctg  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gtgatgcatggtgatgacgatcagatcgttccgtacgaaaacagcggcgtcctgtctgcg  
 781     ---------+---------+---------+---------+---------+---------+    840 
         aaactgctgccgaatggtgccctgaaaacctataaaggctacccgcatggtatgccgacc  
 841     ---------+---------+---------+---------+---------+---------+    900 
         acgcacgccgacgttattaacgcagatctgctggcttttatccgcagtggtaccggcggt  
                                                         KpnI        
 901     ---------+---------+---------+---------+---------+---------+    960 
         ctggcagcactgcggtccgaactggccgcactgaagcaggaactggcggccctgaaacaa  
 961     ---------+---------+---------+---------+---------+---------+    1020 
         Gaactggcagctctgaagcaagatggataag 
 
Protein sequence for Oct-3-4: 
 
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MSYVTTKDGV QIFYKDWGPR DAPVIHFHHG WPLSADDWDA  
        70         80         90        100        110        120  
QLLFFLAHGY RVVAHDRRGH GRSSQVWDGH DMDHYADDVA AVVAHLGIQG AVHVGHSTGG  
       130        140        150        160        170        180  
GEVVRYMARH PEDKVAKAVL IAAVPPLMVQ TPGNPGGLPK SVFDGFQAQV ASNRAQFYRD  
       190        200        210        220        230        240  
VPAGPFYGYN RPGVEASEGI IGNWWRQGMI GSAKAHYDGI VAFSQTDFTE DLKGIQQPVL  
       250        260        270        280        290        300  
VMHGDDDQIV PYENSGVLSA KLLPNGALKT YKGYPHGMPT THADVINADL LAFIRSGTGG  
       310        320  
LAALRSELAA LKQELAALKQ ELAALKQDG  
 
Calculated molecular weight for Oct-3-4: 35645 Da. 
153 
 
DNA sequence for Oct-3-5: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat  
                                                                  NdeI  
 61      ---------+---------+---------+---------+---------+---------+    120 
         atgagttatgtcaccacgaaagatggcgtgcagatcttttataaagactggggtccgcgt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gatgcgccggtgatccatttccatcacggttggccgctgtccgcagatgactgggatgca  
 181     ---------+---------+---------+---------+---------+---------+    240 
         cagctgctgtttttcctggcgcacggttatcgtgtggttgcacatgaccgtcgcggtcac  
 241     ---------+---------+---------+---------+---------+---------+    300 
         ggtcgtagctctcaagtctgggatggccatgacatggatcactacgcggatgacgttgcg  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gccgtcgtggcacatctgggcattcagggtgctgtgcatgttggtcactctaccggcggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         ggcgaagttgtccgttatatggcccgccacccggaagataaagttgcgaaagcagtcctg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         atcgcagctgtgccgccgctgatggttcaaacgccgggtaacccgggtggcctgccgaaa  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tcagtgtttgacggtttccaggcgcaagttgcctcgaatcgtgcacagttttaccgcgat  
 541     ---------+---------+---------+---------+---------+---------+    600 
         gtgccggctggcccgttctatggttacaaccgtccgggcgttgaagcaagcgaaggcatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         atcggtaattggtggcgccagggcatgattggtagcgcaaaagctcattatgatggtatc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         gtggctttttctcaaaccgacttcacggaagatctgaaaggcattcagcaaccggtcctg  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gtgatgcatggtgatgacgatcagatcgttccgtacgaaaacagcggcgtcctgtctgcg  
 781     ---------+---------+---------+---------+---------+---------+    840 
         aaactgctgccgaatggtgccctgaaaacctataaaggctacccgcatggtatgccgacc  
 841     ---------+---------+---------+---------+---------+---------+    900 
         acgcacgccgacgttattaacgcagatctgctggcttttatccgcagtggtaccggcggt  
                                                         KpnI        
 901     ---------+---------+---------+---------+---------+---------+    960 
         ggcctggcagcactgcggtccgaactggccgcactgaagcaggaactggcggccctgaaa  
 961     ---------+---------+---------+---------+---------+---------+    1020 
         caagaactggcagctctgaagcaagatggataag 
 
Protein sequence for Oct-3-5: 
 
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MSYVTTKDGV QIFYKDWGPR DAPVIHFHHG WPLSADDWDA  
        70         80         90        100        110        120  
QLLFFLAHGY RVVAHDRRGH GRSSQVWDGH DMDHYADDVA AVVAHLGIQG AVHVGHSTGG  
       130        140        150        160        170        180  
GEVVRYMARH PEDKVAKAVL IAAVPPLMVQ TPGNPGGLPK SVFDGFQAQV ASNRAQFYRD  
       190        200        210        220        230        240  
VPAGPFYGYN RPGVEASEGI IGNWWRQGMI GSAKAHYDGI VAFSQTDFTE DLKGIQQPVL  
       250        260        270        280        290        300  
VMHGDDDQIV PYENSGVLSA KLLPNGALKT YKGYPHGMPT THADVINADL LAFIRSGTGG  
       310        320        330  
GLAALRSELA ALKQELAALK QELAALKQDG  
 
Calculated molecular weight for Oct-3-5: 35702 Da. 
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DNA sequence for Oct-4-2: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat  
                                                                  NdeI  
 61      ---------+---------+---------+---------+---------+---------+    120 
         atgagttatgtcaccacgaaagatggcgtgcagatcttttataaagactggggtccgcgt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gatgcgccggtgatccatttccatcacggttggccgctgtccgcagatgactgggatgca  
 181     ---------+---------+---------+---------+---------+---------+    240 
         cagctgctgtttttcctggcgcacggttatcgtgtggttgcacatgaccgtcgcggtcac  
 241     ---------+---------+---------+---------+---------+---------+    300 
         ggtcgtagctctcaagtctgggatggccatgacatggatcactacgcggatgacgttgcg  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gccgtcgtggcacatctgggcattcagggtgctgtgcatgttggtcactctaccggcggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         ggcgaagttgtccgttatatggcccgccacccggaagataaagttgcgaaagcagtcctg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         atcgcagctgtgccgccgctgatggttcaaacgccgggtaacccgggtggcctgccgaaa  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tcagtgtttgacggtttccaggcgcaagttgcctcgaatcgtgcacagttttaccgcgat  
 541     ---------+---------+---------+---------+---------+---------+    600 
         gtgccggctggcccgttctatggttacaaccgtccgggcgttgaagcaagcgaaggcatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         atcggtaattggtggcgccagggcatgattggtagcgcaaaagctcattatgatggtatc 
 661     ---------+---------+---------+---------+---------+---------+    720 
         gtggctttttctcaaaccgacttcacggaagatctgaaaggcattcagcaaccggtcctg  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gtgatgcatggtgatgacgatcagatcgttccgtacgaaaacagcggcgtcctgtctgcg  
 781     ---------+---------+---------+---------+---------+---------+    840 
         aaactgctgccgaatggtgccctgaaaacctataaaggctacccgcatggtatgccgacc  
 841     ---------+---------+---------+---------+---------+---------+    900 
         acgcacgccgacgttattaacgcagatctgctggcttttatccgcagtggtaccctggca  
                                                         KpnI        
 901     ---------+---------+---------+---------+---------+---------+    960 
         gcaatcaagtccgaactggccgcaatcaagcaggaactggcggccatcaaacaagaactg  
 961     ---------+---------+---------+---------+---------+---------+    1020 
         gcagctatcaagcaagatgga 
 
Protein sequence for Oct-4-2: 
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MSYVTTKDGV QIFYKDWGPR DAPVIHFHHG WPLSADDWDA  
        70         80         90        100        110        120  
QLLFFLAHGY RVVAHDRRGH GRSSQVWDGH DMDHYADDVA AVVAHLGIQG AVHVGHSTGG  
       130        140        150        160        170        180  
GEVVRYMARH PEDKVAKAVL IAAVPPLMVQ TPGNPGGLPK SVFDGFQAQV ASNRAQFYRD  
       190        200        210        220        230        240  
VPAGPFYGYN RPGVEASEGI IGNWWRQGMI GSAKAHYDGI VAFSQTDFTE DLKGIQQPVL  
       250        260        270        280        290        300  
VMHGDDDQIV PYENSGVLSA KLLPNGALKT YKGYPHGMPT THADVINADL LAFIRSGTLA  
       310        320  
AIKSELAAIK QELAAIKQEL AAIKQDG  
Calculated molecular weight for Oct-4-2: 35502 Da. 
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DNA sequence for Oct-4-3: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat  
                                                                  NdeI  
 61      ---------+---------+---------+---------+---------+---------+    120 
         atgagttatgtcaccacgaaagatggcgtgcagatcttttataaagactggggtccgcgt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gatgcgccggtgatccatttccatcacggttggccgctgtccgcagatgactgggatgca  
 181     ---------+---------+---------+---------+---------+---------+    240 
         cagctgctgtttttcctggcgcacggttatcgtgtggttgcacatgaccgtcgcggtcac  
 241     ---------+---------+---------+---------+---------+---------+    300 
         ggtcgtagctctcaagtctgggatggccatgacatggatcactacgcggatgacgttgcg  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gccgtcgtggcacatctgggcattcagggtgctgtgcatgttggtcactctaccggcggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         ggcgaagttgtccgttatatggcccgccacccggaagataaagttgcgaaagcagtcctg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         atcgcagctgtgccgccgctgatggttcaaacgccgggtaacccgggtggcctgccgaaa  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tcagtgtttgacggtttccaggcgcaagttgcctcgaatcgtgcacagttttaccgcgat  
 541     ---------+---------+---------+---------+---------+---------+    600 
         gtgccggctggcccgttctatggttacaaccgtccgggcgttgaagcaagcgaaggcatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         atcggtaattggtggcgccagggcatgattggtagcgcaaaagctcattatgatggtatc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         gtggctttttctcaaaccgacttcacggaagatctgaaaggcattcagcaaccggtcctg  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gtgatgcatggtgatgacgatcagatcgttccgtacgaaaacagcggcgtcctgtctgcg  
 781     ---------+---------+---------+---------+---------+---------+    840 
         aaactgctgccgaatggtgccctgaaaacctataaaggctacccgcatggtatgccgacc  
 841     ---------+---------+---------+---------+---------+---------+    900 
         acgcacgccgacgttattaacgcagatctgctggcttttatccgcagtggtaccggcctg  
                                                         KpnI        
 901     ---------+---------+---------+---------+---------+---------+    960 
         gcagcaatcaagtccgaactggccgcaatcaagcaggaactggcggccatcaaacaagaa  
 961     ---------+---------+---------+---------+---------+---------+    1020 
         ctggcagctatcaagcaagatgga                                                                    
 
Protein sequence for Oct-4-3: 
 
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MSYVTTKDGV QIFYKDWGPR DAPVIHFHHG WPLSADDWDA  
        70         80         90        100        110        120  
QLLFFLAHGY RVVAHDRRGH GRSSQVWDGH DMDHYADDVA AVVAHLGIQG AVHVGHSTGG  
       130        140        150        160        170        180  
GEVVRYMARH PEDKVAKAVL IAAVPPLMVQ TPGNPGGLPK SVFDGFQAQV ASNRAQFYRD  
       190        200        210        220        230        240  
VPAGPFYGYN RPGVEASEGI IGNWWRQGMI GSAKAHYDGI VAFSQTDFTE DLKGIQQPVL  
       250        260        270        280        290        300  
VMHGDDDQIV PYENSGVLSA KLLPNGALKT YKGYPHGMPT THADVINADL LAFIRSGTGL  
       310        320  
AAIKSELAAI KQELAAIKQE LAAIKQDG  
 
Calculated molecular weight for Oct-4-3: 35560 Da. 
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DNA sequence for Oct-4-4: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat  
                                                                  NdeI  
 61      ---------+---------+---------+---------+---------+---------+    120 
         atgagttatgtcaccacgaaagatggcgtgcagatcttttataaagactggggtccgcgt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gatgcgccggtgatccatttccatcacggttggccgctgtccgcagatgactgggatgca  
 181     ---------+---------+---------+---------+---------+---------+    240 
         cagctgctgtttttcctggcgcacggttatcgtgtggttgcacatgaccgtcgcggtcac  
 241     ---------+---------+---------+---------+---------+---------+    300 
         ggtcgtagctctcaagtctgggatggccatgacatggatcactacgcggatgacgttgcg  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gccgtcgtggcacatctgggcattcagggtgctgtgcatgttggtcactctaccggcggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         ggcgaagttgtccgttatatggcccgccacccggaagataaagttgcgaaagcagtcctg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         atcgcagctgtgccgccgctgatggttcaaacgccgggtaacccgggtggcctgccgaaa  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tcagtgtttgacggtttccaggcgcaagttgcctcgaatcgtgcacagttttaccgcgat  
 541     ---------+---------+---------+---------+---------+---------+    600 
         gtgccggctggcccgttctatggttacaaccgtccgggcgttgaagcaagcgaaggcatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         atcggtaattggtggcgccagggcatgattggtagcgcaaaagctcattatgatggtatc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         gtggctttttctcaaaccgacttcacggaagatctgaaaggcattcagcaaccggtcctg  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gtgatgcatggtgatgacgatcagatcgttccgtacgaaaacagcggcgtcctgtctgcg  
 781     ---------+---------+---------+---------+---------+---------+    840 
         aaactgctgccgaatggtgccctgaaaacctataaaggctacccgcatggtatgccgacc  
 841     ---------+---------+---------+---------+---------+---------+    900 
         acgcacgccgacgttattaacgcagatctgctggcttttatccgcagtggtaccggcggt  
                                                         KpnI        
 901     ---------+---------+---------+---------+---------+---------+    960 
         ctggcagcaatcaagtccgaactggccgcaatcaagcaggaactggcggccatcaaacaa   
 961     ---------+---------+---------+---------+---------+---------+    1020 
         gaactggcagctatcaagcaagatgga 
 
Protein sequence for Oct-4-4: 
 
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MSYVTTKDGV QIFYKDWGPR DAPVIHFHHG WPLSADDWDA  
        70         80         90        100        110        120  
QLLFFLAHGY RVVAHDRRGH GRSSQVWDGH DMDHYADDVA AVVAHLGIQG AVHVGHSTGG  
       130        140        150        160        170        180  
GEVVRYMARH PEDKVAKAVL IAAVPPLMVQ TPGNPGGLPK SVFDGFQAQV ASNRAQFYRD  
       190        200        210        220        230        240  
VPAGPFYGYN RPGVEASEGI IGNWWRQGMI GSAKAHYDGI VAFSQTDFTE DLKGIQQPVL  
       250        260        270        280        290        300  
VMHGDDDQIV PYENSGVLSA KLLPNGALKT YKGYPHGMPT THADVINADL LAFIRSGTGG  
       310        320  
LAAIKSELAA IKQELAAIKQ ELAAIKQDG  
 
Calculated molecular weight for Oct-4-4: 35617 Da. 
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DNA sequence for GFP-mono: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttc  
                                         BglII  KpnI                 
 61      ---------+---------+---------+---------+---------+---------+    120 
         caatccaatattggaagtggattactggctagcaaaggagaagaactcttcactggagtt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gtcccaattcttgttgaattagatggtgatgttaacggccacaagttctctgtcagtgga  
 181     ---------+---------+---------+---------+---------+---------+    240 
         gagggtgaaggtgatgcaacatacggaaaacttaccctgaagttcatctgcactactggc  
 241     ---------+---------+---------+---------+---------+---------+    300 
         aaactgcctgttccatggccaacactagtcactactctgtgctatggtgttcaatgcttt  
 301     ---------+---------+---------+---------+---------+---------+    360 
         tcaagatacccggatcatatgaaacggcatgactttttcaagagtgccatgcccgaaggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         tatgtacaggaaaggaccatcttcttcaaagatgacggcaactacaagacacgtgctgaa  
 421     ---------+---------+---------+---------+---------+---------+    480 
         gtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgacttcaag  
 481     ---------+---------+---------+---------+---------+---------+    540 
         gaagatggcaacattctgggacacaaattggaatacaactataactcacacaatgtatac  
 541     ---------+---------+---------+---------+---------+---------+    600 
         atcatggcagacaaacaaaagaatggaatcaaagtgaacttcaagacccgccacaacatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         gaagatggaagcgttcaactagcagaccattatcaacaaaatactccaattggcgatggc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         cctgtccttttaccagacaaccattacctgtccacacaatctgccctttcgaaagatccc  
                                                        BstBI        
 721     ---------+---------+---------+---------+---------+---------+    780 
         aacgaaaagagagaccacatggtccttcttgagtttgtaacagctgctgggattacacat  
 781     ---------+---------+---------+---------+---------+---------+    840 
         ggcatggatgaactgtacaactga 
 
Protein sequence for GFP-mono: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDLGTENLYF QSNIGSGLLA SKGEELFTGV VPILVELDGD VNGHKFSVSG  
        70         80         90        100        110        120  
EGEGDATYGK LTLKFICTTG KLPVPWPTLV TTLCYGVQCF SRYPDHMKRH DFFKSAMPEG  
       130        140        150        160        170        180  
YVQERTIFFK DDGNYKTRAE VKFEGDTLVN RIELKGIDFK EDGNILGHKL EYNYNSHNVY  
       190        200        210        220        230        240  
IMADKQKNGI KVNFKTRHNI EDGSVQLADH YQQNTPIGDG PVLLPDNHYL STQSALSKDP  
       250        260  
NEKRDHMVLL EFVTAAGITH GMDELYN  
 
Calculated molecular weight for GFP-mono: 30017 Da. 
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DNA sequence for GFP-II-4-N: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatcatattgccgcaatcaagcaggaa  
 61      ---------+---------+---------+---------+---------+---------+    120 
         attgccgcaatcaagcaggaaattgccgcaatcaagcaggaaattgccgcaatcaagcag  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gaaggtggcggtggcggtggtaccgagaacctgtacttccaatccaatattggaagtgga  
                           KpnI                                      
 181     ---------+---------+---------+---------+---------+---------+    240 
         ttactggctagcaaaggagaagaactcttcactggagttgtcccaattcttgttgaatta  
 241     ---------+---------+---------+---------+---------+---------+    300 
         gatggtgatgttaacggccacaagttctctgtcagtggagagggtgaaggtgatgcaaca  
 301     ---------+---------+---------+---------+---------+---------+    360 
         tacggaaaacttaccctgaagttcatctgcactactggcaaactgcctgttccatggcca  
 361     ---------+---------+---------+---------+---------+---------+    420 
         acactagtcactactctgtgctatggtgttcaatgcttttcaagatacccggatcatatg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         aaacggcatgactttttcaagagtgccatgcccgaaggttatgtacaggaaaggaccatc  
 481     ---------+---------+---------+---------+---------+---------+    540 
         ttcttcaaagatgacggcaactacaagacacgtgctgaagtcaagtttgaaggtgatacc  
 541     ---------+---------+---------+---------+---------+---------+    600 
         cttgttaatagaatcgagttaaaaggtattgacttcaaggaagatggcaacattctggga  
 601     ---------+---------+---------+---------+---------+---------+    660 
         cacaaattggaatacaactataactcacacaatgtatacatcatggcagacaaacaaaag  
 661     ---------+---------+---------+---------+---------+---------+    720 
         aatggaatcaaagtgaacttcaagacccgccacaacattgaagatggaagcgttcaacta  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaac  
 781     ---------+---------+---------+---------+---------+---------+    840 
         cattacctgtccacacaatctgccctttcgaaagatcccaacgaaaagagagaccacatg  
                                   BstBI                             
 841     ---------+---------+---------+---------+---------+---------+    900 
         gtccttcttgagtttgtaacagctgctgggattacacatggcatggatgaactgtacaac  
 901     ---------+---------+---------+---------+---------+---------+    960 
         tga 
 
Protein sequence for GFP-II-4-N: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDHIAAIKQE IAAIKQEIAA IKQEIAAIKQ EGGGGGGTEN LYFQSNIGSG  
        70         80         90        100        110        120  
LLASKGEELF TGVVPILVEL DGDVNGHKFS VSGEGEGDAT YGKLTLKFIC TTGKLPVPWP  
       130        140        150        160        170        180  
TLVTTLCYGV QCFSRYPDHM KRHDFFKSAM PEGYVQERTI FFKDDGNYKT RAEVKFEGDT  
       190        200        210        220        230        240  
LVNRIELKGI DFKEDGNILG HKLEYNYNSH NVYIMADKQK NGIKVNFKTR HNIEDGSVQL  
       250        260        270        280        290        300  
ADHYQQNTPI GDGPVLLPDN HYLSTQSALS KDPNEKRDHM VLLEFVTAAG ITHGMDELYN  
 
Calculated molecular weight for GFP-II-4-N: 33342 Da. 
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DNA sequence for GFP-II-5-N: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatcatattgccgcaatcaagcaggaa  
 61      ---------+---------+---------+---------+---------+---------+    120 
         attgccgcaatcaagcaggaaattgccgcaatcaagcaggaaattgccgcaatcaagcag  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gaaattgccgcaatcaagcaggaaggtggcggtggcggtggtaccgagaacctgtacttc  
                                                KpnI                 
 181     ---------+---------+---------+---------+---------+---------+    240 
         caatccaatattggaagtggattactggctagcaaaggagaagaactcttcactggagtt  
 241     ---------+---------+---------+---------+---------+---------+    300 
         gtcccaattcttgttgaattagatggtgatgttaacggccacaagttctctgtcagtgga  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gagggtgaaggtgatgcaacatacggaaaacttaccctgaagttcatctgcactactggc  
 361     ---------+---------+---------+---------+---------+---------+    420 
         aaactgcctgttccatggccaacactagtcactactctgtgctatggtgttcaatgcttt  
 421     ---------+---------+---------+---------+---------+---------+    480 
         tcaagatacccggatcatatgaaacggcatgactttttcaagagtgccatgcccgaaggt  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tatgtacaggaaaggaccatcttcttcaaagatgacggcaactacaagacacgtgctgaa  
 541     ---------+---------+---------+---------+---------+---------+    600 
         gtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgacttcaag  
 601     ---------+---------+---------+---------+---------+---------+    660 
         gaagatggcaacattctgggacacaaattggaatacaactataactcacacaatgtatac  
 661     ---------+---------+---------+---------+---------+---------+    720 
         atcatggcagacaaacaaaagaatggaatcaaagtgaacttcaagacccgccacaacatt  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gaagatggaagcgttcaactagcagaccattatcaacaaaatactccaattggcgatggc  
 781     ---------+---------+---------+---------+---------+---------+    840 
         cctgtccttttaccagacaaccattacctgtccacacaatctgccctttcgaaagatccc  
                                                        BstBI        
 841     ---------+---------+---------+---------+---------+---------+    900 
         aacgaaaagagagaccacatggtccttcttgagtttgtaacagctgctgggattacacat  
 901     ---------+---------+---------+---------+---------+---------+    960 
         ggcatggatgaactgtacaactga 
 
Protein sequence for GFP-II-5-N: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDHIAAIKQE IAAIKQEIAA IKQEIAAIKQ EIAAIKQEGG GGGGTENLYF  
        70         80         90        100        110        120  
QSNIGSGLLA SKGEELFTGV VPILVELDGD VNGHKFSVSG EGEGDATYGK LTLKFICTTG  
       130        140        150        160        170        180  
KLPVPWPTLV TTLCYGVQCF SRYPDHMKRH DFFKSAMPEG YVQERTIFFK DDGNYKTRAE  
       190        200        210        220        230        240  
VKFEGDTLVN RIELKGIDFK EDGNILGHKL EYNYNSHNVY IMADKQKNGI KVNFKTRHNI  
       250        260        270        280        290        300  
EDGSVQLADH YQQNTPIGDG PVLLPDNHYL STQSALSKDP NEKRDHMVLL EFVTAAGITH  
 
GMDELYN  
 
Calculated molecular weight for GFP-II-5-N: 34096 Da. 
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DNA sequence for GFP-LI-4-N: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatcatctggccgcaatcaagcaggaa  
 61      ---------+---------+---------+---------+---------+---------+    120 
         ctggccgcaatcaagcaggaactggccgcaatcaagcaggaactggccgcaatcaagcag  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gaaggtggcggtggcggtggtaccgagaacctgtacttccaatccaatattggaagtgga  
                           KpnI                                      
 181     ---------+---------+---------+---------+---------+---------+    240 
         ttactggctagcaaaggagaagaactcttcactggagttgtcccaattcttgttgaatta  
 241     ---------+---------+---------+---------+---------+---------+    300 
         gatggtgatgttaacggccacaagttctctgtcagtggagagggtgaaggtgatgcaaca  
 301     ---------+---------+---------+---------+---------+---------+    360 
         tacggaaaacttaccctgaagttcatctgcactactggcaaactgcctgttccatggcca  
 361     ---------+---------+---------+---------+---------+---------+    420 
         acactagtcactactctgtgctatggtgttcaatgcttttcaagatacccggatcatatg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         aaacggcatgactttttcaagagtgccatgcccgaaggttatgtacaggaaaggaccatc  
 481     ---------+---------+---------+---------+---------+---------+    540 
         ttcttcaaagatgacggcaactacaagacacgtgctgaagtcaagtttgaaggtgatacc  
 541     ---------+---------+---------+---------+---------+---------+    600 
         cttgttaatagaatcgagttaaaaggtattgacttcaaggaagatggcaacattctggga  
 601     ---------+---------+---------+---------+---------+---------+    660 
         cacaaattggaatacaactataactcacacaatgtatacatcatggcagacaaacaaaag  
 661     ---------+---------+---------+---------+---------+---------+    720 
         aatggaatcaaagtgaacttcaagacccgccacaacattgaagatggaagcgttcaacta  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaac  
 781     ---------+---------+---------+---------+---------+---------+    840 
         cattacctgtccacacaatctgccctttcgaaagatcccaacgaaaagagagaccacatg  
                                   BstBI                             
 841     ---------+---------+---------+---------+---------+---------+    900 
         gtccttcttgagtttgtaacagctgctgggattacacatggcatggatgaactgtacaac  
 901     ---------+---------+---------+---------+---------+---------+    960 
         tga 
 
Protein sequence for GFP-LI-4-N: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDHLAAIKQE LAAIKQELAA IKQELAAIKQ EGGGGGGTEN LYFQSNIGSG  
        70         80         90        100        110        120  
LLASKGEELF TGVVPILVEL DGDVNGHKFS VSGEGEGDAT YGKLTLKFIC TTGKLPVPWP  
       130        140        150        160        170        180  
TLVTTLCYGV QCFSRYPDHM KRHDFFKSAM PEGYVQERTI FFKDDGNYKT RAEVKFEGDT  
       190        200        210        220        230        240  
LVNRIELKGI DFKEDGNILG HKLEYNYNSH NVYIMADKQK NGIKVNFKTR HNIEDGSVQL  
       250        260        270        280        290        300  
ADHYQQNTPI GDGPVLLPDN HYLSTQSALS KDPNEKRDHM VLLEFVTAAG ITHGMDELYN  
 
Calculated molecular weight for GFP-LI-4-N: 33342 Da. 
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DNA sequence for GFP-LI-3-N: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatcatctggccgcaatcaagcaggaa  
 61      ---------+---------+---------+---------+---------+---------+    120 
         ctggccgcaatcaagcaggaactggccgcaatcaagcaggaaggtggcggtggcggtggt  
                                                                  KpnI  
 121     ---------+---------+---------+---------+---------+---------+    180 
         accgagaacctgtacttccaatccaatattggaagtggattactggctagcaaaggagaa  
 181     ---------+---------+---------+---------+---------+---------+    240 
         gaactcttcactggagttgtcccaattcttgttgaattagatggtgatgttaacggccac  
 241     ---------+---------+---------+---------+---------+---------+    300 
         aagttctctgtcagtggagagggtgaaggtgatgcaacatacggaaaacttaccctgaag  
 301     ---------+---------+---------+---------+---------+---------+    360 
         ttcatctgcactactggcaaactgcctgttccatggccaacactagtcactactctgtgc  
 361     ---------+---------+---------+---------+---------+---------+    420 
         tatggtgttcaatgcttttcaagatacccggatcatatgaaacggcatgactttttcaag  
 421     ---------+---------+---------+---------+---------+---------+    480 
         agtgccatgcccgaaggttatgtacaggaaaggaccatcttcttcaaagatgacggcaac  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tacaagacacgtgctgaagtcaagtttgaaggtgatacccttgttaatagaatcgagtta  
 541     ---------+---------+---------+---------+---------+---------+    600 
         aaaggtattgacttcaaggaagatggcaacattctgggacacaaattggaatacaactat  
 601     ---------+---------+---------+---------+---------+---------+    660 
         aactcacacaatgtatacatcatggcagacaaacaaaagaatggaatcaaagtgaacttc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         aagacccgccacaacattgaagatggaagcgttcaactagcagaccattatcaacaaaat  
 721     ---------+---------+---------+---------+---------+---------+    780 
         actccaattggcgatggccctgtccttttaccagacaaccattacctgtccacacaatct  
 781     ---------+---------+---------+---------+---------+---------+    840 
         gccctttcgaaagatcccaacgaaaagagagaccacatggtccttcttgagtttgtaaca  
              BstBI                                                  
 841     ---------+---------+---------+---------+---------+---------+    900 
         gctgctgggattacacatggcatggatgaactgtacaactga 
 
Protein sequence for GFP-LI-3-N: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDHLAAIKQE LAAIKQELAA IKQEGGGGGG TENLYFQSNI GSGLLASKGE  
 
        70         80         90        100        110        120  
ELFTGVVPIL VELDGDVNGH KFSVSGEGEG DATYGKLTLK FICTTGKLPV PWPTLVTTLC  
 
       130        140        150        160        170        180  
YGVQCFSRYP DHMKRHDFFK SAMPEGYVQE RTIFFKDDGN YKTRAEVKFE GDTLVNRIEL  
 
       190        200        210        220        230        240  
KGIDFKEDGN ILGHKLEYNY NSHNVYIMAD KQKNGIKVNF KTRHNIEDGS VQLADHYQQN  
 
       250        260        270        280        290  
TPIGDGPVLL PDNHYLSTQS ALSKDPNEKR DHMVLLEFVT AAGITHGMDE LYN  
 
Calculated molecular weight for GFP-LI-3-N: 32588 Da. 
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DNA sequence for GFP-LL-4-N: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatcatctggccgcactgaagcaggaa  
 61      ---------+---------+---------+---------+---------+---------+    120 
         ctggccgcactgaagcaggaactggccgcactgaagcaggaactggccgcactgaagcag  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gaaggtggcggtggcggtggtaccgagaacctgtacttccaatccaatattggaagtgga  
                           KpnI                                      
 181     ---------+---------+---------+---------+---------+---------+    240 
         ttactggctagcaaaggagaagaactcttcactggagttgtcccaattcttgttgaatta  
 241     ---------+---------+---------+---------+---------+---------+    300 
         gatggtgatgttaacggccacaagttctctgtcagtggagagggtgaaggtgatgcaaca  
 301     ---------+---------+---------+---------+---------+---------+    360 
         tacggaaaacttaccctgaagttcatctgcactactggcaaactgcctgttccatggcca  
 361     ---------+---------+---------+---------+---------+---------+    420 
         acactagtcactactctgtgctatggtgttcaatgcttttcaagatacccggatcatatg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         aaacggcatgactttttcaagagtgccatgcccgaaggttatgtacaggaaaggaccatc  
 481     ---------+---------+---------+---------+---------+---------+    540 
         ttcttcaaagatgacggcaactacaagacacgtgctgaagtcaagtttgaaggtgatacc  
 541     ---------+---------+---------+---------+---------+---------+    600 
         cttgttaatagaatcgagttaaaaggtattgacttcaaggaagatggcaacattctggga  
 601     ---------+---------+---------+---------+---------+---------+    660 
         cacaaattggaatacaactataactcacacaatgtatacatcatggcagacaaacaaaag  
 661     ---------+---------+---------+---------+---------+---------+    720 
         aatggaatcaaagtgaacttcaagacccgccacaacattgaagatggaagcgttcaacta  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaac  
 781     ---------+---------+---------+---------+---------+---------+    840 
         cattacctgtccacacaatctgccctttcgaaagatcccaacgaaaagagagaccacatg  
                                   BstBI                             
 841     ---------+---------+---------+---------+---------+---------+    900 
         gtccttcttgagtttgtaacagctgctgggattacacatggcatggatgaactgtacaac  
 901     ---------+---------+---------+---------+---------+---------+    960 
         tga 
 
Protein sequence for GFP-LL-4-N: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDHLAALKQE LAALKQELAA LKQELAALKQ EGGGGGGTEN LYFQSNIGSG  
        70         80         90        100        110        120  
LLASKGEELF TGVVPILVEL DGDVNGHKFS VSGEGEGDAT YGKLTLKFIC TTGKLPVPWP  
       130        140        150        160        170        180  
TLVTTLCYGV QCFSRYPDHM KRHDFFKSAM PEGYVQERTI FFKDDGNYKT RAEVKFEGDT  
       190        200        210        220        230        240  
LVNRIELKGI DFKEDGNILG HKLEYNYNSH NVYIMADKQK NGIKVNFKTR HNIEDGSVQL  
       250        260        270        280        290        300  
ADHYQQNTPI GDGPVLLPDN HYLSTQSALS KDPNEKRDHM VLLEFVTAAG ITHGMDELYN  
 
Calculated molecular weight for GFP-LL-4-N: 33342 Da. 
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DNA sequence for GFP-WW-7-N: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatcattcttccaacgcgaaatgggat  
 61      ---------+---------+---------+---------+---------+---------+    120 
         cagtggtcttccgattggcagacctggaacgcgaaatgggatcagtggagcaacgattgg  
 121     ---------+---------+---------+---------+---------+---------+    180 
         aacgcgtggcgttctgattggcaggcgtggaaagatgattgggcgcgttggaaccagcgt  
 181     ---------+---------+---------+---------+---------+---------+    240 
         tgggataactgggcgaccggtggcggtggcggtggtaccgagaacctgtacttccaatcc  
                                          KpnI                       
 241     ---------+---------+---------+---------+---------+---------+    300 
         aatattggaagtggattactggctagcaaaggagaagaactcttcactggagttgtccca  
 301     ---------+---------+---------+---------+---------+---------+    360 
         attcttgttgaattagatggtgatgttaacggccacaagttctctgtcagtggagagggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         gaaggtgatgcaacatacggaaaacttaccctgaagttcatctgcactactggcaaactg  
 421     ---------+---------+---------+---------+---------+---------+    480 
         cctgttccatggccaacactagtcactactctgtgctatggtgttcaatgcttttcaaga  
 481     ---------+---------+---------+---------+---------+---------+    540 
         tacccggatcatatgaaacggcatgactttttcaagagtgccatgcccgaaggttatgta  
 541     ---------+---------+---------+---------+---------+---------+    600 
         caggaaaggaccatcttcttcaaagatgacggcaactacaagacacgtgctgaagtcaag  
 601     ---------+---------+---------+---------+---------+---------+    660 
         tttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgacttcaaggaagat  
 661     ---------+---------+---------+---------+---------+---------+    720 
         ggcaacattctgggacacaaattggaatacaactataactcacacaatgtatacatcatg  
 721     ---------+---------+---------+---------+---------+---------+    780 
         gcagacaaacaaaagaatggaatcaaagtgaacttcaagacccgccacaacattgaagat  
 781     ---------+---------+---------+---------+---------+---------+    840 
         ggaagcgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtc  
 841     ---------+---------+---------+---------+---------+---------+    900 
         cttttaccagacaaccattacctgtccacacaatctgccctttcgaaagatcccaacgaa  
                                                  BstBI              
 901     ---------+---------+---------+---------+---------+---------+    960 
         aagagagaccacatggtccttcttgagtttgtaacagctgctgggattacacatggcatg  
 961     ---------+---------+---------+---------+---------+---------+    1020 
         gatgaactgtacaactga 
 
Protein sequence for GFP-WW-7-N: 
        10         20         30         40         50         60  
MHHHHHHSSG VDHSSNAKWD QWSSDWQTWN AKWDQWSNDW NAWRSDWQAW KDDWARWNQR  
        70         80         90        100        110        120  
WDNWATGGGG GGTENLYFQS NIGSGLLASK GEELFTGVVP ILVELDGDVN GHKFSVSGEG  
       130        140        150        160        170        180  
EGDATYGKLT LKFICTTGKL PVPWPTLVTT LCYGVQCFSR YPDHMKRHDF FKSAMPEGYV  
       190        200        210        220        230        240  
QERTIFFKDD GNYKTRAEVK FEGDTLVNRI ELKGIDFKED GNILGHKLEY NYNSHNVYIM  
       250        260        270        280        290        300  
ADKQKNGIKV NFKTRHNIED GSVQLADHYQ QNTPIGDGPV LLPDNHYLST QSALSKDPNE  
       310        320  
KRDHMVLLEF VTAAGITHGM DELYN  
 
Calculated molecular weight for GFP-WW-7-N: 37184 Da. 
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DNA sequence for GFP-FF-7-N: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatcatagcagcaacgcgaaatttgat  
 61      ---------+---------+---------+---------+---------+---------+    120 
         cagtttagcagcgattttcagacctttaacgcgaaatttgatcagtttagcaacgatatg  
 121     ---------+---------+---------+---------+---------+---------+    180 
         aacgcgtttcgcagcgattttcaggcgtttaaagatgattttgcgcgctttaaccagcgc  
 181     ---------+---------+---------+---------+---------+---------+    240 
         tttgataactttgcgaccaaatatcgcggtggcggtggcggtggtaccgagaacctgtac  
                                                   KpnI              
 241     ---------+---------+---------+---------+---------+---------+    300 
         ttccaatccaatattggaagtggattactggctagcaaaggagaagaactcttcactgga  
 301     ---------+---------+---------+---------+---------+---------+    360 
         gttgtcccaattcttgttgaattagatggtgatgttaacggccacaagttctctgtcagt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         ggagagggtgaaggtgatgcaacatacggaaaacttaccctgaagttcatctgcactact  
 421     ---------+---------+---------+---------+---------+---------+    480 
         ggcaaactgcctgttccatggccaacactagtcactactctgtgctatggtgttcaatgc  
 481     ---------+---------+---------+---------+---------+---------+    540 
         ttttcaagatacccggatcatatgaaacggcatgactttttcaagagtgccatgcccgaa  
 541     ---------+---------+---------+---------+---------+---------+    600 
         ggttatgtacaggaaaggaccatcttcttcaaagatgacggcaactacaagacacgtgct  
 601     ---------+---------+---------+---------+---------+---------+    660 
         gaagtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgacttc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         aaggaagatggcaacattctgggacacaaattggaatacaactataactcacacaatgta  
 721     ---------+---------+---------+---------+---------+---------+    780 
         tacatcatggcagacaaacaaaagaatggaatcaaagtgaacttcaagacccgccacaac  
 781     ---------+---------+---------+---------+---------+---------+    840 
         attgaagatggaagcgttcaactagcagaccattatcaacaaaatactccaattggcgat  
 841     ---------+---------+---------+---------+---------+---------+    900 
         ggccctgtccttttaccagacaaccattacctgtccacacaatctgccctttcgaaagat  
                                                           BstBI     
 901     ---------+---------+---------+---------+---------+---------+    960 
         cccaacgaaaagagagaccacatggtccttcttgagtttgtaacagctgctgggattaca  
 961     ---------+---------+---------+---------+---------+---------+    1020 
         catggcatggatgaactgtacaactga 
 
Peptide sequence for GFP-FF-7-N: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDHSSNAKFD QFSSDFQTFN AKFDQFSNDM NAFRSDFQAF KDDFARFNQR  
        70         80         90        100        110        120  
FDNFATKYRG GGGGGTENLY FQSNIGSGLL ASKGEELFTG VVPILVELDG DVNGHKFSVS  
       130        140        150        160        170        180  
GEGEGDATYG KLTLKFICTT GKLPVPWPTL VTTLCYGVQC FSRYPDHMKR HDFFKSAMPE  
       190        200        210        220        230        240  
GYVQERTIFF KDDGNYKTRA EVKFEGDTLV NRIELKGIDF KEDGNILGHK LEYNYNSHNV  
       250        260        270        280        290        300  
YIMADKQKNG IKVNFKTRHN IEDGSVQLAD HYQQNTPIGD GPVLLPDNHY LSTQSALSKD  
       310        320  
PNEKRDHMVL LEFVTAAGIT HGMDELYN  
 
Calculated molecular weight for GFP-FF-7-N: 37069 Da.  
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DNA sequence for GFP-II-4-C: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttc  
                                         BglII  KpnI                 
 61      ---------+---------+---------+---------+---------+---------+    120 
         caatccaatattggaagtggattactggctagcaaaggagaagaactcttcactggagtt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gtcccaattcttgttgaattagatggtgatgttaacggccacaagttctctgtcagtgga  
 181     ---------+---------+---------+---------+---------+---------+    240 
         gagggtgaaggtgatgcaacatacggaaaacttaccctgaagttcatctgcactactggc  
 241     ---------+---------+---------+---------+---------+---------+    300 
         aaactgcctgttccatggccaacactagtcactactctgtgctatggtgttcaatgcttt  
 301     ---------+---------+---------+---------+---------+---------+    360 
         tcaagatacccggatcatatgaaacggcatgactttttcaagagtgccatgcccgaaggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         tatgtacaggaaaggaccatcttcttcaaagatgacggcaactacaagacacgtgctgaa  
 421     ---------+---------+---------+---------+---------+---------+    480 
         gtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgacttcaag  
 481     ---------+---------+---------+---------+---------+---------+    540 
         gaagatggcaacattctgggacacaaattggaatacaactataactcacacaatgtatac  
 541     ---------+---------+---------+---------+---------+---------+    600 
         atcatggcagacaaacaaaagaatggaatcaaagtgaacttcaagacccgccacaacatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         gaagatggaagcgttcaactagcagaccattatcaacaaaatactccaattggcgatggc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         cctgtccttttaccagacaaccattacctgtccacacaatctgccctttcgaaagatccc  
                                                        BstBI        
 721     ---------+---------+---------+---------+---------+---------+    780 
         aacgaaaagagagaccacatggtccttcttgagtttgtaacagccgcggggattacaggt  
 781     ---------+---------+---------+---------+---------+---------+    840 
         ggtggcggaggtggcgagatcgcggcgatcaaacaggagatcgcagcgatcaaacaggaa  
 841     ---------+---------+---------+---------+---------+---------+    900 
         attgccgcaattaaacaggaaattgctgcaattaaacaa 
 
Peptide sequence for GFP-II-4-C: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDLGTENLYF QSNIGSGLLA SKGEELFTGV VPILVELDGD VNGHKFSVSG  
        70         80         90        100        110        120  
EGEGDATYGK LTLKFICTTG KLPVPWPTLV TTLCYGVQCF SRYPDHMKRH DFFKSAMPEG  
       130        140        150        160        170        180  
YVQERTIFFK DDGNYKTRAE VKFEGDTLVN RIELKGIDFK EDGNILGHKL EYNYNSHNVY  
       190        200        210        220        230        240  
IMADKQKNGI KVNFKTRHNI EDGSVQLADH YQQNTPIGDG PVLLPDNHYL STQSALSKDP  
       250        260        270        280        290  
 
Calculated molecular weight for GFP-II-4-C: 32415 Da. 
  
166 
 
DNA sequence for GFP-II-5-C: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttc  
                                         BglII  KpnI                 
 61      ---------+---------+---------+---------+---------+---------+    120 
         caatccaatattggaagtggattactggctagcaaaggagaagaactcttcactggagtt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gtcccaattcttgttgaattagatggtgatgttaacggccacaagttctctgtcagtgga  
 181     ---------+---------+---------+---------+---------+---------+    240 
         gagggtgaaggtgatgcaacatacggaaaacttaccctgaagttcatctgcactactggc  
 241     ---------+---------+---------+---------+---------+---------+    300 
         aaactgcctgttccatggccaacactagtcactactctgtgctatggtgttcaatgcttt  
 301     ---------+---------+---------+---------+---------+---------+    360 
         tcaagatacccggatcatatgaaacggcatgactttttcaagagtgccatgcccgaaggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         tatgtacaggaaaggaccatcttcttcaaagatgacggcaactacaagacacgtgctgaa  
 421     ---------+---------+---------+---------+---------+---------+    480 
         gtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgacttcaag  
 481     ---------+---------+---------+---------+---------+---------+    540 
         gaagatggcaacattctgggacacaaattggaatacaactataactcacacaatgtatac  
 541     ---------+---------+---------+---------+---------+---------+    600 
         atcatggcagacaaacaaaagaatggaatcaaagtgaacttcaagacccgccacaacatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         gaagatggaagcgttcaactagcagaccattatcaacaaaatactccaattggcgatggc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         cctgtccttttaccagacaaccattacctgtccacacaatctgccctttcgaaagatccc  
                                                        BstBI        
 721     ---------+---------+---------+---------+---------+---------+    780 
         aacgaaaagagagaccacatggtccttcttgagtttgtaacagccgcggggattacaggt  
 781     ---------+---------+---------+---------+---------+---------+    840 
         ggtggcggaggtggcgagatcgcggcgatcaaacaggagattgcagccattaaacaagaa  
 841     ---------+---------+---------+---------+---------+---------+    900 
         atcgcagcgatcaaacaggaaattgccgcaattaaacaggaaattgctgcaattaaacaa 
 
Peptide sequence for GFP-II-5-C: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDLGTENLYF QSNIGSGLLA SKGEELFTGV VPILVELDGD VNGHKFSVSG  
        70         80         90        100        110        120  
EGEGDATYGK LTLKFICTTG KLPVPWPTLV TTLCYGVQCF SRYPDHMKRH DFFKSAMPEG  
       130        140        150        160        170        180  
YVQERTIFFK DDGNYKTRAE VKFEGDTLVN RIELKGIDFK EDGNILGHKL EYNYNSHNVY  
       190        200        210        220        230        240  
IMADKQKNGI KVNFKTRHNI EDGSVQLADH YQQNTPIGDG PVLLPDNHYL STQSALSKDP  
       250        260        270        280        290        300  
NEKRDHMVLL EFVTAAGITG GGGGGEIAAI KQEIAAIKQE IAAIKQEIAA IKQEIAAIKQ  
 
Calculated molecular weight for GFP-II-5-C: 33169 Da. 
  
167 
 
DNA sequence for GFP-LI-4-C: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttc  
                                         BglII  KpnI                 
 61      ---------+---------+---------+---------+---------+---------+    120 
         caatccaatattggaagtggattactggctagcaaaggagaagaactcttcactggagtt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gtcccaattcttgttgaattagatggtgatgttaacggccacaagttctctgtcagtgga  
 181     ---------+---------+---------+---------+---------+---------+    240 
         gagggtgaaggtgatgcaacatacggaaaacttaccctgaagttcatctgcactactggc  
 241     ---------+---------+---------+---------+---------+---------+    300 
         aaactgcctgttccatggccaacactagtcactactctgtgctatggtgttcaatgcttt  
 301     ---------+---------+---------+---------+---------+---------+    360 
         tcaagatacccggatcatatgaaacggcatgactttttcaagagtgccatgcccgaaggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         tatgtacaggaaaggaccatcttcttcaaagatgacggcaactacaagacacgtgctgaa  
 421     ---------+---------+---------+---------+---------+---------+    480 
         gtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgacttcaag  
 481     ---------+---------+---------+---------+---------+---------+    540 
         gaagatggcaacattctgggacacaaattggaatacaactataactcacacaatgtatac  
 541     ---------+---------+---------+---------+---------+---------+    600 
         atcatggcagacaaacaaaagaatggaatcaaagtgaacttcaagacccgccacaacatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         gaagatggaagcgttcaactagcagaccattatcaacaaaatactccaattggcgatggc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         cctgtccttttaccagacaaccattacctgtccacacaatctgccctttcgaaagatccc  
                                                        BstBI        
 721     ---------+---------+---------+---------+---------+---------+    780 
         aacgaaaagagagaccacatggtccttcttgagtttgtaacagccgcggggattacaggt  
 781     ---------+---------+---------+---------+---------+---------+    840 
         ggtggcggaggtggcgagctggcggcgatcaaacaggagctggcagcgatcaaacaggaa  
 841     ---------+---------+---------+---------+---------+---------+    900 
         ctggccgcaattaaacaggaactggctgcaattaaacaa 
 
Peptide sequence for GFP-LI-4-C: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDLGTENLYF QSNIGSGLLA SKGEELFTGV VPILVELDGD VNGHKFSVSG  
        70         80         90        100        110        120  
EGEGDATYGK LTLKFICTTG KLPVPWPTLV TTLCYGVQCF SRYPDHMKRH DFFKSAMPEG  
       130        140        150        160        170        180  
YVQERTIFFK DDGNYKTRAE VKFEGDTLVN RIELKGIDFK EDGNILGHKL EYNYNSHNVY  
       190        200        210        220        230        240  
IMADKQKNGI KVNFKTRHNI EDGSVQLADH YQQNTPIGDG PVLLPDNHYL STQSALSKDP  
       250        260        270        280        290  
NEKRDHMVLL EFVTAAGITG GGGGGELAAI KQELAAIKQE LAAIKQELAA IKQ  
 
Calculated molecular weight for GFP-LI-4-C: 32415 Da. 
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DNA sequence for GFP-LL-4-C: 
 
 1       ---------+---------+---------+---------+---------+---------+    60 
         atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttc  
                                         BglII  KpnI                 
 61      ---------+---------+---------+---------+---------+---------+    120 
         caatccaatattggaagtggattactggctagcaaaggagaagaactcttcactggagtt  
 121     ---------+---------+---------+---------+---------+---------+    180 
         gtcccaattcttgttgaattagatggtgatgttaacggccacaagttctctgtcagtgga  
 181     ---------+---------+---------+---------+---------+---------+    240 
         gagggtgaaggtgatgcaacatacggaaaacttaccctgaagttcatctgcactactggc  
 241     ---------+---------+---------+---------+---------+---------+    300 
         aaactgcctgttccatggccaacactagtcactactctgtgctatggtgttcaatgcttt  
 301     ---------+---------+---------+---------+---------+---------+    360 
         tcaagatacccggatcatatgaaacggcatgactttttcaagagtgccatgcccgaaggt  
 361     ---------+---------+---------+---------+---------+---------+    420 
         tatgtacaggaaaggaccatcttcttcaaagatgacggcaactacaagacacgtgctgaa  
 421     ---------+---------+---------+---------+---------+---------+    480 
         gtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgacttcaag  
 481     ---------+---------+---------+---------+---------+---------+    540 
         gaagatggcaacattctgggacacaaattggaatacaactataactcacacaatgtatac  
 541     ---------+---------+---------+---------+---------+---------+    600 
         atcatggcagacaaacaaaagaatggaatcaaagtgaacttcaagacccgccacaacatt  
 601     ---------+---------+---------+---------+---------+---------+    660 
         gaagatggaagcgttcaactagcagaccattatcaacaaaatactccaattggcgatggc  
 661     ---------+---------+---------+---------+---------+---------+    720 
         cctgtccttttaccagacaaccattacctgtccacacaatctgccctttcgaaagatccc  
                                                        BstBI        
 721     ---------+---------+---------+---------+---------+---------+    780 
         aacgaaaagagagaccacatggtccttcttgagtttgtaacagccgcggggattacaggt  
 781     ---------+---------+---------+---------+---------+---------+    840 
         ggtggcggaggtggcgagctggcggcgctgaaacaggagctggcagcgctgaaacaggaa  
 841     ---------+---------+---------+---------+---------+---------+    900 
         Ctggccgcactgaaacaggaactggctgcactgaaacaa 
 
Peptide sequence for GFP-LL-4-C: 
 
        10         20         30         40         50         60  
MHHHHHHSSG VDLGTENLYF QSNIGSGLLA SKGEELFTGV VPILVELDGD VNGHKFSVSG  
        70         80         90        100        110        120  
EGEGDATYGK LTLKFICTTG KLPVPWPTLV TTLCYGVQCF SRYPDHMKRH DFFKSAMPEG  
       130        140        150        160        170        180  
YVQERTIFFK DDGNYKTRAE VKFEGDTLVN RIELKGIDFK EDGNILGHKL EYNYNSHNVY  
       190        200        210        220        230        240  
IMADKQKNGI KVNFKTRHNI EDGSVQLADH YQQNTPIGDG PVLLPDNHYL STQSALSKDP  
       250        260        270        280        290  
NEKRDHMVLL EFVTAAGITG GGGGGELAAL KQELAALKQE LAALKQELAA LKQ  
 
Calculated molecular weight for GFP-LL-4-C: 32415 Da. 
